var title_f13_52_14144="Bicipital tendinitis block";
var content_f13_52_14144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Bicipital tendinitis confirmed by local anesthetic block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 343px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFXAdcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5jFJS0dqBCUveijmkAZpKWimAUUtFACd6KKKAAUopKUUAJSiiigAo7c0UtAhO1Bpe1FAxO9FHeloAKQUvNJSAKXmkpaYCdqKWjtQAUhpaQ96AIW60xutSN1qM9aAI/wCI02ngfM1M70DLS9BS05FZsBVJpWiZR8xA/GgREzYqE81I+BwKjoGJR3paBQAmfWpBTMZzTgcYoAVe9OIpF607FACAc1KBUfap0GQDSGhV74p46UKMH2p6igqxHjpUZXmrBFNK80XE0VznFKDipCKaR7UxDeppCPWnH9KSgQlFL2pKAEJpobinUw0AP3U3dzSHpTScUALk5oqMmigC1RRR3oEFFFLQAUUlLigApKWgUAGaBRRQAdqWkpaBCGilooGAooooEHailpPWgBKUUtHegYlFL3ooEJRS0djQAhHFFLS0AJSN0pygkgAEmtWw8O6nfLmG1cIf4n+UfrSukNJswm61C7HdgCvQ9O8ASkhr6fP+xEP6n/Cuh07wlaWpOyHBz1PJqHUSLUGzy3T9Fu7obtmxD3ate38OpB80itK/uMCvV4dHVRjYAtSHSlyRsGB3rKVWXQ0UF1PKLi1uAhCRbRjsKxprGfqyt+Ne0yaShQkIDWVPo8ZJyg/KpVVp6lezTPIXtZEPKmoHjI616rcaFGw+71rB1Lw43PlrzmtI1k9yXSa2OEIxTsV0L+HbgE/LUa6Mwfacg/StOeJHJIwwvFOIrWfTiidD9apTQlKaknsJxaK3QjmnHvSsvQ04rg1RIw9Kmh5WoyPl+lETbRmkNFodMU4VGG4NODcVJZJ1NNIoU08UIojxkU1lqUjvTTzTuS0QMOKbUj8HFMIz1pkMSm0pFNNMQ00GkJoJ4oASmMakxSbKAIj1ook4ooAtmiiigQUtJiloAMUCigUAAooooAPeilooEgoo70UAFLSe1AFAwpe1FFAgooooAMUGgUtABRjilqW1tprqZYreNpJGPCqM0m7D3IaAK7PSfAOo3Tg3hW2jxnj5mP8ASu30PwPaWiqXiRpAc72UMx/E8D8BUuQ1E8n0zRNQ1N8WdtJIB1YjC/ma6/S/h1M6q9/cbc9UiGf1P+FetW+noihVQDAxV1bXAxtFS5MpJHHaZ4T06xkV4LVFcD7+Mn8zWyliidE5+lbqwcjgZPepFtx1xmp3KvYxUsfQfhUq2Q4BHvWx5GBwBmnCIDk9etRLQFIy0thggrxTWtQFbavPWtYqBt7VHJGQCD09qGrgmYM8YLEAHmqb2owQMf4VvSIDGfT6Vly4CkEYJ/WpaLUjFmtlDklcH1qo9uCSHxx7frWndsoGAeR+VZU8uDk857ioatojVXZRu4E+deAQOo5rBu41DEgAkd61buc7zyc1h3U53HJ70osbVilcgBPl7nkVi3sYxn2NalzJwCDyazrht34VstGZy1MspxgikdRjIqeReTUbrlfet07mFrEGOtNA4IpxB3U0H5hVEkiN8tSKahyMkU8EdqB3JVPSnq2T0qEHmng80mikyUGm0UoGKRYxlyajxzUxHNNYYpohohYcVG1TsBULDOapEsjpQCelLjmnDigQKmOtNdgOlOJqJuT70AQsCTRUu39aKAJ6KKKBC0UUUAFFHagUALRQKBQIKKKKGAtGKKBQAg70vbFFLQMSlooxQIKKfHG0jBI1LMx4A5JrqNG8FahfHdcD7NFx94ZY/h/jQ3YaRyoHTFben+F9VvWGy2MaH+KX5f06/pXpGieCLGzdJPLM0q87pDnB+nSuyt9OVB93J9qi7A830f4eQKqPfSPO/dV+VP8AGu40jQLaxULbWyRDvtXrXSWlkOAFJ9eK04bNuPlx7ipY7mPbaceu0j61oQ2fAA4P0q9N/o6DcM+magN8FYLs+bvz2pOSW40m9hGttoHHHqKesOQDxj3qe2mFwcIOR1Bq35G4denpQlfVBsUFjUnb3+lOMPPSr3lYPTmmOtOwil5eCfrikkUZHTFTyKM55qEsCcipaHchYHPAqNv4gOlPkkAbHHB/Kq0z7ckg4otcCOcDqpG7HI7ViagrKCf4cdRWhPKynhuD0FZ9zIzK2OVpONyouxz1+zA5OTnqTWNeXGEb1Fbl9A0p5z0rCvbZlJxyOmKxa6nRFmNJOz5J6dKzrh2Vjxmta4t2DcqQf51Qnt29CRRBWKkY08hfjuKqyZIrUmtm52iqrQkdelbKxm0ZzrUDHFX5kx1qlIBu9quJlJFdjz70wj5uKfJ96mDpitDMFHINPHfNIOlL0oAVTyKeDUYxmnA0DRMh4p2aiU1J2qWjRMd6UEcGkHTinA8YNK49yF14qFu9WXGRxUBU5q47GciJR1pSR0xR060p6ZoJImzSA46CnFaXHNMBAD+NFLkn2ooAkHSikpe1Ago5opaAEpaMUUALzSUA0ooEFFFFAB1pRRRigApetX9L0m91OYR2dvJJk4LAfKPqa9I8OfDqBYw+pgzyZztBIQf1NJsZ5pp2mXmpSmOxtpJ2HXYOB9T0Fdrovw5upSkmpTLEveNOW+hPQfhmvVtP0W3s4glvAkaAdFXArRS0xg7T+VGrFdI5nSfDtjpygW9vGmBjOOT9T1NbMdsCcbePQCtSGwLHocVoWunDfkrRYVzJt7J2xkYrWt7DH3q1YbQA9sdqtC2xgjPWnyi5ilDbqox0qwkQDAjqBVnyfUU4Rhe340+UVyuYwfvAH0pn2SMMWCKD64q6yccimtkL0yMUNDTZUWAJkqijPpThHgjPFTnHWoiSfx/lRYd2MKjO0jHSqsi5GKsPyvIORVaXcMr3/nUtDRUlOw8D/wCvVOWYk/KB71cmyw4/OqkkLMOp/Cs2iii8rAncOexpjyFxyCKuzQ7YwQCfXNR+TjJCkfyqWUZ0kZYd6qGBwDnp71t/Z9p6cH0pjwZy3X2pFHPSWpJBHJqnLpx3McZx1xXUGAAAFcjH5GoJYdx9sdalpFqRx1xpzAsrKKzZtLyTxzXctagH7xqvLbJt+7yPTvU8pfMcFcaaAORWLeWe3IUcivRLu2jKHAAPpXN6lEB27cUndDvc4S5hIHIINZV0pVq6m8jBJBArntQTaTW0Hd3M5rQynPPvTO9LIfmpAc1uYD04pT7U0fjTucCkACgHBpKTPNMCVTzT91QqR3p4NIaJc04Hios0tKxaY9mFRO1ITz6008mhKwmxp5oVT36U7ApcccUyRCtNK08t60AimBCVxRUjYxRSASlo70UyQ70tJS0AAooopAKKKKWmIMUUUoGTTAAK6Xwx4Vu9YkjldfLtCeX7t9B/WrvgTwu+q3Pn3MZNuv3QeAxr3PR9IWCNFjjAwAOBStcTdilo2hQ2VvHFFGEQDAxW9BZhECoOPpWta6eWILLWrb6eoHC+1WqbZm5GFHZEjJFW4dPLHJX8K6CCxDdRircdpsXhdxHOAK1VInmMOKxwemasJalT0roo7UEAsAD1pRa9sfpV+yJ5zA8hh1GPSlVML61uPZ4HSqz2pHOBUum0PnTM7aBQFX+lWjbkHmmGL8D71HKyrlcpnimMOxHNTMpBPSon3DjNKxRC69aqlWB55/pVpjxUR61A0yA8g9xUUoLMCPWp3TcMimZKqAeRUspEBiAJHryajaIZyM4q0QDgA5xTXQAnHT6Umhq5QaMDgZOeq4pkiEZyOM1dYAg9CTURAIIyME9DWdi0yoy8dKrkYOTkmrjxgcDIqu6DGMc46ipaGmVWOckdfWq7Adj04OOlWmjLdOtV5Y3GQDipZaK0in61VnBbKirjKRt3HNMMYZyCPxpWHzGTcR7B82K5/VYEKk8gjOMV1OoqdoCnp7Vz14rAHkMM8ipkVHU4u8t92SMj61yurIyMQeRXeX0LF+mPcVx+voQWGKKb1KktDlX+8aQGiT7xpoNdhykwNKO9Rg04GgBTTc0ueaaelAD1GTxUi80xOlSCkA7FIfakZhULzBe9BVyRjimM4qB5SelRlieppkk/mgGhpvSq+aM0ASmQmkBYnjNMVgG5GRU6kHp0oAVS2KKBRQK5KKBSUCgBaWkpaQBR3opRQAUoooHtTEKBk11fgnwpca9c7ypW1Qjc2PvewqHwR4XufE2piGHCwJzK57D/ABr6i8M+HLTTbGG3tIlREAHSrjByIlPlMfw34dSyt0SNCFQAAYrrbLTQmGxWxaWcajovH6VoQwbTjGeeuOlbxomDqFSKyBXkH8qux2gA28561eiiJyM/T3qdYj29R1rblijPmbKcNv7VKluBjrxVyOE4APNSrHk8ev5UOaQtWV9gIUYOackGAc8HqTVpUBYZAp7JkYGMn0rNzKUCm0QKn3qrLEGHI5rQEsbsyRkNt4Pt/n+lRSI3zNxxkkDsBVRl3C1tjIniCnJ6dKqzoMHI4rTnOQeMfXtWdOw2nHBNEl1KizPlA2/jVaRtoz3qeZ+CD3rPkkxnPGK5paG6B3285qFpDvP3Sp6e1Ru4yKrNlXJ3Hk9OwrNl2RbDdRn6GkGGGPeqpJ5KjNAlO3J/OlcZZ+VWyAT7inEjjB4xxVQyYXJOT0qJp9q4zjsBSGWpGAbBH/1qhYIVyD+XWs66uXJ+XB/Gs+W9kB+ZtrDsam40brxZHDg4HWoXhZutYy37HI3YPf3qVNU2gAsT9e1LQZdkiZcdqgkBGSc1Uk1JioC4wKBeuTlyApPf1rOxSHuQcHPNRnB6+tS+dGw+bFRSujMFHShIooX0ZfaV+vJrKnixnCgnoD6VvXAUqDnjtWbIN2c9aGioPocrf2O777sM9NorlNXsGYlEUtxXpM0IaXBIrOuLRNxOBWdrO6NVseJ6jYSQuxKECsxgQa9h1nR454n+UEkV53rOkvayHC8VvCpfRmM6VtUYPenKaHUgmmdK1MSUGgHmmKc0o45oAmUgUySYAcHmoZX7CoqAHNIxPWm0lLQAUUUUABpKKKAClUkHIpKKAJ1kBGDxRUFFAF+lzSUtAg5paTvS9qAClFJR0oAdVrTLY3d7FCpC7j1PQVVHNaWlWSXMyiQkLznnFNIls9k8Ha3onh6yFrZiS+uv4orVNzM3u3QfnXoWmax4pvo1NvodpZITgNdXJc4Pfao/rXF/DnTLa2SMxxBeMkivYLFcomD/APWrdJvrY5pSSe1zOtrbxjM3z6rpUA7LHZM2PxL1pW9l4uQljrGnMccBrIgfo9b1om5c46f4Vpxr044rdUla7b+9mbqeS+45YJ42RQRLpMmcfL5bjHr3qzBqPiy2QfadLs7ggcmByM/gTXXRbSSew7VIjKw65B9O9ZtW6sfNfojj4fFupwti98P3Ea9AVfd/TH61LaeOrFyfMtrmI553Y4/WuvVFIyQMkd+1KbWF+WjUnGORmocrblpPoYI8XaUYy++XPZTGQSf5VVnvbzXFS2so5reFuZJSMcdgD/hXTrp9orEpbwg47IBU5QdF4Oc0lNIfK+pmadYx2FksMbM20/fYkk+9SMxIzjBxjrUs7MgJUZBHFZslyucONvPPtxWkbdSGn0I7gncwP1xWXdP8x46Vp3GGGRnnpWZdKCDWk9hQMq5Zdwy+N3SqUm7efSrk6gZ/ziqT5yR6d65ZbnSmVn9qhbhifXFWJBgcjBNRHrg1DHuRkHHBqCZimOfzqcDDHnOaimXdk88UhpkEkpCjng9KrNKXUEdRUrrgHOcfWmFQM461JSZVkcliMiqs8bNztzjuK1WjUDkEHHWopY+xYZ9cVLKTMKVHXOM4NU/McAq6nPqBWzNHIchR+YqhJHkddrDuaTRSZUSbuc8VP9qOODx3qldttc4POOKz3uxE24nHY+hqXoh7m216p5zgioXvdzAEj3xWG90GJIPWoluGyef8az0NEjopb47duQcVFHcbu/PWsCa6wR83PTmkS8KsMnIPGc0m9bAkb7yBuCQD61FIN3OR6VQSTf8Ah71M0gxjtmlfsaXGTqCCAM1zWt2kcqNkAV0dw67Tgday7thgrnJPSly+ZSZ5Xq9mYZmwOKyWGK7rXbZW3AdetcdeReW5GK6qcro5qkbPQqjg0u7imnikqzMaxyabTjTaACiiloAKSiigAooooAKKKKACiiigC/mgUUUCFoFJ3pRSAUcUUlOFMCWGMu2B3rpPDtiTfRLjecbsL0+lY2nrjD7sdua7HwoALuMnGDxkH+dUkZykeu+EI1itI8qUbHOK9E0+T5AQcjHTFed6PMqIAdoGMcGu20u73RgEH8K6YnI9Tr7WbKjHBxzWlExOBu7c89q561mPmN2A4q/FcYOB+ddKd0YtGsj/ADAqeP5VZjnwuRjrWTG5VgQeMY+tWYpTycGk43C9jUimDDJ4JHWp0lU9+tZIcEYUgEDmnpNhecDHHNYypXNY1bGxkYyDTZnESlmztHXHYVSS62jJx/jUsl0pGAeo54rH2TTNvapopDWbSZF3749w/jUjGemajnhjlUMoDEgZwc560+7gtp0PmIpYjGRx3/8A1VydzdXWg3JKnfaueS3RvXjsa15FbQzU22blwWST5RkDkYqhO+9WB4I7HtU1jqNtqVuJ4iFwdpU9uar3wAYuuM/zqXdK/QtWenU5GbxPZv4mXRYkkacEh34CqcZx71puBjBBrjNMtVt/ibqLSjBmgaSMkepGa7JmG33rO99TRq2xDIM+/wCNRSKCOO1Mu2eORWHK+lPDBlBGOc5qOth9LkBySeOlQyjn0qUkhivY1A5BAAJxSaGmQsRjnnNNC9wM8UpwOO9ICBgAZFQWhQwwOopswBUYGaGOH/nUbtsXjkZ/rSKKkrAZ28is+blTkfhWjKEYHHBPBxVKSMD/AGqXqMx7qI7iQMjrzWdc2wkU4A565roJYwRxVOSEFic4OalopM5ttNy2QxAPvQ0Pljg5H1rblQY+QYPfNZVzxyOvpUcqWxXM2Y9yGZ8VWHmIRzwOtaz7Cw3DBJ/Omyxpt+UYFTbUtEMF1lcOADVj7QNp2k496ptAM9SDTX+UbSWP0qIpsq5Ze5Gw9azry5BGS1BBGQScj2qpMm/PTj1oV9mUUL2QOPc9zXMapGCciujulIBB5FY2oRjFbU9EZ1NTnnXFR1fWyuLqXZbW8szk4CxoWJ/Kuk0r4Z+KtSwU0t7dDzuumEX6Hn9K2uYPTc4s0mK9Zs/gjrMmDealp8A7hC8hH6AfrWxb/A6AEG51529o7UD9S1OxPMu54bijBr6Dtvg34ehINzeajOR1AdFB/wDHc/rW5a/D7wjaoFXSIpCP4pZHcn65OKA5kfMccTyMFRGZj2Aya1tP8La7qEipaaRfSFuh8lgv/fRGBX09p1jpekBhplha2m77xhjCk/UjrVh9QUdT+tAcx89RfCnxY4+axij/AN+4j/oTVlfhF4mI5Fkp9DP/AICvdm1JSOCOKjGohh1FK4XZ4ePhD4j7yaePrM3/AMTS/wDCodfzj7VpgPp5r/8AxFe3m9BHJqGWWKYYY4PZh1FJyHqeLH4QeIB1udN/7+v/APEUV7HYagJXltZWzcQHBP8AeHY0VKncex8x0d6TvS1oIXvRSA8CigB2KenXJqOpOAvXmgC1HJggDjnsOtdV4Xb96p+6x756/WuOjfHHFdDoFyI5QeOB1NNGclY9i0OYyoVB24Pp1rttKkKDLHHb2ryzRL8echWUAMM8V3NjehkQM4DDnGa2TuczO9tZsx5z/wDWq7HKpdC3GK5e1ujhRnqM1eiushTnitVIzsdMlzlevGM5qzFdDywGf8c1zC3RQ84K1bt71SmOMVaqag4HQ/aCOpwR05pxuQec9uRWGLkE5DEYpftR9R7EGr5xch0C3IABzwOtJJcDqGB+lYX2sY684xSm7Djhs0vaIOQ2Guc4z26d6rXMqTxPE4DIwwVNZrXBAGTzjtVWS5weG/8ArUvaFchxniG5vvC+qC7tGaSxlYbkJ/T611Ol+IINX09LiFvlbqpGCDWX4kjjvrGWGU5yuVYHlT6ivMfBGsrZa8LDzW8uQsrKx4DdsflXNJ8rutmdMbSWu6Ox+Ik1xYTadr1kC7WTkSoD1Q9c/wCe9dHpuqw6pp8F5bHMUyhlz1HqP0rA1S1guriRZjI0c0O1lErAH8AfevPND1lvDeqTaPqN7eWtqCTE8eCFz0OGVsg1lflbRduZaHtEzhlw3Q8VEHCjaOg/WsSweZ7dJoNVNzE4yrTQoeP+ABKWeS/VGMMlm7DoGjdPwzub+VDfVog0WlXpmqs0jBSVHPWvN/Eh1C21lNX1KabT4UQKotpfPDSdgc7cA+pzSS+PL+F2E1hhM8fKwOO1JtLVlJX2N/QPFEuoaxdafeWy280WSuCTuAPv+ddMXOBgYryL+3HbxBDq9raFJdpRo2yqvxjrzzzXaaN4rjvpJkvY1sXAyrbi6n1zxkflU3TdrlvRXOqZuAR3qJ2z3rMs9Viu3i2tHskLYbJGMHGTxxn2qpqmrCObyIXH3jhh0POP1/pV+yfUj20TXLlSfT0qpKem0/hWbIbx3VjeOoB5VUQZ9s4zWadQ1fzrmOOKxkWJgFLSMpwRnspGfxqGrGidzbd+flOR6VXkfBzgD1qu9xPxhYySP4TWRe+I1tY5Xu7OdIYztZwuR9cDnB7HpUuLZSkjYlyclcZ+tZd0ME+9Z9r4tsLnBEV0u45GY8jb2Jx61YGrafd+WYrkESHanyMNxx0BIocWgUkyu/D8YzSum4c9B6GrMkKdVYEeuahCEg7QDnuDWThK+xrGS7lZ0YqWXoKqYLDgggHsa0WibOChz7iq3lYP3Qoz1Pas7NbGl0JY6dc6hcCC2jLNjr0Vfqe1dFaeA96Z1DUI4j/dhXf+px/KqNn4ht7CIwwhUx1bqSfXNLL4tjAyZgRW0aSa95nPKrN/CbEHgfw/C4a4nu7jHVS4UH8hn9a04NJ8L2WDFpdoWHRpV8w/+PZrhLnxSrA7JD9Kp2V7caxeeV58kUYXczJ1/WtIwitkRJyesmesHXrSCMJEyRoOAq4A/KoT4ghPSQfnXjWuRfZ5z5F1O4zgF25rOt9Uu4D98tj1NXJtaNEqCaume3S+IFPC5NV21qRvuAmvKIvFF5HwFjHuRmnP4r1A8LKqn/ZUUrj5D09r+6fn7v1NQS37rkSTqD9a8puPEeoyfeupT/wLFZs2o3MjZaZyfdqNx8p61c6usef9IU/jWZc+IYEB3XCD8a8uaWRjlmJ+pqaKZCCssalfUdaVtCkrHdDxVAkmftKMPYGrcfiS3ZhtlzmvLpABIQhytPWR0wVJFKzsPQ9TOvRY4kNNHiKJDy5rzP7ZPgYc4prXUzdWyKXKOx6Hd+II4L2G9ibnBR/cYorzl55HXaWJFFYzpOTumVddTGzzQOtJmiukyHdKM0maKAHL1FSGmR+tO70AOUc81o2bNDICrArjqDWcCR0p6sc5BOaaJd2djp2qNFKpzuUDHFegafqSXEEfkyAMoyyE815FaXDSOu9iTjFdLp188TLk4I+6yirTsZONz1ex1QbQQxJHBWtm1vwwGSRkdM157p2qxzgLIfnHQ9/xrUi1CS3k2Pnaej9qal5mfL0O/wDtYwrDkHrz0qaK62t8vKkZzmuStdShYDc+M/3ea0Ib5cAlgapMmzR063jKRyCBUkd3gYb8jXPxXm0c8jPXFSLd7jlWBHUetO4G79pyflzS+fg46A9KwzOyZI+YHpSLeofvNj6Gi40bou17tz2qlLcYbOTWf9o4Ow7sdBULznjg59KV2Ow7U7seRK2flCnPrXg+gyMvimGRSV3XHQ9ua9P8car/AGfot1KBufbtAPqeK8p8FQNd6/CxB2xZkf8Ap+uKU1dGlJ2uz2eS7EjxY5IBB5/z6Vl+IdFttdsgk+5ZUP7uVfvLVWOcrcqA3Ga1oJdyt1/CuanU5mkayVloc34ItdZ0LUrm1uP3lgwG1i2Bn1A+nUV3QuAwAJIxWYTkZOT3FKpOARnPuf0rXRGbd9xNYtI9T0+e1l5SRNvuD2P51xvhjWotFkl0XXlSMxsRHM4+UqfXPT2NdsuNueDkdjVHVNMtNThKXcCSKe5HI+hp+YLscn4gntNU8SabYaW0HzE+e0BHTrjI74FdGfCtqqA27zgjqGcHP6ZqPQ/C2m6RffabSJhMQQC7lsA+ma6eP5Tz19ql23L3VjCstFaytTCfMbg4YHpyTVOTTJZtYt4sZAkid/ZRvOfzrqz06801X2sGXb5ijAOOfpVc91ZmfsrO8TCSwnBtd0Ui4jmkbOeGJ4B/M4rKtvNigWZiw3i4uWHrg4AP4H9K7F55ipO9T+FZ8QW3iMUaZTJbG49zk1lbzNdTmjLcB7SFnDGVkRiRyfk3sR9a4r4iajs0tbeKRQZrp3lT+LC/Kv4YH516rNJHvDGH5l5ByCRxjjIrgvHGgS6hZQG0tzPcxyNwyqpKMScZz2Jpp2HY5bwdKTE0ryFXmkMSsW+VQF5/wrrNG2R2+5tsjhVYMOv7w8KKzvDmhz21u0N7p7b0dyjBvl5AHY+1dJpWlWaWsUcvmxOTE0meQCgHHT2rdVE9DncHdsVZQTKjKWEbMhPUcDJ/DmsvTNLtIZFuXgRLl18wKB8qAnjA7HpWpqNlb29jdC2uSzFZiBjkljkd/wAKbLaTMzvDMuGEQUHIwFbJqG1J3ZcbpWEnKTwlVm27gdrKQSOxI+lczDYwmZLi5v5wpUfIQwB9Mnp0xxWxPHdWtjKWK5jsxGDkcNzu/pWJqU7JqjxmBjGAFcqoPAAAwSp2/XI/Ck7PVlK+yNxIbWaISBIpYyOGA6/iKsR6LYPbRzMIz5hZfKSU7kxjkjHAOeOexqTTyqabbB7fP7sEn1JGato9v5a4idPxrSKg97GUnJbFL/hG7OY7YvNDHsCDUlnpUOlmdxITkY57VdUxDJV3U44471T1CESQrGs6x5OSW71ryxWqI5pPRnJa+D5g24Izkc81jMWx9w/lXYXuis8Q8u7hldhyoYj8Olc/deHtSEjGOHcueMOtZezbdzoVRJGNLJg88fWoWnUHlx+daMuiamv3ref8Bn+VVJdOuYsmWCQAd2Sly2WpXNcqNdR93H51G11H/ezWxZ+H9R1CNXttHuLlP78UDYP4rxV7/hX+uTEGHSL6MejquP1IP6VnzLdFXOXN2pHGfyqP7TgjANdlZfDjxB9vhW606RbYsPMcMpwvfjOaNd8Fa7Jcu1ro1wI84XaijjtwDSTuFzjvthzyhxTxdoR1I+orUfwf4iT72i6h+EDH+lVLjw/q8HE2lX6f71u4/pS5l1KsyD7TGeNwoMyH+IVBNZ3EJPnW8sZH99CKr7RmmmnsFmXvNA6EUVnlRnmiloA2gUlLTJDrSjpSA0qjJFAEyDC0tLjA+lJ3oAUc0qHBzSAcUoHFAizA4WQEVsWd0wXbsUc5BPWsNe3OKt2srCTJ59ulMlo7ayuFcKc4Pfd3roYJ0kRVdkxXDWd+CpBUn+lalreORuWJivcmmpJaGfIzuTbyQgtE++LH3R2q1Y3CugU8Edmrm9PvZ87QrAe561prN5yD5Cr+vFVdbomzWjN+OQoTtDEfpTkuSrdwDWLDdXELhJAzRHjr0q4LhJNvIXPFNMTRsC4BUZB/wpTIuCcr+VZOSuecD88VNBNtBJIb6U7iLYnO4Y6Gklm2qS0gxjv2qhdXqLA0j5j25PPp6151q2ralr1wYLBJfJcAFTgAH1zTTS3Gk5FTx/qk+o6v9kgmEsCYVVTux9fxrqPC+knSrEKwHnSDLnvn0pfDfhtdMTzbpEmuycl+u36f41vso5z2qX5l36IyLhnS5x26itawm/dcgms+6QSyYGQR39avWsW1AAOe9ccKbjVbWxs5XgaCyA45Oc9ql3Bjk8e1U0UgEYyPUdalXPY49VrqMSwOuVx7CkZeDjnI4NMUk8ADHrinptbqD7UhofAzJgcsferQkJHUDnFVlV8fL+tPXhcP9OKWxaZNk4Iz0qMlshqY24dPmB9aTzNoORkGpaLHnb1HU1TlXeWIByTUvmDPBNRs4x1I+tICrLuVsdW7k1C5Jb26ZqeY/N0zxVdzyW/SkMay9T1qGQkA8j2pxf0PHvUZBJNIorytkEDPHXNQMWJHyjHuKsynax71Xkbj+lQ5NPcqyI5UVkZGBZWGCDnGPSmPtC/OgYe4BxTHlWNSXYgCqM+twRMQFDH1IzQpS7ktR7Gok6gZKMAOM54FW49StcbiVz/tCuTk8RFnwGIzS3usRyoqFVOBjOKtVJIh00zqDfQSuAhTJOAAa0rKzguJALzIjXJyCAa4HQZFl1iFd4Aznk+1dstwYp8OTjPetoSbTbMZxsy1Ppdm6lZIhnopPWsa78PlcmLzF/3Sa1pr7zUbD8+gqnBczqSJpm2Y6UXu7DaaMux0a/mudi3skMQ6u/zY+gPeu40zTrCyKuGaeUdHlIJ/IcV5PceLZxcNyQueBmpoPGUgPzbsYzwetHM+4+Q9okvCFGxse3aqkmpSKeWry228YMfvM/51c/4SMSAEsefepbuCjY9COrMP4qQavk84+ua88bWt2SJCT9aYNYyf9Yfxo2KR6YmpA9WA/GpVvlbv+teax6u3/PQj8avW+r5UHeaE2OyO9Nyh68/jUTGE8+Uh/wCAiuUi1QEfM5/OrCaoOPmP51L1GdAY7c8+TF/3yKKw01MHvxRUtpDPm/NLmm0taCFzUsAy3NQ1YtRy1AMlxTcc1Jim45NAkABoC4oGacCcUACjnvVqJRkZAFVgKtQFeAxPHammSzZs2jUY3cduOa0bW+kiPzZb0IrGt5VifMace9bcNz5kaqVHPGRRfzJsbFpO8vMKMO+AOtaFsZDt8yN1PsDWRp0sqnKfLW1aXVxsGfmUnr6UKzFJNGmPnwJA4X1INIE8liMZ564psfnSEEscY4zUyo4z+9OD/DWjIRJHkkh+B78U2RWRz5QBY988U9og68t+fSnldqjGCB0NCQFBtMN23+lzsy5zszwK0La1gtE2QxIi9QFXFINhzyfqKXfk7Rn6mnsLce7EHjp7VC5zwDjFK2c+hHFMkYBSf0FSykVTjeWPzetXociPqMVnIQrMRkAnmrcMgG3ZUop+RdDYA5yc1OuMcLgdapoxI4J/KrETjIABx3oAsgFjnC4PQ55FSBGIyDz3zUIbHCgEe/SpUbHUDJHOOlFhjwxLYIzntSgYOckcVG2OMgD6UqbWU5z170rjQrJ3HHrg1HIM/Snk9feoJWwDk1LZoiKR2HXFQNKSPUUssgxnPJqqWyx60hkjy5PB+lMZgV+YYphG1c5FROSRxS2GDuCwwR+NRuwA4/yKaRt5xx6VG8hYbcYqWAszFjxVZx6HGR0qZOc+lD4/DHWoepaOS8S3EkciR7jtC5rDW+iRcMoY+tdbrFkl6oGcOOhrkLzS5oZCGQkeo5FWmtiWmU724R2Ji4qqLiTPWrLWhHUGlFp6Bj9BVXQtSOO7kU8d60rTVJ41+aRj6ZOcVBHYSEcRn8eKc1nIo+ZlX6c0KwWNq28QyQDJAJHc1WvfFdxICFbH0FZkWmXFzMsVvHJK7HHA4/E9q6Gx+H13Kc313BAvpH87f0H60077CaSOTkcXILqRu7iqEm6M5HbtXrem/D/Rk4ee4eX+8xAH5UzVvhgksLtp97iTqqyD5T+I5H61Sv2J51ex5Ot669OKeupSjoa2NY8F61pbkTWUkif34B5i/pz+dc/NA8LlJEZGHBDDBov0KLqarKB1NTLq0gwS1ZIXrSFadxWNxNadf4jViLXSowGOK5nFLj5aTQzro/EWMfNVlPEZH8Q/OuI5oyaLAd/H4h4Hz/rRXAh2Heip5QIRSg03vS+lUAv1q5ajEefWqY61oRDCKKTEx3amsOtOpKCRuOPenD6UnIan07gGDUqHmmCpRgcjrTWmrEaNkUzhgDx0rcsoCVzsyPQmucgk2AEA59a2LDUpYXAXoeDnmk33FZ9Do7YIjL19614FQjl9ufTpWHEdwBx71o2kjD7ik8dzTTs9SbXNqLqOelWQikAsaz4ZzjgANVpJX/iXA+laXIJQAjEZNI0hU8jC5qF5QT/FimSZ25BJ9j2padAsWfPQkAr+NNaQDIB49DVNmZeGGB2NOL5+vQ0J9x8pM82QeuPX0pHlAjY9SOM5quZT6HFV5pBtOGx268VEpFqI+SYsDg5+tSWkrEbd34VkGY5NSWU5JwCOnbvUXLsdBHIcjP8AOrSsDj+h71jrMyITwRVu3mDKCf51VybGtE/TuR3qRJVU4YDjvVFZD/wIUvmH0ouUkjR8xWGM4P8AOoyxB6/rVISEMecYpBPlTk0myki2XYqDz+VRyy8fMSABVYzfNjnjvUUkvBAOM9qV2Mc7ZBKn5ccVWYORnJwO+acHzx2+tBIyAPunrRcRE0gUEMT0701pRj5Tk+tLLGpB9fSoHAX04qHoMRnZyecg96jzwR096eQODwfamuwUE4ANQ9WXEY5wp64z1qKWX0OR/KmSScHnioC2V647VLVixWYZ5P0qGUqpx1c9Ka8gXtzURcZySDQt7DsQXA8wkY5qOOykmcJCjO5OAqjJq3aRfaryOJTje2M9a7/SFtNNiCwoN/dj1NXFSkZzkonOaT4C1K7iD3Mkdqh7ONz/AJf/AF66K38BWVnHumIupe7SLx+ArU/tlFB+YfnUM2vKB98fTNaRppb6mLnJmbd2P2WPZHCqoOm0YArGfzY2yH49M1qajrsPlvll6etcJqviFUY+Ww/OrasEdTqo9QSP/WHBq5H4mhtvvSAgdia8nutdmmY7Tj3zVGW+kfO6Qn2zSTfQpwvueq6p49gRT9nj3H1zgfnXm3iPxHLqlw7SkMuflHBArEmud5wz4A7Zqu0in7gLH6U7u2rBRS2HuHKl8qP9moBIcfMBTxb3jruEMm312moJYZR98EfhQMf5y/3f1pPNXHOah2UFBQBMZY/Wk81PU1DsFOQDOGoAnUqV3djRQRhQB0ooAr0A0MNvWkoAlgG6RRWgKpWa5fPoKu96TJYuO9FOUcYoPSixFxAPxpyjHUUKCKevTnrRa4XAL+VP49KFGKkUdODVNaAh8Y4wcYq1EnAI61DEvsMVegjzgqefSk2UjWs53VQHGR2rcsSZh8pXI7GsmzCPEwH+s6c/4VpWxmg4CjHXiknqS1c17eMn5cAEHt1q6sUmMrk461RjZjh0wD3GK0I2ZvmJbHtWq1M2iJ0faTUa7kHzZI9c9KuOVIIy2feq7nqO/rRoCK8rDoWGaaWB4wM4zxRcHAOOapNIQMjA+lQ5a3LS0JpJPm9D3qhfXCbQucOTxTnmVufm59ay7uTJwp3Y7ms5PQ0iiVJgUOT+NLaSfO2Cf8KpNJlT2JpbNjuyDzQtFqNnQxSZUY61cVwSDx9ayYJMfezg96uKPlyrAe1O7FY0Y5cEZLenWn+f2BrJkuCASwJHYioo7va3zN17mpcikjZeTcODjjtUJmZeCc1WSX3PNSFg2OCaTkkOw/7V6kinb85Oc/SqjsBxzSLJ2PP41PNcLF1JQB14pXkBbII4qmJFZdvSkY570+YLFhp1Y8Mcjriommxnd096gIxlh1PWopHweeaV2x6Fp5Ocg8VXmbccgnFN3HsAB3pjBsHHFSUiF25PtTN3c/8A6qc4IOR+VMZjzmjdlXGEluAcVC+AcZHpTXOFxkknnio+cZPPpSEhJ5XhQyRNhhzxVf8A4Se5j4fJNP8AvZLdOlUrqwSTODg+natIMUlfUfL4tk75/OqNx4nkcfKWH41Xl0pif9YuKjGkoM7nJ9gMVonchorXGsXU2RvbB96o+aznA3Ma1LLSXvL5YVwiZ5JPQV3Vlo2l2Kgois4HVuTTbfQWiPPrfSdRuhlIWVT3Nbml+C57p1+1XkcSdwMk10t5dwwghWAHbFYlzrYiP7tufWp1Yzq9L8C+H4FUzO9zIByGOB+VdBFp+jWkey3tYE2/3UGfzry+HxHIrbjKce1WU8UKoJaQ5qkkuhDTfU7LVfs5UhI1x71wmvWMTI7DANQ3/ilpAQjED6Vg3eryTZBYmqGtClOgVuKrng055S5pmCaQxRRS7SKTBoAkjkxw/SiojRQBZlj3DjrVUgjrWgRwagkjyPegSH2Q+VjVnpUVouIhn1qTIpEvckUin46+lRA5xUy8jmmiGKAMU5R2oUcc1Ki5NUlpcVxESpljpyLU6JwM80SZSGpHjpVmNT1zTQvGMcVPCDkZ/KpZSNW0xLt5KkDqK1LcsFCs2cd6z7FWUhlBx6gVsoiyoOx96SEy3bqCQQ/NXEJQjJJB7VmxLJG3yAkeo7VeR2xtIOD3NXF22JaLRdiuMcD05qGYFeeRk08OQBjjPYUO/q2O2Kd7klJ2J64+pqgzxF3VJFLDqM1pXCnGe/asmSALIzhQGPcDmpejLWpRu2IPJrLklLHGT161o3wGD24rHz82e2ayZqkSyHC1PYylSOfxqmzcZJpYXxnB/wDr0vMDoDIuwNTkuAGGQKzYZGC8Z+gpJJAAc9PftSeo0aMsynOefbtSIFfoOtYwv0QgyMCfStK0uIp0yrbTUN9xpFyAOjEZ+X1q4G+XjgehqlFJu4/OnFsEKoJzRe+lhsdLMA2GJyKrySZGF6Uy5ztz1x2qFH3LgginpsBdifHBzVkNu+tZ0bEsM81OJBRYC3x0B9qjkTdmo/N460okJHrTQhAhHGeKlZQR+tQ7zkNkZ74pGlx+NK4wlGz8elU3bnAz61NJIpAAP1quxH3hRfUaEYDHrVdsE9eKdvGDnp2qF25yevSluwFbHPtULt8pJPJoZSwwMY+tQMccdapJlEcxBJwMVDuIYE9B2p55Y46elMkHHzNzWi0IepDKzxNvhYjvVGXVLwZHmGrczZ6GqMy+uKtLqTsVpdQuX+82aqPNI3U1JMSD2FVXkbFMQu5/WkJPdqhLE9SaSkBKWUd800uOwqOigB5kPoKPMbsaZRQA/wAx/Wje3rTKKAHb29aKbRQBr00jIqQikP8AOgkUDCCmsacRgVGxpCJEapkbnpVMVLG/NNaA0Xl59cVPCBn2qpE2evSrkByaozLMSEnOKtLHwOlNtwMc9auogbGKT0GtStsxzipoV5HXNWltyRxUkEBVxx+dZORokWbOJgRtJC1t2iYXBAb69qZYRjgADH1rZt4ECbu9aRREmQwoGOOn0GKkeHZyoJFWfKwePlPXmnAPt5wfwq7dyLlZVwMdfWleMBckjGeg609kIJOenUDtQyNk8nBpDIGTcMnGKoXEeW45U1pkMuOhqpIrDORxSlqUjnNVjJP4VjtFge9beo/60g1Q4HUVg3qjVbGPP8uc1HHIV7VoXEYP0NVhAWHA49aoC1b3QRMk4qvd6koYbuT+lV5baZziPnHpSwabhwbjcQDnFS9BpEVwyhfMW2YrnIY0tpfuJAUUKuOgGKs6jqkS27xRwMwHp0x71zsN44j+UAD6dKVrlJ23O1gunEm4lcMM4FXRMWG8HH0NcPbX7/xEbRxV5dYVV25/WjlYNo6WeUncd2Pxqt5wztzz71hLqQZwRyanF2pGQeT602hI2klAPUYqTzuOOlYiznjJOBU32hcDaQTQk0gbNUz/ADdc1NHKccnFY8cpVc5/CpDMQMk47YqUrAajS7RjA/rVd3Zs85qmbjHWkWfJJNPcZZ3EnJ5FNd+CAMCoDLwWzxUZlAB/Wk9AFLHjJzSKd3NM3Z6DHrS7gAMU7ajHO4VMYxVV2GMkfhTpmBySeQKqcs3XFVGNguOLe+MelROeOacUGepxUMpyfaritBXG9iTVOdsAnPsKtMcLk/hWbcyZNWQU7lsnnvVNutTzHJ5qBqQDaKKKACiiigAooooAKKKKACiiigDbIppp5GKbQRcWQfLx3qFh+FWW+6pqKQfzoBMh9jSpnd7UuKVR+NAyxG3rirMUm01SBxTVkaRwkY+Y007Ii1zSkvxCBzTYdadG5zivSvhl8HL7xJBDqepTxW1gW4B+aSQey9APc/lX0jbeDPDcdmlq+j2bxIoUCSIHIxitFSqVFdL7zGeIhTdt2fKHh/UIb3CEjdXSiwBGRz3r17xH8DfDd8r3Hh8Po+odVaMloifQoTwPpivN2stQ0bUn0rXbcw3KZCvj5JR/eU9xWMouLtNWNadWNTWBUtYtvGPzrUt4vkIPFMaPyycUJPtwD/8AWprQpq5bUA4+b8T1pe2UbA6ZI5quZB1J+gpr3GzuMenrVXJsWQqgnqfXNRGQchQMUwzgr0J44waieQhsnoeo9KAsSSKGXcO3NU7iUbCSKlacbevQGufvr9TvCnocGpbsUlco6lLmU89apLnp1qOSUvNmn7uOmawbvqbWshsyjblulVt+TgflVpvmWo40VWy3NV5ElywszOM/drR+wiJwHO4E9cZqvYXAjPPC+ma0pbxJI6lq40ylrukINNmFsiguhBcDp9favJfMMchR8grwQa9pi1EoowVI+gryvx1CsXiGRkAAlUOcdM1pDW4jOMoxgGoyxJ4qCPNTL+VWBYhkKjA6mr8MhAGTk+1ZiNjpUyT7amwGupbq749Bmnxzgng5+lYjXTu2M8VNHME4Bp2A21uCuctUiTgdyTWIJyeen1pxuSO/NLl0Hc2zcKBknNNE5POeD+tYyTknPUe1T/aMYycn09KTiFzUefjqBTBMSe2Pes5Zt+c9BT1kz06etFguaImwvFBl2rz1qmJjn5aXPG5jxmiwXJTJ6kYpgJJ4zTBy2R0FSMQB6+lP0GhJGKr15qsXA5PJokclsZqCVlA461UdhMbPJnOTWfK2SamkfPFQMO1MRVkBqE9TVmYflVZqQDaKWigApKWkoAWkoooAKKKKACiiigDoGXvURFWGFRMKcjNCryoprDjFPi6EUjjk0hdSDHemlhUjjjmus+Ffg9/GHidLeUMthAPMuXHHHZfx/wAacU27IHJRXMyj4d8Hax4k8v7BBiJztEj8A+uPWty68Eav4D1qwuNSSOZbndFHsG4gkY6HvzX1X4Q8P2dpIstvAkdvCgigUDhQO4rzH9pWW5tbrSLiIELDJuj+o5rWpS9lHmb10OWliJVanIloze01b3RfDtrCyvGVUHr3PJr0DTdQ821RmOflFc/4W1W08X+DbK8wpkKASL6MOorR0qEbhGPuIea9CKa22ONu91Jao6uxP7rzG/i+6Kp+JtDtNe0uS1vIwcjKPj5o27MDVm2c4HHQcVczkVjUjfRhB9j5Z1VpbK7ltblTHPCxR1PYis4Xg6A5PtXsPxl8Gvqmnvq2kwltRgGZETrNGPbuR2r5z+2sshV8qwOCCMEV5tROEuVnr0ZqpG6OvW7Yjg/4VJ5wZTkjj1rloL/dwXP51oQTFjy3B44oUmW0atveMZmRguzsc81JLMzY6DmsqIKJs5DD19KvTSL5W5eT0A96Tk0h2Vx0oJHBPPYck+wqSXwN4huU3x2Cxg84lmUH8s13HgfQY0WK8vYw9znKBuRH9Pf3rupsgYHSnCi56ydjKdfkdonzRrOgatorE39lIkYGTInzoPqR0/Gs+J9/XpX0TrNuZI3GNwIwQehrxLxnpH9l3Xn2qbbeQ4KDoh9vaonSlDXcuFVT0Zjyuir1qk045HOfaoppiRg1UZmByD+tCWpoaa3B461IbxcffOfrWI8sinI6GmrdL0k603C4rmt9pxj96APUHNcn4nkSTURsfeAgyc55qxcyICWilwfTtWLdSGW4ZiQe3FVGNtQbuNQ1KDUK9acDVCJt3FITmmZpc0AODY6Gl3kHNR54pKAJTKx70ock47VDTgQB15oAuxttAL/gBUokLkAAf0FZ5lJp6yhRxnNKwGhvC/eJPtT/ADcgc9e1Z6FnPrVuFcDJ6Z6k0wL0RAXk4/maXdu5OQBVcMxOeg9alXO3rxUsZYDjGFUY7mmSyAAYpuTj6VBK5z14FNLUAZ+CT1qrIx/Old+c9qiZ8c4yae4hCfmFIQDznFITgc1BNJgcGmBHO3zHHSq5OaVjmm0gClooxQAdqSlooASiiigAooooAKKKKAOkao25FPNMbpVsxQkfBI45pWx1NNU/NSP0NSHUa5BFevfC3xFbaN4MmtLNc6nd3GJTjomQAAf89a8g4xyRmuk+HsgHiaxjkP7tpVBHrzx+taUpOMtOpFSKlGzPuDRSBpcJ6HYCa85+OOmDWPC6XP8Az6zKM+uc12EVw4trdIDzjOPbFRePrF734fX0dom6b5XCjrkGuzExXs5HmUW41E/M8B+Enib+xdT1HSpCTBIvmx+zDr+le6+H73z4UZehwT718kCSa11eaRSyzIenfryK+h/BerxPp9qolTJRSw3cgmowlXmpq/Q68XTtO/c9ZtpRjj86uKe9c9p12rgAMMVtQuCO5ronHqjiWhJKoYda+a/2gPCU2na2NdtIibO8wJtowElAxk+xHOfXNfShcdw35VR1C2tr+2ltrmOOaGRSrxuMgg+ornrUvaw5epvRq+ylzI+I4H59607Wcce35VvfFbwFdeDtTa6tUaXRZ3/dS/8APMn+Bvf09a4eO5IYeme1eck1pY9aMlNXR0LXRHC9MjrV7Qbj7RrFnCxyC28++KwTOhhJfHAqLwpqIXxGrk4RRgfnQlqrj6M+mNFI8lMVrNkjiuW8NXyTWyMDmulR8iuxbHC9GQTrkEY/SvPfiVozXGhzyQZ3RsHIXrgHmvSyAe1U720juInjkUFWBB9xUzXMrBF2d0fKlwjoP7w+lUGcBiDxXo3xC8HXOhA3drulsGY5wDmL6+3vXms7/N0z71zLsztTUldEpZSOP1qCZTj7oIPcGkDA8Yz9Ks27oDg8H0IqmBiTwTBGaTO1azRXQ63On2VlQYZjg81zwFAxwpwpozSjPpQA/NGabzS0ALRSUoBoAM0lTRW80vCRk1dg0tiR5zbe+OpouBm8ngVatrKSUbmG1PU1uwWVtEgAQF+uWwT+VOcxL1UMw/GktQM6GBEH7sNI3qRgD/GiRNnzO2T2z/hV0vJOcRr9Sv8AjT0sgCHlIY+lJgUoo5JfUD2q0qrGgyATUspI4GBVaWUL0wTTW4CSPgHn8qqO27inSS7u3NRZ2/Wi2gCMe2OabwBzQW5JJqvPLnimgEkfqc8VTdtxJp0j54qOgApaSloAKWkpaAD60lLSUAJRRRQAUUUUAFFFFAHROaiZqV2qFm4qmzJIerfNQxPtUSt84+tPkOD1qB2GnkVt+DBE/iKySfcIzKudpwawiw6Vp+GXCa1asTgBxVw+JCkvdZ9m+FCzBW3mSMDajH0967RIRJbvEw+V1IIrg/Bd0hsoVU8BRXdQSgLwc16klpoeJLc+QPinpy6D49u0ZSIJWyP+Bf8A16vfD7VJ4JDAIwUVuu4A1q/tL2rLr0NxgbXXb+tec6FeNHf2k0ZOJMBsevevNovkm49metJe0pRl5H1P4euyY1ZlPT611dveDjOa898Ks72sRII+UHk12NqOBk16UWec1c6FLkEYokKSD5gKpQ1YXGBRyoRR1TTYtQtJrW6jjuLWVSrxSDIIr5f+KXgX/hEtYDWUcx0uf5onIJCHuhb/AB7V9WsxA4BNZ2oQ295C8F1As0TjDI67lI9xXNXoc+sdGdFGq4PyPiC/udkLIvBNZ+lXHk36MTjPFew/Er4N6la3D3vhhHvrSSQ/6Ko/eRA9Mf3h29a84uPh94tgI3+H9SB9oCf5Vwu6dpKx6MakZK6Z6b8PNbYyLA7c54r2G3bKg14f8M/CHiJdRhl1PT5bO3jILPPhS3sF65/Cvckj2DArejdrU5q7XNoTg8U1yAMmoiSKa0hrVoyRHcwiVDvZwD2DYzXk/jD4UJfXsl3od5FbNISzwT/dJ9VKjj6Yr1ZmBPU0zispQTNYzcdj5qu/AfiazkZW0mWZQfvwkODjvwc1mvaz2jiO8tJ7dweksZUj86+pSeKilRZVKyAMO4IyKzcGtmaqr3R8neKGQwRIqgOG59650LX1Hr/w88OavG5kshbzEHbLbkoVP0+6fyryDxd8N77w8n2iOVbyyzzIqlWQf7Q/qDUu8dzSM09Dz3ac05Y2OODW7b6UHYDrW1ZaEh6gVLl2LOOjtJX6Katw6PPJj5SM+1d9BpcUSjAUN7irUawx8Mq5H0pOTHocRF4bkJG84+pq/H4bdDwjP9FH+Ndak8W4bFGe2KsJcAKSRx6dKPVgcn/YsyqAYWX0y2P0FINJuV42MB67cfr1rq5LoJjqao3d25XAU1Lduo0c4+mSgsC6qOvIJNRGwAPJeQj2wK1JXc8vVWW5CA4ovqMiS32j5iFHtUdxKkIJByfWo57stx61UZwxye3NWkIilmZ+2Aart0qSSRarPJnhabRI4nAPrUZNI3GSxzVWaUk4FMB00oBwO1VWYk0jHmm0AFKKSnquaAG4oqTFNNADaKWkoAKSiigAooooAKKKKACiiigDYZqiY4oopkIaDhhViTj8aKKlje5CRmprF2Sbep5HIooqo6sUtmfQvwh8WC4SOCcnf06H0r3vT5w8YIoor1KL54XZ5GKioS0PGP2mNN8zTbW8QcrJg/iP/rV4R4QRp9ThgyeJAw/PmiiuCf8AGaOzDu+HPp/wxHi3jx2AFddbLyKKK74nGy+smBxTw5x6UUVbEhrSN6momaiioZaIZJSc4JxVWRuDmiismy0ipL14qsxx3oorNloiY1EzUUVDLRGTTGIFFFSMazUhbrRRQNEZIqCdUkQq6hgRyCOKKKhlI4/XfA2m3itLYqLO5PRkHyH6r/hXnGqQT6TqE1lclDJGeq9COooorGpFK1janJt2ZX+0uc4PFNSc5JyT7GiioehsSrdAYJ/Ska/UDIzxRRVLuBG2oKwyCfrimSXwA+br7Ciip3QylPdlwTzisuaQux25Aooq+lxFWQ7TyaryTdhRRVCIix6nJphmCiiikBXlnZqgLE0UUwEpKKKAHIMmpwOKKKAGtxTDRRQA00lFFACUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The point of needle entry is between the lesser and greater tubercles of the humerus, 1 inch (2.5 cm)&nbsp;below the anterior corner of the acromion. A 1.5 inch (4 cm)&nbsp;22-gauge needle is inserted perpendicular to the skin to a depth of 1 to 1.5 inches (2.5 to 4 cm), and&nbsp;1 mL of lidocaine is injected into the deltoid and 1 mL into the bicipital groove.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14144=[""].join("\n");
var outline_f13_52_14144=null;
var title_f13_52_14145="Carbimazole: International drug information";
var content_f13_52_14145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbimazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Basolest (NL);",
"     </li>",
"     <li>",
"      Carbimazol Aliud (AT);",
"     </li>",
"     <li>",
"      Carbimazol Henning (DE);",
"     </li>",
"     <li>",
"      Neo-Mercazole (AU, CH, DK, FR, GB, IE, IN, NO);",
"     </li>",
"     <li>",
"      Neo-Thyreostat (DE);",
"     </li>",
"     <li>",
"      Neo-Tomizol (ES);",
"     </li>",
"     <li>",
"      Tyrazol (FI)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antithyroid Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperthyroidism, thyrotoxicosis, and preparation of patients for thyroidectomy.",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 15-60 mg/day taken as 2-3 divided doses until thyroid activity returns to normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance regimen: Gradually decrease dosage to maintain normal thyroid activity. Maintenance dosage can vary from patient to patient in the range 5-15 mg/day. Therapy is usually continued for 12-18 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Block-replacement regimen: Dosage is maintained at the initial high level (ie, 20-60 mg/day) and supplemental thyroxine (50-150 mcg/day) is also given in order to prevent an underactive thyroid induced by the high carbimazole dosage. Therapy is usually continued for 12-18 months.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 5 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10350 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14145=[""].join("\n");
var outline_f13_52_14145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304143\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978111\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978114\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978107\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821226\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978113\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14146="Patient information: Tricuspid stenosis (The Basics)";
var content_f13_52_14146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83897\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"           Person having an ECG",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tricuspid stenosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tricuspid-stenosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2365516871\">",
"      <span class=\"h1\">",
"       What is tricuspid stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tricuspid stenosis is a rare condition in which 1 of the valves of the heart, called the tricuspid valve, doesn&rsquo;t open fully. The heart valves keep blood flowing in only 1 direction. When the heart valves work normally, they open all the way to let the blood flow through them.",
"     </p>",
"     <p>",
"      Blood comes into the upper right heart chamber (right atrium) from the body. The blood then flows through the tricuspid valve into the right lower heart chamber (right ventricle) (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). In tricuspid stenosis, the tricuspid valve gets stuck and does not open fully. This makes the valve opening narrow. When this happens:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood can get backed up in the veins leading to the heart",
"       </li>",
"       <li>",
"        Not as much blood flows out of the right ventricle",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2365516920\">",
"      <span class=\"h1\">",
"       What are the symptoms of tricuspid stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with tricuspid stenosis have no symptoms. They might find out they have it when their doctor or nurse hears a heart murmur on a routine exam. A heart murmur is an extra sound in the heartbeat that doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p>",
"      When tricuspid stenosis causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Belly pain (because an organ called the liver gets swollen)",
"       </li>",
"       <li>",
"        Swelling in the belly, legs, or feet",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with tricuspid stenosis also have a problem with another valve in the heart, called the mitral valve (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"UTD.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). Mitral valve problems can cause trouble breathing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2365516952\">",
"      <span class=\"h1\">",
"       Is there a test for tricuspid stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for tricuspid stenosis and see how severe it is, your doctor will probably order an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Your doctor might also order:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A chest X-ray &ndash; This can show the size and shape of your heart, as well as changes in your lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2365517007\">",
"      <span class=\"h1\">",
"       How is tricuspid stenosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and how severe your condition is. If you do not have symptoms from your tricuspid stenosis, you might not need any treatment. But your doctor will follow you to see if your tricuspid stenosis gets worse or you start having symptoms.",
"     </p>",
"     <p>",
"      If you have symptoms from your tricuspid stenosis, you will likely need treatment. Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Certain medicines used to treat heart problems &ndash; These usually include medicines called &ldquo;diuretics.&rdquo; Diuretics help reduce swelling by making you urinate a lot.",
"       </li>",
"       <li>",
"        A procedure to open the tricuspid valve &ndash; For this procedure, a doctor inflates a balloon in the narrowed tricuspid valve to try to open it. Doctors call this procedure &ldquo;balloon valvotomy.&rdquo;",
"       </li>",
"       <li>",
"        Surgery &ndash; If medicines don&rsquo;t help enough and a balloon valvotomy will not work for your situation, your doctor might do surgery to open or fix your tricuspid valve.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2365517022\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/52/14146?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83897 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-ADE86C94E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14146=[""].join("\n");
var outline_f13_52_14146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2365516871\">",
"      What is tricuspid stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2365516920\">",
"      What are the symptoms of tricuspid stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2365516952\">",
"      Is there a test for tricuspid stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2365517007\">",
"      How is tricuspid stenosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2365517022\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"        Person having an ECG",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14147="Nystatin (oral): Pediatric drug information";
var content_f13_52_14147=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nystatin (oral): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11539?source=see_link\">",
"    see \"Nystatin (oral): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=see_link\">",
"    see \"Nystatin (oral): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9490173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Nystatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral candidiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylaxis: 100,000 units/dose 4 times/day divided as 50,000 units to each side of the mouth (Ganesan, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment: 100,000-400,000 units/dose 4 times/day; one study of 14 patients (neonates and infants) found higher cure rates using 400,000 unit/dose 4 times/day (Hoppe, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11539?source=see_link\">",
"      see \"Nystatin (oral): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral candidiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 200,000-400,000 units 4 times/day or 100,000 units to each side of mouth 4 times/day; one study of 14 patients (neonates and infants) found higher cure rates using 400,000 unit/dose 4 times/day (Hoppe, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults: 400,000-600,000 units 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intestinal infections: Adults: Oral: 500,000-1,000,000 units every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9490278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding: 50 million units (10 g); 150 million units (30 g); 500 million units (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100,000 units/mL (5 mL, 60 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500,000 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9490174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake suspension well before use; suspension should be swished about the mouth and retained in the mouth for as long as possible (several minutes) before swallowing. For neonates and infants, paint nystatin suspension into recesses of the mouth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible cutaneous, mucocutaneous, and oral cavity fungal infections normally caused by the",
"     <i>",
"      Candida",
"     </i>",
"     species",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9490168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nystatin may be confused with HMG-CoA reductase inhibitors (also known as \"statins\"; eg, atorvaSTATin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), Nitrostat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9490196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10503641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nystatin or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9490199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9490191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adverse events in the fetus or newborn have not been reported following maternal use of vaginal nystatin during pregnancy. Absorption following oral use is poor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10503668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     KOH smears or cultures should be used to confirm diagnosis of cutaneous or mucocutaneous candidiasis.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to sterols in fungal cell membrane, changing the cell wall permeability, allowing for leakage of cellular contents",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10503664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Symptomatic relief from candidiasis: Within 24-72 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10503665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Poorly absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: In feces as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10503669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=see_link\">",
"      see \"Nystatin (oral): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if irritation or sensitization occur during therapy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dismukes WE, Wade JS, Lee JY, et al, \"A Randomized, Double-Blind Trial of Nystatin Therapy for the Candidiasis Hypersensitivity Syndrome,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(25):1717-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14147/abstract-text/2247104/pubmed\" id=\"2247104\" target=\"_blank\">",
"        2247104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ganesan K, Harigopal S, Neal T, et al, \"Prophylactic Oral Nystatin for Preterm Babies Under 33 Weeks' Gestation Decreases Fungal Colonisation and Invasive Fungaemia,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2009, 94(4):F275-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14147/abstract-text/19036756/pubmed\" id=\"19036756\" target=\"_blank\">",
"        19036756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppe JE, \"Treatment of Oropharyngeal Candidiasis and Candidal Diaper Dermatitis in Neonates and Infants: Review and Reappraisal,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16(9):885-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14147/abstract-text/9306485/pubmed\" id=\"9306485\" target=\"_blank\">",
"        9306485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman DA, \"Challenging Issues in Neonatal Candidiasis,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2010, 26(7):1769-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14147/abstract-text/20513206/pubmed\" id=\"20513206\" target=\"_blank\">",
"        20513206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16028 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14147=[""].join("\n");
var outline_f13_52_14147=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490173\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443926\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503666\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490278\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490174\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503667\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503640\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490168\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490196\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503641\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299777\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490199\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490191\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887304\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503668\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503643\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503664\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503665\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503669\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11539?source=related_link\">",
"      Nystatin (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=related_link\">",
"      Nystatin (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14963?source=related_link\">",
"      Nystatin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/55/35700?source=related_link\">",
"      Nystatin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16771?source=related_link\">",
"      Nystatin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14148="Chronic obstructive pulmonary disease (COPD) treatments";
var content_f13_52_14148=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/52/14148/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14148/contributors\" id=\"au1818\">",
"       Stephen I Rennard, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/52/14148/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14148/contributors\" id=\"se5969\">",
"       James K Stoller, MS, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/52/14148/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14148/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/52/14148?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     COPD, or chronic obstructive pulmonary disease, is a condition in which the airways in the lungs become damaged, making it increasingly difficult for air to pass in and out.",
"    </p>",
"    <p>",
"     There are two major kinds of damage that can cause COPD:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The airways in the lungs can become scarred and narrowed.",
"      </li>",
"      <li>",
"       The air sacs in the lung, where oxygen is absorbed into the blood and carbon dioxide is excreted, can become damaged.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When the damage is severe, it may become difficult to get enough oxygen into the blood and to get rid of excess carbon dioxide. These changes lead to shortness of breath and other symptoms.",
"    </p>",
"    <p>",
"     Unfortunately, the symptoms of chronic obstructive pulmonary disease cannot be completely eliminated with treatment and the condition usually worsens over time. However, treatment can control symptoms and can sometimes slow the progression of the disease.",
"    </p>",
"    <p>",
"     This article discusses treatment options for people with chronic obstructive pulmonary disease. Treatment of suddenly worsening symptoms, which often requires hospital treatment, is not discussed here. A review of the risk factors and diagnosis of COPD is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHRONIC OBSTRUCTIVE PULMONARY DISEASE MEDICATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications that help open the airways, called bronchodilators, are a mainstay of treatment for chronic obstructive pulmonary disease. Bronchodilators help to keep airways open and possibly decrease secretions.",
"    </p>",
"    <p>",
"     Bronchodilators are most commonly given in an inhaled form using a metered dose inhaler (MDI), dry powder inhaler (DPI), or nebulizer. It is important to use the inhaler properly to deliver the correct dose of medication to the lungs. If you do not use the inhaler correctly, little or no medicine reaches the lungs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There are several types of bronchodilators that can be used alone or in combination. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"      \"Management of stable chronic obstructive pulmonary disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Short-acting beta agonists &ndash; Short-acting beta agonists, sometimes called rescue inhalers, can quickly relieve shortness of breath and can be used when needed. Examples of short-acting beta agonists include albuterol, levalbuterol, and pirbuterol.",
"      </li>",
"      <li>",
"       Short-acting anticholinergics &ndash; Short-acting anticholinergic medication (ipratropium, Atrovent) improves lung function and symptoms. If symptoms are mild and infrequent, short-acting anticholinergic medication may be recommended only when you need it. Or, if symptoms are more severe or more frequent, it may be recommended on a regular basis.",
"      </li>",
"      <li>",
"       Short-acting combination inhaler &ndash; A combination inhaler that contains albuterol and ipratropium (Combivent) is also available. Combination inhalers may be used just when needed or regularly, depending on the frequency and severity of your symptoms.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Long-acting treatments are often recommended for people who must use medication on a regular basis to control COPD symptoms.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Long-acting beta agonists &ndash; Long-acting beta agonists may be recommended if your symptoms are not adequately controlled with other treatments. Examples of long-acting beta agonists include salmeterol, formoterol, and arformoterol.",
"      </li>",
"      <li>",
"       Long-acting anticholinergics &ndash; The long-acting anticholinergic medication, tiotropium (Spiriva), which is taken once daily, improves lung function while decreasing shortness of breath and flares of COPD symptoms. Aclidinium (Tudorza), a long-acting anticholinergic that is taken twice daily, also improves lung function. This type of medication may be recommended if your symptoms are not adequately controlled with other treatments, such as the short-acting bronchodilators.",
"      </li>",
"      <li>",
"       Theophylline &ndash; Theophylline in slow release form (eg, Theo-Dur, Slo-bid) is a long-acting bronchodilator that is taken in pill form. Theophylline is not commonly used, but may be beneficial to some people with more severe, but stable chronic obstructive pulmonary disease. The dose of theophylline must be monitored carefully by blood tests because of its potentially toxic effects.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids (also called steroids, although they are very different from muscle building steroids) are a class of medication that has anti-inflammatory properties. Glucocorticoids can be taken with an inhaler, as a pill, or as an injection. Inhaled glucocorticoids may be recommended if your symptoms are not completely controlled with bronchodilators",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     if you have frequent flares of chronic obstructive pulmonary disease.",
"    </p>",
"    <p>",
"     Glucocorticoids taken in pill form are sometimes used for short term treatment (eg, for flares of COPD), but are not generally used long-term because of the risk of side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Combination treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Combinations of short and long-acting bronchodilators, anticholinergics,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     glucocorticoids are often used in people whose symptoms are not completely controlled with one medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Cough medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cough medicines are not generally recommended for people with COPD because they have not been shown to improve COPD symptoms. Although cough can be a bothersome symptom, cough suppressants should be avoided since suppressing cough may increase the risk of developing an infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SUPPLEMENTAL THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Stop smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the MOST important treatments for chronic obstructive pulmonary disease is for current smokers to stop smoking. Studies of people with COPD show that the disease progresses more slowly after stopping smoking. Most people who stop smoking will cough less and produce less sputum, although this may take several months. A detailed discussion of ways to quit smoking is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Oxygen",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with advanced chronic obstructive pulmonary disease can have low oxygen levels in the blood. This condition, known as hypoxemia, can occur even if the person does not feel short of breath or have other symptoms. The oxygen level can be measured with a device placed on the finger (pulse oximeter) or with a blood test (arterial blood gas). People with hypoxemia may be placed on oxygen therapy, which can improve survival and quality of life. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"      \"Use of oxygen in patients with hypercapnia\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some people with COPD who travel by air may be prone to hypoxemia during travel because of the changes in air pressure inside the plane. If a clinician determines that you are at risk for hypoxemia during a flight, in-flight oxygen can be prescribed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"      \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Supplemental oxygen must never be used while smoking. Oxygen is explosive, and smoking while using oxygen can lead to severe burns. Fatal fires have occurred in people attempting to smoke while using oxygen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Nutrition",
"     </span>",
"     &nbsp;&mdash;&nbsp;More than 30 percent of people with severe COPD are not able to eat enough because of their symptoms (shortness of breath, fatigue). Unintended weight loss caused by shortness of breath usually occurs in people with more advanced lung disease. Not eating enough can lead to malnutrition, which can make symptoms worse and increase the likelihood of infection. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=see_link\">",
"      \"Nutritional support in advanced lung disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     To increase the number of calories you eat:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Eat small, frequent meals with nutrient-dense foods (eg, eggs)",
"      </li>",
"      <li>",
"       Eat meals that require little preparation (eg, microwaveable)",
"      </li>",
"      <li>",
"       Rest before meals",
"      </li>",
"      <li>",
"       Take a daily multivitamin",
"      </li>",
"      <li>",
"       Nutritional supplements (liquids or bars) are also good sources of extra calories because they are easy to eat and require no preparation",
"      </li>",
"      <li>",
"       If you continue to lose weight, a prescription medication may be recommended to stimulate your appetite",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Pulmonary rehabilitation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pulmonary rehabilitation programs may include education, exercise training, social support, and instruction on breathing techniques that can ease symptoms of breathlessness. Pulmonary rehabilitation programs have been shown to improve a person's ability to exercise, enhance quality of life, and decrease the frequency of exacerbations of COPD. Even people with severe shortness of breath can benefit from a rehabilitation program. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"      \"Pulmonary rehabilitation in COPD\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery, such as lung volume reduction surgery or lung transplantation, may be helpful in reducing symptoms in some patients with emphysema.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Lung volume reduction surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lung volume reduction surgery involves removing the areas of lung that are most abnormal, which allows the remaining lung to expand and function more normally. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"      \"Lung volume reduction surgery in COPD\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This procedure may be an option for people who have severe symptoms after trying all other routine therapies, including pulmonary rehabilitation. Not all patients will benefit from this surgery, and some may actually become worse. An imaging test, such as a CT scan, may be recommended to help determine if surgery is likely to be of benefit.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Lung transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lung transplantation may be considered in cases of severe chronic obstructive pulmonary disease. If successful, transplantation is likely to improve symptoms. However, lung transplantation has not yet been shown to prolong the life of people with COPD. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"      \"Lung transplantation: General guidelines for recipient selection\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Other therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other treatments for COPD are occasionally recommended, including: noninvasive ventilatory support (the use of a special mask and breathing machine to improve symptoms), anti-anxiety or anti-depressant medications, or morphine-like medications to reduce shortness of breath.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PREVENTION AND TREATMENT OF INFECTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     People with chronic obstructive pulmonary disease are at risk for worsening symptoms as a result of respiratory infections. Avoiding these infections and treating them quickly if they occur are important parts of COPD therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Vaccines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Everyone with chronic obstructive pulmonary disease should have a pneumococcal vaccination, which helps prevent a type of pneumonia. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      \"Patient information: Pneumonia prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with COPD should also get an annual flu shot before flu season, generally in the late fall or early winter. For patients who get the flu, antiviral medications may be prescribed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are of some benefit in people with a bacterial respiratory infection who have worsening COPD symptoms. However, most respiratory infections are caused by viruses, which will not improve with antibiotic treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"      \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Continuous use of antibiotics to prevent infection is not currently recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Although chronic obstructive pulmonary disease usually worsens over time, it is difficult to predict how quickly this will occur. A number of factors play a role in the severity of COPD symptoms, including whether you continue to smoke, are underweight, have underlying medical problems, and how your lungs function during exercise. People with COPD who have less severe symptoms, are a healthy weight, and do not smoke tend to live longer.",
"    </p>",
"    <p>",
"     The BODE index is an example of an index that clinicians use to predict survival and to guide the timing of lung transplantation. It uses a combination of body mass index (BMI), severity of airflow obstruction on spirometry, degree of shortness of breath with exertion, and distance walked in six minutes. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link\">",
"      \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      END OF LIFE DECISIONS IN COPD",
"     </span>",
"    </p>",
"    <p>",
"     Although discussions about death and dying can be uncomfortable for patients, family members, and healthcare providers, the subject is important, especially for people with severe chronic illnesses. Not everyone with COPD will die as a result of their disease. However, discussions about what you want at the end of your life should occur well before you become seriously ill. This is particularly important for people with COPD, who are at risk for being placed on a ventilator (breathing machine) when they are very ill.",
"    </p>",
"    <p>",
"     Important questions to consider include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Who do I want to make medical decisions for me if I cannot communicate?",
"      </li>",
"      <li>",
"       Are there specific treatments that I do or do not want at the end of my life?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Certain legal documents, called a healthcare proxy and living will, are used to communicate your preferences. The document you need depends upon where you live. In the United States, state-specific documents can be downloaded from the internet (such as",
"     <a class=\"external\" href=\"file://www.caringinfo.org/\">",
"      www.caringinfo.org",
"     </a>",
"     ) and do not require a lawyer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865643999\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24619060\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=see_link\">",
"      Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24619084\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H865643992\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28568?source=see_link\">",
"      Bullectomy for giant bullae in COPD",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6089?source=see_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=see_link\">",
"      Dynamic hyperinflation in patients with COPD",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23641?source=see_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link\">",
"      Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=see_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/copdchronicobstructivepulmonarydisease.html\">",
"      www.nlm.nih.gov/medlineplus/copdchronicobstructivepulmonarydisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Alpha-1 Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.alphaone.org/\">",
"      www.alphaone.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       COPD Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://copd.about.com/forum\">",
"      file://copd.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/52/14148/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/52/14148?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Global Initiative for Chronic Obstructive Lung Disease, Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2006, www.goldcopd.com (Accessed April 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14148/abstract/2\">",
"      Man SF, McAlister FA, Anthonisen NR, Sin DD. Contemporary management of chronic obstructive pulmonary disease: clinical applications. JAMA 2003; 290:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14148/abstract/3\">",
"      Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9:CD006829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14148/abstract/4\">",
"      Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147:633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_52_14148=[""].join("\n");
var outline_f13_52_14148=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHRONIC OBSTRUCTIVE PULMONARY DISEASE MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SUPPLEMENTAL THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PREVENTION AND TREATMENT OF INFECTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           END OF LIFE DECISIONS IN COPD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14149="Vasopeptidase inhibition in the management of hypertension";
var content_f13_52_14149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasopeptidase inhibition in the management of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14149/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14149/contributors\">",
"     Raymond R Townsend, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14149/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14149/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14149/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14149/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/52/14149/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopeptidase inhibitors (VPIs) are a new class of antihypertensive agents that block both angiotensin-converting enzyme (ACE) and neutral endopeptidase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/1\">",
"     1",
"    </a>",
"    ]. These agents are",
"    <strong>",
"     not",
"    </strong>",
"    currently available in the United States because of safety concerns. At least one agent (ilepatril, Sanofi-Aventis) is still in development [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An introduction to the mechanisms of action and antihypertensive effect of these agents will be reviewed here. Their possible use in congestive heart failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=see_link\">",
"     \"Possibly effective emerging therapies for heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopeptidase inhibitors simultaneously inhibit both angiotensin converting enzyme (ACE) and neutral endopeptidase. These combined effects result in significant lowering of the systemic blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibition contributes to blood pressure reduction by preventing the conversion of angiotensin I to angiotensin II; the latter is a potent vasoconstrictor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"       \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blockade of neutral endopeptidase prolongs the actions of multiple compounds including the natriuretic peptides, such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). Since an intravenous infusion of either ANP or BNP increases urinary sodium excretion, enhances cyclic GMP (cGMP) excretion, and promotes vasodilation, the inhibition of neutral endopeptidase alone may lower blood pressure via increased vascular smooth muscle relaxation and natriuresis. The latter effect is somewhat controversial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      .) Additional effects of neutral endopeptidase inhibition include increased kinin and adrenomedullin levels, both of which are likely to contribute to a hypotensive effect with VPIs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The simultaneous targeting of ACE and neutral endopeptidase, as with one agent such as a VPI, is particularly attractive as their substrates and end-products affect blood pressure and volume status in coordinated but opposite ways. As an example, enhanced levels of angiotensin II appear to ameliorate any antihypertensive effect observed with neutral endopeptidase inhibition alone. The combination may also provide antifibrotic and antiinflammatory effects, factors thought to enhance end-organ damage in hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, antihypertensive therapy with a VPI is similar, both in theory and efficacy, to combination therapy utilizing a diuretic and either an ACE inhibitor or an angiotensin receptor blocker. The antihypertensive response to diuretics is frequently limited by the hypovolemia-induced increase in renin release; this effect is neutralized by converting enzyme inhibition or angiotensin receptor blockade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .) With VPI therapy, renin release is blocked by the potentiation of the effect of ANP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive therapy with VPIs, such as omapatrilat, sampatrilat, and fasidotril, provides substantial benefit in a wide range of settings, including high, normal, and low renin animal models of hypertension. As an example, the administration of omapatrilat significantly lowers blood pressure in sodium depleted spontaneously hypertensive rats (high renin), deoxycorticosterone acetate-salt hypertensive rats (normal renin), and spontaneously hypertensive rats (low renin) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar antihypertensive benefits have been observed in a number of clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest experience comes from the Omapatrilat Cardiovascular Treatment Assessment Versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      (OCTAVE) trial, which included 25,000 hypertensive patients who were randomly assigned to either omapatrilat or enalapril [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/11\">",
"       11",
"      </a>",
"      ]. Compared to the ACE inhibitor, omapatrilat resulted in significantly lower systolic blood pressures (by an average of 3 mmHg). However, the incidence of angioedema was significantly higher among those treated with omapatrilat (2.2 versus 0.7 percent). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Side effects'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a far smaller study of black hypertensive patients, VPIs appeared to result in a greater blood pressure response than that obtained with ACE inhibitor therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Black hypertensive patients relatively resistant to ACE inhibitors were randomly assigned to sampatrilat (50 to 100 mg daily) or an ACE inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      at 10 to 20 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/6\">",
"       6",
"      </a>",
"      ]. After a nearly two month period, blood pressure as determined by ambulatory monitoring was significantly lower with sampatrilat (minus 7.8 and 5.2 mmHg for systolic and diastolic blood pressure, respectively, versus no change compared with pretreatment levels for lisinopril).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VPI may also be effective in the treatment of diabetic neuropathy, a disorder with frequently disappointing therapeutic results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/12\">",
"     12",
"    </a>",
"    ]. In a rodent study of streptozotocin-induced diabetes, there was a substantial improvement with a VPI known as AVE7688 (supplied by Sanofi-Aventis) in endoneuronal blood flow in the spinal column, motor and sensory nerve conduction velocities, and preservation of hind-paw pain sensation in a rodent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since VPIs inhibit angiotensin converting enzyme, they can induce cough and a flushing reaction. This latter reaction tends to occur in the first two to four hours after initial dosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .) In addition, preliminary data in individuals with heart failure suggest that a marked increase in BUN and creatinine occurs less often with omapatrilat than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1412327184\">",
"    <span class=\"h2\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPIs can induce",
"    <strong>",
"     angioedema",
"    </strong>",
"    , which may be life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. In the OCTAVE trial mentioned above, the incidence of angioedema was significantly higher among patients treated with omapatrilat compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (2.2 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/11\">",
"     11",
"    </a>",
"    ]. Because of this effect, a Federal Drug Administration (FDA) hearing on the new drug application filed by Bristol-Myers Squibb for omapatrilat was postponed pending the acquisition of further data on clinical safety.",
"   </p>",
"   <p>",
"    As of April 2007, human development of VPI therapy was largely inactive, although ilepatril is still in development. The angioedema rate in a series of approximately 1600 patients treated with ilepatril was 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In searching for mechanisms that lead to angioedema and the possibility of finding clinical markers that might predict who is at risk, attention has focused on the enzymes aminopeptidase P (APP) and dipeptidyl peptidase IV (DPP-IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    When angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) are blocked, APP is able to continue to metabolize bradykinin, which is a mediator of angioedema including that induced by ACE inhibitors. Omapatrilat blocks APP, which may contribute to its tendency toward angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/17\">",
"     17",
"    </a>",
"    ]. Genetic-based abnormalities in APP activity such as low plasma concentrations predispose to angioedema by VPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of angioedema: Pathogenesis and causes\", section on 'Bradykinin-mediated etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less is known with respect to DPP-IV and angioedema, VPIs do not seem to affect the activity of DPP-IV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary studies suggest it may be possible to perform biotesting that predicts angioedema risk in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other agents that inhibit angiotensin converting enzyme, it is expected that, if they are approved for clinical use, there will be a black box warning concerning the use of VPIs in pregnancy. The use of ACE inhibitors in pregnancy, particularly after the first trimester of pregnancy, has been associated with fetal malformations and death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link&amp;anchor=H2#H2\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\", section on 'Risk of adverse fetal/neonatal effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033806\">",
"    <span class=\"h1\">",
"     DUAL INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN II RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dual inhibition of neutral endopeptidase and angiotensin II receptors may provide additive antihypertensive effects without the risk of angioedema since angiotensin receptor blockers have a lower risk of angioedema compared to ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H14#H14\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A proof-of-concept trial compared the antihypertensive effect of varying doses of LCZ696, which inhibits both the angiotensin II receptor and the neutral endopeptidase, neprilysin, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    and placebo on blood pressure among 1328 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14149/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with mild to moderate hypertension (baseline mean blood pressure",
"    <span class=\"nowrap\">",
"     156/100)",
"    </span>",
"    received 100, 200 or 400 mg of LCZ696, or 80, 160 or 320 mg of valsartan, or placebo. At eight weeks, LCZ696 provided a greater reduction in mean diastolic and systolic blood pressures compared to the comparator dose of valsartan (by a mean of 2.17 and 4.20 mmHg respectively). LCZ696 was well tolerated and there were no cases of angioedema. However, the number of patients treated with this drug was small and a low rate of angioedema could have been missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033593\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasopeptidase inhibitors (VPIs) are a class of antihypertensive agents that block both angiotensin-converting enzyme (ACE) and neutral endopeptidase. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blockade of neutral endopeptidase prolongs the actions of multiple compounds including the natriuretic peptides, such as atrial natriuretic peptide and brain natriuretic peptide. This may lower blood pressure via increased vascular smooth muscle relaxation and natriuresis. Neutral endopeptidase inhibition may also increase kinin and adrenomedullin levels, both of which are likely to contribute to a hypotensive effect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical studies have suggested VPIs are effective antihypertensive agents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VPIs appear to induce, among a number of patients, significant",
"      <strong>",
"       angioedema",
"      </strong>",
"      , which may be life-threatening. Because of safety concerns, human development with VPI therapy remains largely inactive. These agents are",
"      <strong>",
"       not",
"      </strong>",
"      available in the United States because of safety concerns. &nbsp;(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dual inhibition of neutral endopeptidase and angiotensin II receptors may provide the antihypertensive effect of VPIs without the risk of angioedema, though additional studies are necessary to determine their utility and safety. (See",
"      <a class=\"local\" href=\"#H1033806\">",
"       'Dual inhibition of neutral endopeptidase and angiotensin II receptors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/1\">",
"      Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/2\">",
"      Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/3\">",
"      Perlini S. The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. J Hypertens 2005; 23:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/4\">",
"      Trippodo NC, Robl JA, Asaad MM, et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/5\">",
"      Laurent S, Boutouyrie P, Azizi M, et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 2000; 35:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/6\">",
"      Norton GR, Woodiwiss AJ, Hartford C, et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999; 12:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/7\">",
"      Zusman, R, Atlas, S, Kochar, M. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor. Am J Hypertens 1999; 12:125A.",
"     </a>",
"    </li>",
"    <li>",
"     OCTAVE study. February 2002 Scientific sessions of the American College of Cardiology.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/9\">",
"      Mitchell GF, Izzo JL Jr, Lacourci&egrave;re Y, et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002; 105:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/10\">",
"      Cheng ZJ, Gr&ouml;nholm T, Louhelainen M, et al. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. J Hypertens 2005; 23:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/11\">",
"      Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/12\">",
"      Yorek MA. The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets 2008; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/13\">",
"      Davidson EP, Kleinschmidt TL, Oltman CL, et al. Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease. Diabetes 2007; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/14\">",
"      Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/15\">",
"      Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/16\">",
"      Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 2002; 303:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/17\">",
"      Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/18\">",
"      Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002; 39:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/19\">",
"      Sulpizio AC, Pullen MA, Edwards RM, Brooks DP. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther 2004; 309:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/20\">",
"      Molinaro G, Carmona AK, Juliano MA, et al. Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J 2005; 385:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/21\">",
"      Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol 1998; 38:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14149/abstract/22\">",
"      Ruilope LM, Dukat A, B&ouml;hm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 375:1255.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3865 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14149=[""].join("\n");
var outline_f13_52_14149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1033593\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1412327184\">",
"      Angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1033806\">",
"      DUAL INHIBITION OF NEUTRAL ENDOPEPTIDASE AND ANGIOTENSIN II RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1033593\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14150="Methyldopa and hydrochlorothiazide: Drug information";
var content_f13_52_14150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyldopa and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/33/534?source=see_link\">",
"    see \"Methyldopa and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methazide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage titrated on individual components, then switch to combination product; maintain initial dose for first 48 hours, then decrease or increase at intervals of not less than 2 days until an adequate response is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     Methyldopa 250 mg and hydrochlorothiazide 15-25 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     methyldopa 250 mg and hydrochlorothiazide 15 mg 3 times daily; alternatively, methyldopa 500 mg and hydrochlorothiazide 30-50 mg may be administered once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maximum daily dose, based on the",
"      <b>",
"       hydrochlorothiazide",
"      </b>",
"      content:",
"     </i>",
"     Oral: 50 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F195122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Based on hydrochlorothiazide component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use. Usually ineffective with GFR &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anuria: Contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methyldopa 250 mg and hydrochlorothiazide 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methyldopa 250 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldoril may be confused with Aldomet, Elavil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      methyldopa",
"     </b>",
"     component: Hypersensitivity to methyldopa or any component of the formulation; active hepatic disease; liver disorders previously associated with use of methyldopa; concurrent use of MAO inhibitors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on",
"     <b>",
"      hydrochlorothiazide",
"     </b>",
"     component: Hypersensitivity to hydrochlorothiazide or any component of the formulation, thiazides, or sulfonamide-derived drugs; anuria; renal decompensation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypokalemia, hypochloremic alkalosis, and hyponatremia can occur with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Rare cases of reversible granulocytopenia and thrombocytopenia have been reported with methyldopa. May rarely produce hemolytic anemia; positive Coombs' test occurs in 10% to 20% of patients usually occurring between 6 and 12 months of therapy; perform CBC periodically. If Coombs'-positive hemolytic anemia occurs during therapy, discontinue use and do not reinitiate; Coombs&rsquo; test may not revert back to normal for weeks to months following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Methyldopa may rarely produce liver disorders including fatal hepatic necrosis; use with caution in patients with previous liver disease or dysfunction. Periodically monitor liver function during the first 6-12 weeks of therapy or when unexplained fever occurs; discontinue use if fever, abnormal liver function tests, or jaundice is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular effects: Patients with severe bilateral cerebrovascular disease have exhibited involuntary choreoathetotic movements with methyldopa (rare); discontinue use if these symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Usually transient, sedation may occur with initiation or whenever the methyldopa dose is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use hydrochlorothiazide with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use hydrochlorothiazide with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use hydrochlorothiazide with caution in patients with hypokalemia; correct before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia. The active metabolites of methyldopa accumulate in uremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to high risk of CNS adverse effects; may also cause orthostatic hypotension and bradycardia; not recommended for route use as an antihypertensive (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Fixed-dose therapy is not indicated as the initial treatment for hypertension.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Methyldopa may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Methyldopa.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Methyldopa. Management: Consider separating doses of these products by 2 or more hours to minimize this interaction; however, the success of this action appears limited.  Monitor for decreased therapeutic effects of methyldopa with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methyldopa-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-15 mg (100): $95.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-25 mg (100): $113.09",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dopatens-H (GR);",
"     </li>",
"     <li>",
"      Hydromet (BR, JP, NL);",
"     </li>",
"     <li>",
"      Tensifort (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14936432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa stimulates central alpha-adrenergic receptors by a false transmitter that results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14150/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14150/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14150/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14150/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9741 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14150=[""].join("\n");
var outline_f13_52_14150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709041\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195117\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195132\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195120\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195121\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195122\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195106\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195095\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195108\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195137\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195130\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195111\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195098\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299699\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195102\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195103\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195113\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195124\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524686\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195114\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14936432\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195110\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/33/534?source=related_link\">",
"      Methyldopa and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14151="Formoterol: Drug information";
var content_f13_52_14151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Formoterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/56/23430?source=see_link\">",
"    see \"Formoterol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/26/11686?source=see_link\">",
"    see \"Formoterol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Foradil&reg; Aerolizer&reg;;",
"     </li>",
"     <li>",
"      Perforomist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Foradil&reg;;",
"     </li>",
"     <li>",
"      Oxeze&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma treatment:",
"     </b>",
"     Inhalation:",
"     <b>",
"      Note:",
"     </b>",
"     For asthma control, long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists (LABAs) should be used in combination with inhaled corticosteroids and not as monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Foradil&reg; Aerolizer&reg;: 12 mcg every 12 hours (maximum: 24 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foradil&reg;: 12 mcg every 12 hours; in severe cases, 24 mcg every 12 hours may be given (maximum:  48 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oxeze&reg; Turbuhaler&reg;: 6 mcg or 12 mcg every 12 hours (maximum: 48 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of exercise-induced bronchospasm:",
"     </b>",
"     Inhalation:",
"     <b>",
"      Note:",
"     </b>",
"     If already using for asthma maintenance, then should not use additional doses for exercise-induced bronchospasm. Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Foradil&reg; Aerolizer&reg;: 12 mcg  at least 15 minutes before exercise on an occasional &ldquo;as needed&rdquo; basis; additional doses should not be used for another 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Oxeze&reg; Turbuhaler&reg;: 6 mcg or 12 mcg at least 15 minutes before exercise on an occasional &ldquo;as needed&rdquo; basis (maximum: 48 mcg/24-hour period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      COPD maintenance treatment:",
"     </b>",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foradil&reg; Aerolizer&reg;: 12 mcg every 12 hours  (maximum: 24 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Perforomist&reg;: 20 mcg twice daily (maximum dose: 40 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Foradil&reg;: 12 mcg or 24 mcg twice daily (maximum dose: 48 mcg daily)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F174105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/26/11686?source=see_link\">",
"      see \"Formoterol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma treatment:",
"     </b>",
"     Inhalation:",
"     <b>",
"      Note:",
"     </b>",
"     For asthma control, long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists (LABAs) should be used in combination with inhaled corticosteroids and not as monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Foradil&reg; Aerolizer&reg;: Children &ge;5 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foradil&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-16 years: 12 mcg every 12 hours (maximum:  24 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oxeze&reg; Turbuhaler&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-16 years: 6 mcg or 12 mcg every 12 hours (maximum: 24 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of exercise-induced bronchospasm:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     If already using for asthma maintenance, then should not use additional doses for exercise-induced bronchospasm. Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Foradil&reg; Aerolizer&reg;: Children &ge;5 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Oxeze&reg; Turbuhaler&reg;: Children &ge;6 years and Adolescents: 6 mcg or 12 mcg at least 15 minutes before exercise on an occasional &ldquo;as needed&rdquo; basis (maximum: 24 mcg/24-hour period)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15142898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation, as fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foradil&reg; Aerolizer&reg;: 12 mcg/capsule (12s, 60s) [contains lactose 25 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization, as fumarate dihydrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perforomist&reg;: 20 mcg/2 mL (60s)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral inhalation, as fumarate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxeze&reg; Turbuhaler&reg;: 6 mcg/inhalation [delivers 60 metered doses; contains lactose 600 mcg/dose]; 12 mcg/inhalation [delivers 60 metered doses; contains lactose 600 mcg/dose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088602.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088602.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Foradil&reg; Aerolizer&reg;: Remove capsule from foil blister",
"     <b>",
"      immediately",
"     </b>",
"     before use. Place capsule in the capsule-chamber in the base of the Aerolizer&reg; Inhaler. Capsules must not be swallowed whole; must only use the Aerolizer&reg; Inhaler. Press both buttons",
"     <b>",
"      once only",
"     </b>",
"     and then release. Keep inhaler in a level, horizontal position. Exhale fully. Do not exhale into inhaler. Tilt head slightly back and inhale (rapidly, steadily, and deeply). Hold breath as long as possible. If any powder remains in capsule, exhale and inhale again. Repeat until capsule is empty. Throw away empty capsule; do not leave in inhaler. Do not use a spacer with the Aerolizer&reg; Inhaler. Always keep capsules and inhaler dry.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Perforomist&reg;: Remove unit-dose vial from foil pouch",
"     <b>",
"      immediately",
"     </b>",
"     before use. Solution does not require dilution prior to administration; do not mix other medications with formoterol solution. Place contents of unit-dose vial into the reservoir of a standard jet nebulizer connected to an air compressor; assemble nebulizer based on the manufacturer&rsquo;s instructions and turn nebulizer on; breathe deeply and evenly until all of the medication has been inhaled. Discard any unused medication immediately; do not ingest contents of vial. Clean nebulizer after use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oxeze&reg; Turbuhaler&reg; (Canadian availability): Hold inhaler upright. Turn colored grip as far as it will go in one direction and then turn back to original position; a clicking sound should be heard which means the inhaler is ready for use. Exhale fully. Do not exhale into mouthpiece of inhaler. Place mouthpiece to lips and inhale forcefully and deeply. Do not chew or bite on mouthpiece. Clean outside of mouthpiece once weekly with a dry tissue. Avoid getting inhaler wet. If the inhaler is accidently dropped or shaken, or if the patient exhales into the inhaler, the dose will be lost and a new dose should be loaded.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: Treatment of asthma (only as concomitant therapy with an inhaled corticosteroid) in patients with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma (Foradil&reg; Aerolizer&reg;); maintenance treatment of bronchoconstriction in patients with COPD (Foradil&reg; Aerolizer&reg;, Perforomist&reg;); prevention of exercise-induced bronchospasm when administered on an as-needed basis (monotherapy may be indicated in patients without persistent asthma) (Foradil&reg; Aerolizer&reg;)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Treatment of asthma (only as concomitant therapy with an inhaled corticosteroid) in patients with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma (Foradil&reg;, Oxeze&reg; Turbuhaler&reg;); maintenance treatment of COPD (Foradil&reg;); prevention of exercise-induced bronchospasm when administered on an as-needed basis (monotherapy may be indicated in patients without persistent asthma) (Oxeze&reg; Turbuhaler&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Foradil&reg; may be confused with Toradol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Foradil&reg; capsules for inhalation are for administration via Aerolizer&reg; inhaler and are",
"       <b>",
"        not",
"       </b>",
"       for oral use.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Foradil [U.S., Canada, and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (2% to 3%), palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (2%), dizziness (2%), fever (2%), insomnia (2%), dysphonia (1%), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5%), nausea (5%),  xerostomia (1% to 3%), vomiting (2%), abdominal pain, dyspepsia, gastroenteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps (2%), tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Infection (3% to 7%), asthma exacerbation (age 5-12 years: 5% to 6%; age &gt;12 years: &lt;4%), bronchitis (5%), pharyngitis (3% to 4%), sinusitis (3%), dyspnea (2%), tonsillitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute asthma deterioration, anaphylactic reactions (severe hypotension/angioedema), agitation, angina, arrhythmia, atrial fibrillation, bronchospasm (paradoxical), cough, fatigue, hyperglycemia, hypertension, hypokalemia, glucose intolerance, malaise, metabolic acidosis, nervousness, QTc prolongation, tachycardia, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to formoterol or any component of the formulation (Foradil&reg; Aerolizer&reg; only); treatment of status asthmaticus or other acute episodes of asthma or COPD (Foradil&reg; Aerolizer&reg; only); monotherapy in the treatment of asthma (ie, use without a concomitant long-term asthma control medication, such as an inhaled corticosteroid)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Presence of tachyarrhythmias",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs) increase the risk of asthma-related deaths. Formoterol should only be used in asthma patients as adjuvant therapy in patients who are currently receiving but are not adequately controlled on a long-term asthma control medication (ie, an inhaled corticosteroid).",
"     </b>",
"     Monotherapy with an LABA is contraindicated in the treatment of asthma. In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate and the LABA can be discontinued (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose or frequency; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foradil&reg; Aerolizer&reg;: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute bronchospasm. Short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating asthma; reports of severe (sometimes fatal) respiratory events have been reported when formoterol has been initiated in this situation. Corticosteroids should not be stopped or reduced when formoterol is initiated. Formoterol is not a substitute for inhaled or systemic corticosteroids and should not be used as monotherapy. During initiation, watch for signs of worsening asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Perforomist&reg;: Not FDA approved for the treatment of asthma; safety and efficacy  in asthma patients have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, HF, or aneurysm); beta-agonists may cause elevation in blood pressure and heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias and prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic obstructive pulmonary disease (COPD): Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute episodes of COPD. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose. The effect is usually transient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Exercise-induced bronchospasm: Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium, possibly through intracellular shunting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma; may worsen symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Foradil&reg; Aerolizer&reg;:",
"     <b>",
"      [U.S. Boxed Warning]: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients.",
"     </b>",
"     In general, a combination product containing a LABA and an inhaled corticosteroid is preferred in patients &lt;18 years of age to ensure adherence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Foradil&reg; Aerolizer&reg;:  The contents of the capsules are for inhalation only via the Aerolizer&reg; device. There have been reports of incorrect administration (swallowing of the capsules).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients using inhaled, short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be instructed to discontinue routine use of these medications prior to beginning treatment; short-acting agents should still be provided to patients; however, use should be reserved for symptomatic relief of acute symptoms. Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use of short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may indicate deterioration of asthma or COPD, and medical evaluation must not be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance/Tachyphylaxis: Tolerance to the bronchodilator effect, measured by FEV",
"     <sub>",
"      1",
"     </sub>",
"     , has been observed in studies.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: May enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When given orally to rats throughout organogenesis, formoterol caused delayed ossification and decreased fetal weight, but no malformations. There were no adverse events when given to pregnant rats in late pregnancy. Doses used were &ge;70 times the recommended daily inhalation dose in humans. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk to the fetus. Beta-agonists interfere with uterine contractility so use during labor only if benefit outweighs risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F174067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Foradil Aerolizer Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mcg (12): $54.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Perforomist Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mcg/2 mL (2 mL): $9.24",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F174069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acarol Dry Syrup (KP);",
"     </li>",
"     <li>",
"      Asmelor Novolizer (FR);",
"     </li>",
"     <li>",
"      Atimos (BG);",
"     </li>",
"     <li>",
"      Atimos Modulite (GB);",
"     </li>",
"     <li>",
"      Atock (JP, TW);",
"     </li>",
"     <li>",
"      Broncoral (ES);",
"     </li>",
"     <li>",
"      Fesema (CO);",
"     </li>",
"     <li>",
"      Foradil (AT, BE, BF, BJ, BR, CH, CI, CZ, DK, EE, ET, FI, FR, GH, GM, GN, GR, HK, IE, IL, IT, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, NZ, PE, PH, PL, PT, RU, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Foradil Aerolizer (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Foradil P (DE);",
"     </li>",
"     <li>",
"      Foradile (AU);",
"     </li>",
"     <li>",
"      Foratec (IN);",
"     </li>",
"     <li>",
"      Fordilen (AR);",
"     </li>",
"     <li>",
"      Formoair (FR);",
"     </li>",
"     <li>",
"      Lexoma (KP);",
"     </li>",
"     <li>",
"      Oxis (AU, BB, BF, BJ, BM, BS, BZ, CH, CI, CL, CR, DE, DO, ET, GH, GM, GN, GT, GY, HN, HU, IE, IL, JM, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, PA, PH, PR, SC, SD, SE, SG, SL, SN, SR, SV, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Oxis Turbuhaler (MX);",
"     </li>",
"     <li>",
"      Oxis turbuhaler (PL);",
"     </li>",
"     <li>",
"      Sortel (KP);",
"     </li>",
"     <li>",
"      Tempus (PY);",
"     </li>",
"     <li>",
"      Zafiron (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     receptors with little effect on heart rate. Formoterol has a long-acting effect.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Powder for inhalation: Within 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Powder for inhalation: 80% of peak effect within 15 minutes; Solution for nebulization: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Improvement in FEV",
"     <sub>",
"      1",
"     </sub>",
"     observed for 12 hours in most patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly into plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 61% to 64%",
"     <i>",
"      in vitro",
"     </i>",
"     at higher concentrations than achieved with usual dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via direct glucuronidation and O-demethylation; CYP2D6, CYP2C8/9, CYP2C19, CYP2A6 involved in O-demethylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Powder: ~10-14 hours; Nebulized solution: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Maximum improvement in FEV",
"     <sub>",
"      1",
"     </sub>",
"     in 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-12 years: Urine (7% to 9% as direct glucuronide metabolites, 6% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Urine (15% to 18% as direct glucuronide metabolites, 2% to 10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cazzola M, Centanni S, Regorda C, et al, &ldquo;Onset of Action of Single Doses of Formoterol Administered Via Turbuhaler in Patients With Stable COPD,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2001, 14:41-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14151/abstract-text/11162418/pubmed\" id=\"11162418\" target=\"_blank\">",
"        11162418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cazzola M and Donner CF, &ldquo;Long-Acting Beta",
"      <sub>",
"       2",
"      </sub>",
"      -Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 60:307-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/52/14151/abstract-text/10983735/pubmed\" id=\"10983735\" target=\"_blank\">",
"        10983735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8946 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-82E6EA8F2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14151=[""].join("\n");
var outline_f13_52_14151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708810\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174082\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174083\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174122\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174085\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174105\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174086\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174087\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15142898\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174059\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950044\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174045\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874607\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174062\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174060\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174129\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174120\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174065\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174049\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174116\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174055\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174068\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174090\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174067\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174057\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174069\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174048\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174064\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/56/23430?source=related_link\">",
"      Formoterol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/26/11686?source=related_link\">",
"      Formoterol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14152="Scabies wrists";
var content_f13_52_14152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50111%7EPC%2F58595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50111%7EPC%2F58595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies. Lesions are present on the flexor wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies burrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scabies. This close-up view shows a burrow (arrow) on the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14152=[""].join("\n");
var outline_f13_52_14152=null;
var title_f13_52_14153="Emergent evaluation of headache in children";
var content_f13_52_14153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergent evaluation of headache in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Christopher King, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14153/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/52/14153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although headaches occur frequently among children, most do not seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Caretakers may bring children to the emergency department or primary care provider for headaches that are more severe or have not responded to nonprescription medications. In one retrospective series from a busy children's hospital emergency department, 1 percent of visits were for a chief complaint of headache [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The terms \"primary\" and \"secondary\" may be used to describe headaches. Primary headaches (ie, migraine, tension-type, or cluster headaches) are typically self-limited and diagnosed based on symptom profiles and patterns of headache attacks. Secondary headaches have identifiable etiologies. Although the vast majority of secondary headaches in children have benign etiologies (ie, viral infections), the goal of the emergent evaluation of children with headaches is to identify as a first priority those with serious or life-threatening causes. This can generally be accomplished with a careful history and physical examination and, occasional selected ancillary testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Headache can be the symptom of life-threatening complications for children with various underlying conditions (ie, those with immunodeficiencies who develop opportunistic infections or patients with ventriculoperitoneal shunts that malfunction causing obstruction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link&amp;anchor=H27#H27\">",
"     \"Hydrocephalus\", section on 'Complications'",
"    </a>",
"    .) Evaluation of headache in these children (which is often guided by specific protocols that include neuroimaging and consultation with a specialist) will not be discussed here.",
"   </p>",
"   <p>",
"    This topic will review the emergent evaluation of children with headaches who do not have predisposing conditions, such as those described above. Children with headaches who present nonurgently and those with well-established histories of migraine or tension-type headaches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link\">",
"     \"Approach to the child with headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children who are evaluated emergently for headaches are diagnosed with viral illnesses or migraine headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. This is similar to the causes of headache among children seen in primary care settings and adults seen in emergency departments (EDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The challenge for the emergency clinician is to identify patients with secondary headaches who require urgent diagnosis and treatment (",
"    <a class=\"graphic graphic_table graphicRef78979 \" href=\"UTD.htm?16/20/16716\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening causes of headache are those that may result in brain injury or death from various mechanisms including inflammation, increased intracranial pressure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with life-threatening infections as the cause of headache typically have other worrisome clinical features, such as altered mental status or focal neurologic findings. These manifestations may be subtle in younger children who cannot describe their symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial meningitis &ndash; The irritable or lethargic child with fever, neck",
"      <span class=\"nowrap\">",
"       pain/stiffness,",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headache may have bacterial meningitis. The incidence of bacterial meningitis among children has declined since the introduction of conjugate vaccines against Haemophilus influenza type b and pneumococcus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral encephalitis &ndash; Progressive symptoms of fever, headache, and abrupt onset of altered sensorium (ie, bizarre behavior or hallucinations) are associated with viral encephalitis. In otherwise healthy children, Herpes simplex virus causes 10 to 20 percent of sporadic cases of encephalitis and is the only treatable pathogen in this condition. Infection with specific arthropod-borne viruses may be suggested by seasonal patterns (ie, Eastern equine encephalitis or West Nile virus) or recent travel. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"       \"Herpes simplex virus type 1 encephalitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link\">",
"       \"Arthropod-borne encephalitides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orbital or cerebral abscess &ndash; Children with focal infections, such as orbital or cerebral abscesses typically have focal findings on ocular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic examination. Conditions that may be associated with CNS abscess formation include immunocompromise and congenital heart disease with right to left intracardiac shunting. Cerebral abscess and CVT are uncommon, but life-threatening, complications of orbital, sinus, ear, or dental infections [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic progressive headache (increasing in frequency and severity over time) is a common presenting symptom among children with brain tumors. However, very few children evaluated in the emergency department (ED) for headache have brain tumors as the cause. In a large multicenter pediatric series describing children with brain tumors, 62 percent of patients had headaches at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/10\">",
"     10",
"    </a>",
"    ]. In comparison, in a small prospective series, less than 3 percent of children presenting to the ED with headaches had newly diagnosed brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early symptoms of brain tumors are often nonspecific and diagnosis may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/11\">",
"     11",
"    </a>",
"    ]. At the time of diagnosis, the overwhelming majority of children with brain tumors as the cause have other symptoms in addition to headache [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/12\">",
"     12",
"    </a>",
"    ]. Over 99 percent of children in the multicenter report and all of the children in the ED series had at least one other symptom or sign (ie,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    visual disturbance, ataxia, or abnormal eye movements) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage is an uncommon, but life-threatening, cause of headache among children. Headache is rarely the sole manifestation of hemorrhage that occurs as the result of trauma (ie, epidural or subdural hematoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nontraumatic intracranial hemorrhage (typically subarachnoid) can develop in association with an aneurysm, vascular malformation, coagulopathy, or hemoglobinopathy. In one retrospective series that described children with nontraumatic intracranial hemorrhage, more than half presented with headache and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/13\">",
"     13",
"    </a>",
"    ]. Frequent signs included hemiparesis and seizures. Among patients with sickle cell disease, intracranial hemorrhage accounts for about one third of cerebrovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link&amp;anchor=H15#H15\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Intracranial hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Carbon monoxide poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of mild to moderate carbon monoxide poisoning are nonspecific but typically include headache [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/14\">",
"     14",
"    </a>",
"    ]. Children may develop carbon monoxide poisoning from occult sources, such as improperly vented home heating systems, space heaters, or automobile exhaust fumes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypertensive crisis may present with headache as one manifestation of hypertensive encephalopathy. Hypertensive encephalopathy is uncommon among children and is typically caused by systemic illness or renovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Pheochromocytoma is an exceptionally rare pediatric tumor that usually presents with headache and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link\">",
"     \"Pheochromocytoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children evaluated in the ED for headache, infection is the most common cause [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; Children with fever (related almost entirely to infection) frequently complain of headache. Headaches associated with fever are thought to be due to vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral meningitis &ndash; Headache, with or without neck discomfort, is a typical presentation of viral meningitis among older children and adolescents. Other clinical manifestations (ie, rash or mouth lesions with enterovirus) may suggest a specific virus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H3#H3\">",
"       \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharyngitis &ndash; Headache, sore throat, and abdominal pain are the classic symptoms of streptococcal pharyngitis. Influenza virus infection can cause similar symptoms, including exudative pharyngitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H2#H2\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Etiology and clinical clues'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Otitis media, sinusitis, and dental infections can cause headache. Localized pain and signs of inflammation suggest the specific diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H13#H13\">",
"       \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H21#H21\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several observational series describing children evaluated in EDs for acute headache, migraine was second only to viral illness as the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. Migraine headaches are typically chronic and remitting, with characteristic patterns that are easily described by patients or parents (",
"    <a class=\"graphic graphic_table graphicRef50876 \" href=\"UTD.htm?11/31/11773\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/19\">",
"     19",
"    </a>",
"    ]. Children with significant changes in the quality, severity, or timing of headaches should be carefully evaluated for other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tension-type headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache is the term designated by the International Headache Society to describe what were previously called tension, muscle-contraction, stress, or psychogenic headaches. Tension-type headaches occur in 10 to 25 percent of school children and adolescents, making them as common as migraine headaches (",
"    <a class=\"graphic graphic_table graphicRef68064 \" href=\"UTD.htm?40/58/41899\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/20\">",
"     20",
"    </a>",
"    ]. Among children, they appear to be associated with depression, oromandibular dysfunction, and muscular stress [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to headaches related to brain tumors, pain is typically intermittent and recurring (but nonprogressive) and the neurologic examination is unremarkable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=see_link&amp;anchor=H12875674#H12875674\">",
"     \"Tension-type headache in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Temporomandibular joint dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporomandibular joint dysfunction occurs in children with primary and mixed dentition. Children typically report increased pain while chewing and have point tenderness over the mandibular condyle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/22\">",
"     22",
"    </a>",
"    ]. Headache occurs more frequently among older children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Idiopathic intracranial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with idiopathic intracranial hypertension (IIH) have papilledema, increased intracranial pressure with normal cerebrospinal fluid content, normal neuroimaging, the absence of neurologic signs except cranial nerve VI palsy, and no known cause. Headache is the most common chief complaint among children who are old enough to describe their symptoms. Although IIH has been described in young children, most patients are adolescents and typically female. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cluster headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headaches are rare in children younger than 10 years of age. However, they have been reported in children as young as three years and must be included in the differential diagnosis of primary headaches. These headaches are always unilateral and usually frontal-periorbital in location. The pain of cluster headaches is severe and lasts less than three hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=see_link&amp;anchor=H661158085#H661158085\">",
"     \"Approach to the child with headache\", section on 'Cluster headaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying conditions, such as ventriculoperitoneal shunts or immunodeficiencies, who develop headaches must receive thorough evaluations in accordance with specialized protocols developed for those conditions. For most other children requiring emergent evaluation for acute headache, the combination of history and physical findings, with selective laboratory testing and neuroimaging, generally identifies those with significant underlying conditions (ie, meningitis or intracranial pathology) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic examination and approach to neuroimaging in children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link&amp;anchor=H10928992#H10928992\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this discussion will focus on the emergent evaluation specific to children with headache, including identification of those patients with serious causes of headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Headache characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics of the headache that may help to identify a cause include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mode of onset &ndash; The abrupt onset of an extremely painful headache (thunderclap, \"worst headache of my life\") may represent an intracranial hemorrhage (ie, from an arteriovenous malformation or aneurysm). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Timing &ndash; A headache that awakens a child from sleep should raise suspicion about a possible brain tumor. Tension-type headaches typically develop late in the day and rarely cause a patient to awaken from sleep.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Severity/quality",
"      </span>",
"      &ndash; Descriptions from children of the severity and quality of headache pain may not be as useful for identifying a cause as those obtained from older patients. This was demonstrated in one prospective study describing children evaluated in an emergency department (ED) for headache in which 98 percent of children selected the most severe rating on a pain scale to describe the severity of their headaches [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3\">",
"       3",
"      </a>",
"      ]. Children with upper respiratory infections were more likely to be able to describe the quality of headache pain than those with brain tumors and ventriculoperitoneal (VP) shunt malfunctions. When able to describe the headache, the following characteristics are helpful in identifying an etiology:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Laterality: Unilaterality suggests migraine headache, although in children under age 10 years the pain in this condition may be bilateral. Also, unilateral headaches occur with focal infections, such as sinusitis.",
"     </li>",
"     <li>",
"      Location: Cluster headaches are usually temporal or retro-orbital in location. Pain may also localize to specific regions in secondary headaches, such as with sinusitis or dental abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pattern of previous headaches &ndash; The following temporal headache patterns often suggest a specific diagnosis (",
"      <a class=\"graphic graphic_table graphicRef54034 \" href=\"UTD.htm?35/21/36188\">",
"       table 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute: This pattern describes a single episode of headache without a history of previous events. Acute headaches are typically secondary headaches, often caused by infection.",
"     </li>",
"     <li>",
"      Acute recurrent: These headaches typically have consistent characteristics that are easily described by patients or parents. They are usually primary headaches (ie, migraine or tension-type) (",
"      <a class=\"graphic graphic_table graphicRef68064 \" href=\"UTD.htm?40/58/41899\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Common conditions'",
"      </a>",
"      above.) Children with significant changes in the quality, severity, or timing of headaches should be carefully evaluated for other causes.",
"     </li>",
"     <li>",
"      Chronic progressive: Chronic progressive headaches increase in frequency and severity over time. This is a worrisome pattern associated with space occupying lesions, such as brain tumors, abscesses, or hemorrhage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life-threatening conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic nonprogressive: Frequent persistent headaches that have not changed in character are usually tension-type headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following additional historical features may suggest a specific diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; The majority of children who are evaluated in EDs for headache have some type of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/3,5,6\">",
"       3,5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Meningeal signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an abrupt change in mental status suggest life-threatening infections, such as meningitis or encephalitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life-threatening conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with localized pain may have specific infections, such as pharyngitis, otitis media, sinusitis, or dental infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Common conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children with headache who have brain tumors, additional symptoms are almost always present at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/10,24\">",
"       10,24",
"      </a>",
"      ]. In addition to a chronic progressive pattern, the following symptoms suggest the possibility of an intracranial mass, such as a brain tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/12\">",
"       12",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Association with vomiting, especially progressive vomiting",
"     </li>",
"     <li>",
"      Behavioral changes",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Polydipsia/polyuria",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      visual field deficits (suggestive of craniopharyngioma)",
"     </li>",
"     <li>",
"      Other neurologic symptoms, such as ataxia, change in coordination, \"clumsiness,\" blurred vision, or diplopia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma &ndash; Intracranial hemorrhage may cause headache for a child who has had a head injury. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Environmental exposure &ndash; Abrupt onset of headache and nausea in several members of one household (or headache and syncope in a child) may be the result of carbon monoxide poisoning. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Carbon monoxide poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Change in visual acuity &ndash; Patients with idiopathic intracranial hypertension may report a deterioration in visual acuity along with severe, unrelenting headache. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Idiopathic intracranial hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autonomic symptoms &ndash; Sweating or other autonomic symptoms may accompany cluster headaches.",
"     </li>",
"     <li>",
"      Aura &ndash; Migraine headache, particularly in children over 10 years of age, may involve an aura, such as scintillations or scotomata.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to children with immunodeficiencies or ventriculoperitoneal shunts, headaches in those with the following conditions may be life-threatening. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Life-threatening conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy &ndash; Life-threatening conditions that can cause headache among children with known malignancies include infection, hemorrhage, and metastatic disease.",
"     </li>",
"     <li>",
"      Coagulopathy &ndash; Intracranial hemorrhage must always be considered as a cause of headache for patients with coagulation defects, including those taking anticoagulant medication.",
"     </li>",
"     <li>",
"      Sickle cell disease &ndash; Cerebrovascular accident is the leading cause of death among children with sickle cell disease. Intracranial hemorrhage accounts for about one third of these cerebrovascular events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link&amp;anchor=H15#H15\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Intracranial hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cyanotic heart disease &ndash; Headache may be the manifestation of brain abscess among children with cyanotic heart disease and a right to left intracardiac shunt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed, including vital signs (with temperature and blood pressure measurements) and a thorough neurologic examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General appearance &ndash; Most children with serious causes for their headaches are ill-appearing.",
"     </li>",
"     <li>",
"      Vital signs &ndash; The vital signs must include temperature and blood pressure measurements. Fever suggests infection or, rarely, intracranial hemorrhage. Elevated blood pressure may be causing headache or be a response to increased intracranial pressure.",
"     </li>",
"     <li>",
"      Head and neck &ndash; The head and neck should be examined for evidence of trauma. Other findings on examination that may suggest a diagnosis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The diagnosis of otitis media can be determined with otoscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H19#H19\">",
"       \"Acute otitis media in children: Diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with maxillary or frontal sinusitis may have facial tenderness to palpation or purulent rhinorrhea.",
"     </li>",
"     <li>",
"      Streptococcal pharyngitis as a cause of headache may be evident with swelling, erythema, and exudates of the tonsillar pillars.",
"     </li>",
"     <li>",
"      The teeth and gingiva should be examined for evidence of inflammation or abscess.",
"     </li>",
"     <li>",
"      Tenderness over the temporomandibular joint (TMJ)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      masseter muscles suggests TMJ dysfunction.",
"     </li>",
"     <li>",
"      Nuchal rigidity can be a sign of meningitis, intracranial hemorrhage, or in rare cases, brain tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin &ndash; Children with neurocutaneous syndromes (ie, neurofibromatosis or tuberous sclerosis) may have brain lesions causing headaches. Skin should be carefully examined for characteristic features, such as caf&eacute;-au-lait spots or ash leaf spots. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link&amp;anchor=H17#H17\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Brain lesions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of children with headaches who have serious neurologic conditions have abnormalities on neurologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/18\">",
"     18",
"    </a>",
"    ]. The elements of the pediatric neurologic examination are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link&amp;anchor=H10928992#H10928992\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Neurologic examination'",
"    </a>",
"    .) The following findings are significant for children with headaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Altered mental status may be the result of encephalitis, intracranial hemorrhage, elevated intracranial (ICP), or hypertensive encephalopathy.",
"     </li>",
"     <li>",
"      Fundoscopic examination should be performed for all children who are being evaluated for headache. Adequate visualization of disks is often not possible in young or uncooperative patients. Papilledema, hemorrhages, exudates, and abnormal vessels are important manifestations of serious intracranial pathology, but the absence of these findings does not exclude significant conditions.",
"     </li>",
"     <li>",
"      Extraocular muscle palsies or nystagmus may be the result of elevated ICP or direct compression by a mass lesion.",
"     </li>",
"     <li>",
"      Motor asymmetry, gait disturbance, or difficulty with fine motor coordination suggests a focal intracranial lesion.",
"     </li>",
"     <li>",
"      Some children with migraine headaches develop focal neurologic abnormalities (ie, ophthalmoplegia, motor weakness, or ataxia) as part of their migraine syndromes (",
"      <a class=\"graphic graphic_table graphicRef68064 \" href=\"UTD.htm?40/58/41899\">",
"       table 3",
"      </a>",
"      ). Caretakers can generally confirm that the pattern is typical for the child's headaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with headache and normal neurologic examinations who are evaluated emergently do not require ancillary studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts suggest that neuroimaging in the emergency department is warranted for children with the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic progressive headache",
"     </li>",
"     <li>",
"      Worst",
"      <span class=\"nowrap\">",
"       headache/thunderclap",
"      </span>",
"      headache",
"     </li>",
"     <li>",
"      Abnormal neurologic examination",
"     </li>",
"     <li>",
"      Skin lesions suggestive of neurocutaneous syndromes",
"     </li>",
"     <li>",
"      Age &lt;3 years of age with unexplained severe headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) is readily available and generally identifies any condition that requires immediate treatment. Some children may require subsequent magnetic resonance imaging (MRI) to provide clearer definition of abnormalities noted on CT or to identify lesions that may not be seen on CT (ie, some infections, hemorrhagic processes, or cerebral venous thrombosis). Because CT can be performed quickly and safely, imaging should never be delayed in order to obtain an MRI for a child with a suspected space-occupying intracranial lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergent evaluation of a child with headache should include a lumbar puncture in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected nonfocal infection (meningitis, encephalitis)",
"     </li>",
"     <li>",
"      Concern for subarachnoid hemorrhage not diagnosed on neuroimaging",
"     </li>",
"     <li>",
"      To measure opening pressure for suspected idiopathic intracranial hypertension (after neuroimaging)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with focal neurologic examinations should have a CT performed before lumbar puncture (",
"    <a class=\"graphic graphic_algorithm graphicRef74865 \" href=\"UTD.htm?34/44/35521\">",
"     algorithm 1",
"    </a>",
"    ). There is a risk of herniation syndrome when lumbar puncture is performed in patients with increased intracranial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link&amp;anchor=H32#H32\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\", section on 'Cerebral herniation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic therapy should not be delayed for children with suspected meningitis who are unstable or must receive neuroimaging before an LP is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Initiation of empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Blood testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum electrolytes, blood urea nitrogen, creatinine, and a urinalysis should be obtained for any child with headache who has sustained and significant elevated blood pressure measurement. A complete blood count and blood cultures should be obtained for a child with a possible serious infectious process causing headaches, such as meningitis or viral encephalitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ALGORITHMIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic approach to the emergent evaluation of children with headaches (including a focused history, careful physical examination, and selected ancillary studies) generally identifies those who have conditions that require emergent diagnosis and treatment (",
"    <a class=\"graphic graphic_table graphicRef78979 \" href=\"UTD.htm?16/20/16716\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef65204 graphicRef58858 \" href=\"UTD.htm?31/42/32418\">",
"     algorithm 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children with headaches who are immunocompromised, have ventriculoperitoneal shunts, or have been injured require specific evaluations that frequently include ancillary studies, such as neuroimaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link&amp;anchor=H27#H27\">",
"     \"Hydrocephalus\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link\">",
"     \"Minor head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     History of chronic or recurrent headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children who present with typical headache patterns and no additional findings, the diagnosis of migraine or tension headache can usually be made following a careful history and thorough physical examination. Those with a change in the headache pattern or new clinical features (ie, fever or stiff neck) may require ancillary studies as directed by the history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Normal neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with headache who have normal neurologic examinations, including fundoscopic examination, generally do not require neuroimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with headache, fever, and meningeal signs, cerebrospinal fluid (CSF) evaluation for glucose and protein levels, cell count, and culture should be performed. Central nervous system infection can usually be diagnosed by CSF evaluation (",
"    <a class=\"graphic graphic_table graphicRef76324 \" href=\"UTD.htm?13/55/14204\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Interpretation of CSF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with normal CSF studies and those with headache and fever, without meningeal signs (who typically do not require CSF evaluation) likely have infectious causes for headache, such as viral syndrome, sinusitis, or dental abscess. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Common conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     No fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with headache, a normal neurologic examination, and no fever, who has no other abnormal features identified on history or physical examination, may be experiencing a first migraine or a tension-type headache. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Common conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical features identified by history or physical examination that suggest a specific diagnosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to improperly vented home heating systems, space heaters, or automobile exhaust fumes suggests carbon monoxide poisoning. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Carbon monoxide poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertensive encephalopathy may be the cause of headache for children with elevated blood pressure measurements. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with tenderness to palpation over sinuses, teeth, or temporomandibular joints (TMJ) may have focal infections or TMJ syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Common conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Temporomandibular joint dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Focal neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergent evaluation of children with headache who have focal findings on neurologic examination or papilledema includes neuroimaging. Computed tomography (CT) is readily available and generally identifies any condition that requires immediate treatment. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     CT scan abnormal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that cause headache and focal neurologic findings that may be identified with CT include mass lesions (ie, brain tumors or hematomas), hydrocephalus, and intracranial hemorrhage. Patients with abnormal CT scans require emergency",
"    <span class=\"nowrap\">",
"     neurologic/neurosurgical",
"    </span>",
"    evaluation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Life-threatening conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     CT scan normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture (LP) for CSF evaluation and opening pressure should be performed for children with focal neurologic findings who have extremely severe headaches",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck stiffness and whose head CTs are normal. The following abnormalities suggest a specific diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red blood cells in CSF (with a nontraumatic LP) may indicate subarachnoid hemorrhage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An elevated white blood cell count is consistent with central nervous system inflammation, such as occurs with infection (",
"      <a class=\"graphic graphic_table graphicRef76324 \" href=\"UTD.htm?13/55/14204\">",
"       table 5",
"      </a>",
"      ). In children with focal neurological findings and CSF pleocytosis, Herpes simplex virus should be strongly considered as some patients may benefit from treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Interpretation of CSF'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"       \"Herpes simplex virus type 1 encephalitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with papilledema, normal head CT scans, and elevated opening pressures on lumbar puncture may have idiopathic increased intracranial hypertension (IIH). Rarely, patients with these findings have cerebral venous thromboses (CVT). Magnetic resonance imaging is required to distinguish CVT from IIH. Consequently, children with apparent IIH who are asymptomatic (except for headache) and are well enough to be discharged from the emergency department should be evaluated by a neurologist within the next several days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with apparent papilledema who have normal CT scans, normal CSF evaluations, and normal opening pressures on LP may have pseudopapilledema with headaches from unrelated etiologies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A child with a moderately severe headache, no neck stiffness, focal neurologic findings that have resolved, and a normal head CT may have a migraine with aura.",
"   </p>",
"   <p>",
"    The International Headache Society notes that aura associated with a migraine headache typically lasts for less than 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14153/abstract/26\">",
"     26",
"    </a>",
"    ]. A patient with a new or atypical headache and focal findings that last for longer than one hour may have a more serious cause for headache. Children in this situation who are ill-appearing should have an MRI obtained immediately. Those whose symptoms have improved and who look well may be scheduled for MRI as an outpatient within several days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H15#H15\">",
"     \"Classification of migraine in children\", section on 'Complications of migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=see_link\">",
"       \"Patient information: Headaches in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of children who are evaluated emergently for headaches have self-limited conditions, a few may have serious causes that require urgent diagnosis and treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with headaches who are immunocompromised, have ventriculoperitoneal shunts, or have been injured must be carefully evaluated (usually with ancillary studies, including neuroimaging) for serious conditions in accordance with specific protocols not discussed in this topic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link&amp;anchor=H27#H27\">",
"       \"Hydrocephalus\", section on 'Complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"       \"Initial approach to severe traumatic brain injury in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link\">",
"       \"Minor head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Life-threatening causes of headache (ie, bacterial meningitis, tumors, or intracranial hemorrhage) may cause brain injury or death. Common conditions (ie, viral infections and migraines) typically resolve without sequelae (",
"      <a class=\"graphic graphic_table graphicRef78979 \" href=\"UTD.htm?16/20/16716\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life-threatening conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Common conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A combination of historical features, physical examination, and ancillary testing (usually computed tomography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CSF evaluation) typically identifies children with a life-threatening cause of headache. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An algorithmic approach to the emergent evaluation of children with headache may be useful (",
"      <a class=\"graphic graphic_algorithm graphicRef65204 \" href=\"UTD.htm?18/11/18623\">",
"       algorithm 2A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef58858 \" href=\"UTD.htm?14/13/14559\">",
"       algorithm 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/1\">",
"      Anttila P, Mets&auml;honkala L, Sillanp&auml;&auml; M. Long-term trends in the incidence of headache in Finnish schoolchildren. Pediatrics 2006; 117:e1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/2\">",
"      van der Wouden JC, van der Pas P, Bruijnzeels MA, et al. Headache in children in Dutch general practice. Cephalalgia 1999; 19:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/3\">",
"      Burton LJ, Quinn B, Pratt-Cheney JL, Pourani M. Headache etiology in a pediatric emergency department. Pediatr Emerg Care 1997; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/4\">",
"      Kabbouche MA, Linder SL. Acute treatment of pediatric headache in the emergency department and inpatient settings. Pediatr Ann 2005; 34:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/5\">",
"      Lewis DW, Qureshi F. Acute headache in children and adolescents presenting to the emergency department. Headache 2000; 40:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/6\">",
"      Kan L, Nagelberg J, Maytal J. Headaches in a pediatric emergency department: etiology, imaging, and treatment. Headache 2000; 40:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/7\">",
"      Locker TE, Thompson C, Rylance J, Mason SM. The utility of clinical features in patients presenting with nontraumatic headache: an investigation of adult patients attending an emergency department. Headache 2006; 46:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/8\">",
"      Hafidh MA, Keogh I, Walsh RM, et al. Otogenic intracranial complications. a 7-year retrospective review. Am J Otolaryngol 2006; 27:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/9\">",
"      Corson MA, Postlethwaite KP, Seymour RA. Are dental infections a cause of brain abscess? Case report and review of the literature. Oral Dis 2001; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/10\">",
"      The epidemiology of headache among children with brain tumor. Headache in children with brain tumors. The Childhood Brain Tumor Consortium. J Neurooncol 1991; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/11\">",
"      Dobrovoljac M, Hengartner H, Boltshauser E, Grotzer MA. Delay in the diagnosis of paediatric brain tumours. Eur J Pediatr 2002; 161:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/12\">",
"      Honig PJ, Charney EB. Children with brain tumor headaches. Distinguishing features. Am J Dis Child 1982; 136:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/13\">",
"      Al-Jarallah A, Al-Rifai MT, Riela AR, Roach ES. Nontraumatic brain hemorrhage in children: etiology and presentation. J Child Neurol 2000; 15:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/14\">",
"      Hampson NB, Hampson LA. Characteristics of headache associated with acute carbon monoxide poisoning. Headache 2002; 42:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/15\">",
"      Jones BV, Egelhoff JC, Patterson RJ. Hypertensive encephalopathy in children. AJNR Am J Neuroradiol 1997; 18:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/16\">",
"      Pavlakis SG, Frank Y, Chusid R. Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol 1999; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/17\">",
"      Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 2006; 118:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/18\">",
"      Schobitz E, Qureshi F, Lewis D. Pediatric headaches in the emergency department. Curr Pain Headache Rep 2006; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/19\">",
"      Anttila P, Mets&auml;honkala L, Helenius H, Sillanp&auml;&auml; M. Predisposing and provoking factors in childhood headache. Headache 2000; 40:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/20\">",
"      Anttila P. Tension-type headache in childhood and adolescence. Lancet Neurol 2006; 5:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/21\">",
"      Anttila P, Mets&auml;honkala L, Aromaa M, et al. Determinants of tension-type headache in children. Cephalalgia 2002; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/22\">",
"      Bonjardim LR, Gaviao MB, Carmagnani FG, et al. Signs and symptoms of temporomandibular joint dysfunction in children with primary dentition. J Clin Pediatr Dent 2003; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/23\">",
"      Farsi NM. Symptoms and signs of temporomandibular disorders and oral parafunctions among Saudi children. J Oral Rehabil 2003; 30:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/24\">",
"      Wilne SH, Ferris RC, Nathwani A, Kennedy CR. The presenting features of brain tumours: a review of 200 cases. Arch Dis Child 2006; 91:502.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. ACR appropriateness criteria. Headache - child. Available at file://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/HeadacheChild.pdf. Accessed August 6, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14153/abstract/26\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6432 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14153=[""].join("\n");
var outline_f13_52_14153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tension-type headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Temporomandibular joint dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Idiopathic intracranial hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cluster headaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Headache characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Blood testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ALGORITHMIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      History of chronic or recurrent headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Normal neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - No fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Focal neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - CT scan abnormal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - CT scan normal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6432|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/44/35521\" title=\"algorithm 1\">",
"      Management of suspected meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/11/18623\" title=\"algorithm 2A\">",
"      Emergent evaluation of pediatric headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/13/14559\" title=\"algorithm 2B\">",
"      Pediatric headache and focal neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/20/16716\" title=\"table 1\">",
"      Headache causes in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11773\" title=\"table 2\">",
"      Diagnostic criteria migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/58/41899\" title=\"table 3\">",
"      Common headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/21/36188\" title=\"table 4\">",
"      Etiology of headache children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/55/14204\" title=\"table 5\">",
"      CSF analysis in CNS infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14154="Ventricular septal defect in adults";
var content_f13_52_14154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ventricular septal defect in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Naser M Ammash, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Candice Silversides, MD, MS, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/52/14154/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/52/14154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26371595\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular septal defects (VSD), the most common congenital heart defect at birth, accounts for only 10 percent of those defects in adults because many close spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. About five percent of patients with VSDs have chromosomal abnormalities including trisomy 13, 18, and 21 syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3\">",
"     3",
"    </a>",
"    ]. VSDs are of various sizes and locations, can be single or multiple, and in adults may be complicated by subpulmonary stenosis, pulmonary hypertension (PHTN),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic regurgitation (AR), making their clinical presentation, natural history, and treatment quite variable and sometimes challenging. Although, VSDs are associated with other congenital heart defects including atrial septal defect (35 percent), patent ductus arteriosus (22 percent), right aortic arch (13 percent), pulmonic stenosis and more complex defects such as transposition of the great arteries and tetralogy of Fallot, the majority of congenital VSDs in adults present as an isolated defect, which is the focus of this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventricular septal defects occurring after acute myocardial infarction are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the interventricular septum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371603\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventricular septum is a nonplanar, three-dimensional partition of the ventricle, composed of five components: the membranous, muscular (also known as trabecular), infundibular, inlet and atrioventricular segments (",
"    <a class=\"graphic graphic_figure graphicRef53692 \" href=\"UTD.htm?38/10/39077\">",
"     figure 1",
"    </a>",
"    ). Ventricular septal defects result from deficient growth or failure of fusion of these components and vary in size from tiny apertures to very large defects with virtual absence of the septum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/5\">",
"     5",
"    </a>",
"    ]. In 2000, the Society for Thoracic Surgery and the European Association for Cardiothoracic Surgery established a unified reporting system for congenital heart disease including VSDs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/6\">",
"     6",
"    </a>",
"    ]. They classified VSD into four types (",
"    <a class=\"graphic graphic_figure graphicRef65508 \" href=\"UTD.htm?20/25/20882\">",
"     figure 2",
"    </a>",
"    ). Type 1 includes defect in the infundibular septum, type 2 in the membranous septum, type 3 in the inlet septum and type 4 in the muscular septum.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infundibular VSD (type 1, also referred to as supracristal, subarterial, subpulmonary, conal, or doubly committed juxta-arterial VSD) results from deficiency in the septum above and anterior to the crista supraventricularis, beneath the aortic and pulmonary valves (",
"      <a class=\"graphic graphic_figure graphicRef59434 \" href=\"UTD.htm?8/8/8323\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86958 graphicRef72186 \" href=\"UTD.htm?24/31/25080\">",
"       image 1A-B",
"      </a>",
"      ). The resultant loss of support of the right",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the left cusp causes cusp prolapse into the VSD leading to progressive AR, which is the hallmark of this defect [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Infundibular VSD are more common in Asia where they account for one third of VSD compared to a much lower frequency in the USA (6 percent of VSDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A membranous VSD (type 2, also known as conoventricular) results from deficiency of the membranous septum and is the most common type of VSD (80 percent of VSDs in the US) (",
"      <a class=\"graphic graphic_figure graphicRef59434 \" href=\"UTD.htm?8/8/8323\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75794 graphicRef86958 \" href=\"UTD.htm?5/27/5559\">",
"       image 1C",
"      </a>",
"      ). This defect is inferior to the crista supraventricularis and borders the septal leaflet of the tricuspid valve. The defect may extend into the muscular septum and is then referred to as a perimembranous (or paramembranous) VSD.",
"     </li>",
"     <li>",
"      Inlet defects (type 3, also known as AV canal type), result from deficiency of the inlet septum located beneath both mitral and tricuspid valves (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79923 \" href=\"UTD.htm?20/16/20736\">",
"       image 2",
"      </a>",
"      ). Despite proximity to those valves, this type of defect is not associated with mitral or tricuspid regurgitation unless associated with atrioventricular canal defect. This typically large defect is often associated with Down syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathophysiology and clinical features of atrial septal defects in adults\", section on 'Primum ASD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and diagnosis of Down syndrome\", section on 'Heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Muscular defects (type 4), which account for 5 to 20 percent of VSD, are bordered only by muscle within the trabecular septum, away from the cardiac valves. Muscular defects can be small or large, single or multiple, and occasionally oblique with multiple exits resembling Swiss cheese.",
"     </li>",
"     <li>",
"      The least common VSD is the atrioventricular VSD or Gerbode defect caused by deficiency of the membranous septum separating the left ventricle from the right atrium causing a left ventricular to right atrial shunt. This defect has also been reported as an acquired lesion following endocarditis and valve replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371611\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direction and severity of the shunt associated with VSD are determined by its functional size and, in the absence of right ventricular outflow obstruction, by the ratio of pulmonary to systemic vascular resistance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small or restrictive VSDs are defined as those with an orifice dimension less than or equal to 25 percent of the aortic annulus diameter. Small VSDs cause small left to right shunts with no left ventricular volume overload or pulmonary hypertension (PHTN).",
"     </li>",
"     <li>",
"      Moderate sized defects, measuring more than 25 but less than 75 percent of the aortic annulus diameter, cause moderate sized shunts and result in mild to moderate volume overload of the pulmonary arteries, left atrium, and left ventricle and no or mild PHTN. Large VSDs, defined as those with diameters equal to or greater than 75 percent of that of the aortic annulus, generally cause moderate to large left to right shunts with LV volume overload and, if they remain uncorrected, significant PHTN due to longstanding unobstructed pulmonary flow with resultant pulmonary arterial obstructive disease.",
"     </li>",
"     <li>",
"      With progressive pulmonary arterial hypertension, the right ventricular pressure can reach systemic levels leading to reversal of the shunt so that it is directed right to left with resultant hypoxemia and cyanosis; this is known as Eisenmenger syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      .) Eisenmenger syndrome in association with VSD is often referred to as Eisenmenger complex. Elevated right ventricular and right atrial pressures cause right ventricle hypertrophy and right atrial enlargement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Right atrial enlargement is associated with a VSD in three settings: (1) Eisenmenger complex, (2) a Gerbode defect, and (3) in the presence of double chambered right ventricle (DCRV).",
"   </p>",
"   <p>",
"    Double-chambered right ventricle (DCRV) is an acquired subpulmonic stenosis caused by hypertrophy of an aberrant muscle bundle in the right ventricle in the direction of the jet created by a membranous VSD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58886 \" href=\"UTD.htm?18/52/19269\">",
"     image 3",
"    </a>",
"    ). As its name implies, in DCRV the right ventricle is divided into two chambers: a proximal high-pressure chamber close to the tricuspid valve and a distal low pressure chamber underneath the pulmonary valve separated by the obstructive muscle bundle. This condition occurs in 3 to 10 percent of membranous VSDs and protects against the development of PHTN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aortic regurgitation occurs in association with infundibular VSD and less commonly with membranous VSD. It results from deficiency or hypoplasia of the conal septum causing an anatomically unsupported coronary cusp and aortic sinus. During systole, a Venturi effect drives the right or left coronary cusp into the right ventricle through the VSD, thus making the VSD smaller (",
"    <a class=\"graphic graphic_figure graphicRef77305 \" href=\"UTD.htm?5/25/5522\">",
"     figure 4",
"    </a>",
"    ). During diastole the intraaortic pressure forces the other aortic valve cusps to close, but the unsupported cusp is pushed down into the left ventricular outflow tract away from the other coronary cusps, resulting in prolapse, progressive AR and progressive left ventricular volume and left ventricular overload [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371619\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5506780\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated VSD generally presents with one of the following clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an isolated small restrictive defect with small left to right shunt (often referred to as &lsquo;maladie de Roger&rsquo;) generally remain asymptomatic in adulthood, but aortic regurgitation may develop and there is a low risk of endocarditis. (See",
"      <a class=\"local\" href=\"#H26371692\">",
"       'Natural history'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with moderate sized VSDs may remain asymptomatic or develop symptoms of mild heart failure in childhood. Heart failure usually resolves with medical therapy and with time as the child grows and the VSD get smaller in absolute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relative terms.",
"     </li>",
"     <li>",
"      The following scenarios may occur with large VSDs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most patients with large VSDs have early large left to right shunting with development of heart failure during infancy.",
"     </li>",
"     <li>",
"      In rare cases, the pulmonary vascular resistance does not fall normally post natally, left to right shunting is less marked and presentation with Eisenmenger syndrome occurs sometime during late childhood to early adulthood. The right to left shunt causes cyanosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dyspnea and fatigue in patients with VSDs result from either progressive left ventricular overload due to the VSD or from significant AR, PHTN or DCRV. Syncope is often exertional and caused by severe PHTN, or right ventricular outflow obstruction due to a large prolapsing aortic valve cusp, or large aneurysm of the membranous septum or DCRV. Patients with VSDs may also present with arrhythmias or sudden death.",
"   </p>",
"   <p>",
"    It is also not uncommon for patients to present with a change in the murmur characteristics caused by the development of DCRV or PHTN or AR. Membranous VSD may close spontaneously via adherence of the septal leaflet of the tricuspid valve which forms an aneurysm of the membranous septum; this septal aneurysm may cause a new midsystolic click and may lead to syncope due to right ventricular outflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371633\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most VSDs can be readily identified by cardiac examination depending on their type, size and associated hemodynamic abnormalities. The smaller the VSD, the louder is the associated murmur. Small defects cause a loud high-frequency systolic murmur often accompanied by a palpable thrill in the third or fourth left intercostal space [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/16\">",
"     16",
"    </a>",
"    ]. The aortic closure sound may be normal or masked by the loud murmur. Although, the VSD murmur is a typically a holosystolic plateau-shaped murmur, it may stop well before the second sound with some muscular defects because of midsystolic obliteration of the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link&amp;anchor=H26#H26\">",
"     \"Auscultation of cardiac murmurs\", section on 'Ventricular septal defect'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical holosystolic VSD murmur may be replaced by a &ldquo;diamond-shaped&rdquo; (crescendodecrescendo) midsystolic murmur or simply consist of a systolic ejection component in the presence of pulmonic stenosis. Similarly, double-chambered right ventricle (DCRV) with VSD is associated with a loud midsystolic crescendo-decrescendo systolic murmur at the left sternal border, often associated with a thrill [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/18\">",
"     18",
"    </a>",
"    ]. An infundibular VSD allows blood to be shunted directly into the pulmonary artery and therefore the resultant murmur is systolic ejection murmur heard maximally in the second intercostal space. As shown in the table (",
"    <a class=\"graphic graphic_figure graphicRef56343 \" href=\"UTD.htm?33/3/33850\">",
"     figure 5",
"    </a>",
"    ), the cardiac examination of patients with VSD and valvular or subvalvular pulmonary stenosis depends on the severity of the latter lesion.",
"   </p>",
"   <p>",
"    Patients with infundibular or membranous VSDs who develop AR demonstrate typical features of AR such as a wide pulse pressure, pistol shot and collapsing pulses, as well as a to-and-fro,",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    murmur, best heard in the upper sternal border, composed of a systolic VSD murmur and a separate high-frequency diastolic murmur of AR. This may simulate continuous murmurs such as those heard with patent ductus arteriosus. However, in patients with VSD and AR, the systolic component stops at or before the second heart sound and does not envelop it as continuous murmurs do. The presence of significant AR will also intensify the degree of left ventricular enlargement which can be detected on cardiac examination.",
"   </p>",
"   <p>",
"    When VSD is complicated by pulmonary vascular obstructive disease and severe PHTN as in Eisenmenger complex, the patients have central and peripheral cyanosis with dusky lips, and clubbed fingers and toes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\", section on 'General features'",
"    </a>",
"    .) The typical findings on cardiac examination in Eisenmenger complex include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of the typical holosystolic murmur of VSD due to systemic right ventricular pressure that equalizes the left ventricular pressure and therefore abolishes the left-to-right shunt",
"     </li>",
"     <li>",
"      Jugular venous examination demonstrating an &ldquo;a&rdquo; wave due to right ventricular hypertrophy and later a &ldquo;v&rdquo; wave due to tricuspid regurgitation often accompanied by a systolic murmur that increases with inspiration.",
"     </li>",
"     <li>",
"      Signs of right heart failure such as hepatomegaly, ascites and edema",
"     </li>",
"     <li>",
"      Prominent right ventricular impulse and palpable loud pulmonary closure sound, which often fuses with the aortic closure sound producing a single S2 (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link&amp;anchor=H23#H23\">",
"       \"Auscultation of heart sounds\", section on 'Single S2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Midsystolic pulmonary ejection click due to dilated pulmonary artery (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link&amp;anchor=H35#H35\">",
"       \"Auscultation of heart sounds\", section on 'Pulmonary ejection sound'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diastolic blowing murmur of pulmonary regurgitation, the Graham-Steell murmur, may be heard in the left upper sternal border. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371641\">",
"    <span class=\"h1\">",
"     CLINICAL TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371648\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with isolated VSD, especially when small, are in normal sinus rhythm and have a normal electrocardiogram on presentation (eg, 66 percent in a medically managed group of patients with VSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. However, various electrocardiographic abnormalities such as intraventricular conduction delay or right bundle branch block have been observed among those with larger defects. In addition, electrocardiographic signs of left atrial enlargement and left ventricular enlargement or hypertrophy can be present with significant left ventricular volume overload due to VSD shunt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AR.",
"   </p>",
"   <p>",
"    In the presence of Eisenmenger complex, or significant right ventricular outflow obstruction such as caused by DCRV, the electrocardiogram reflects the elevated right ventricular pressure with findings including right axis deviation and evidence of right atrial enlargement and right ventricular or biventricular hypertrophy. The prevalence of atrial and ventricular premature beats and arrhythmias increases as the right ventricular pressure increases and therefore may be incidentally noted on the electrocardiogram. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371655\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray in patients with uncomplicated small VSD demonstrates a normal cardiac silhouette and pulmonary vascular markings. With larger VSDs, the chest x-ray may show cardiomegaly with prominent left ventricular contour and left atrial and pulmonary artery enlargement due to volume overload directly related to the magnitude of the shunt. The CXR may also show evidence of shunt vascularity. Evidence of cardiomegaly on chest x-ray is indicative of a significant left to right shunt through the VSD with a pulmonary to systemic flow ratio",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    &gt;2 or the presence of significant AR, or both. In the presence of Eisenmenger complex, the associated cardiomegaly has a right ventricular contour due to right ventricular hypertrophy and is frequently accompanied by right atrial enlargement and prominent central pulmonary arteries with pruning of outer pulmonary vessels. In the presence of right ventricular outflow obstruction caused by DCRV, the pulmonary vascularity is reduced whereas in the presence of valvular pulmonary stenosis, the chest x-ray shows enlarged proximal left pulmonary artery due to post stenotic dilatation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371662\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive echocardiography examination is the single most important clinical test needed in evaluating a VSD, its hemodynamic burden, associated congenital defects, and potential long-term complications. Echocardiography has an excellent detection rate (88 to 95 percent) for VSD depending on the size, location of the defect, and technical expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/14\">",
"     14",
"    </a>",
"    ]. Echocardiography is most sensitive for VSD larger than 5 mm and those located in the membranous, inlet, or infundibular septum, while being least sensitive for those in the apical trabecular septum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=see_link\">",
"     \"Echocardiographic evaluation of ventricular septal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough echocardiographic examination is best achieved by imaging the ventricular septum and surrounding structures in multiple planes with color flow and spectral Doppler. The parasternal long axis views allow the distinct visualization of muscular, membranous, and infundibular defects (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75794 \" href=\"UTD.htm?15/14/15584\">",
"     image 1C",
"    </a>",
"    ). The latter two defects are both seen below the aortic valve and are sometimes difficult to differentiate from each other. On parasternal short axis imaging these are clearly distinguished with a membranous defect adjacent to the tricuspid valve whereas an infundibular defect is below the pulmonary valve (",
"    <a class=\"graphic graphic_figure graphicRef59434 \" href=\"UTD.htm?8/8/8323\">",
"     figure 3",
"    </a>",
"    ). The parasternal views also enable visualization of an aneurysm of the membranous septum and assists in the evaluation of AR in presence of infundibular or supracristal VSD (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72186 \" href=\"UTD.htm?30/40/31363\">",
"     image 1B",
"    </a>",
"    ) and DCRV in the presence of membranous defect (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58886 \" href=\"UTD.htm?18/52/19269\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The apical views enable assessment of inlet muscular and Gerbode defects. Inlet defects are adjacent to the mitral and tricuspid valves as seen in (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79923 \" href=\"UTD.htm?20/16/20736\">",
"     image 2",
"    </a>",
"    ) and extend into the chordal attachments of the tricuspid valve whereas the muscular defects are located in the trabecular septum away from the cardiac valves. Gerbode defects are best visualized within the cardiac crux on apical four-chamber view in which color flow Doppler demonstrates a left ventricular to right atrial shunt.",
"   </p>",
"   <p>",
"    In addition to the accurate identification of the morphologic features of the VSD, its size and borders, echocardiography also provides a hemodynamic assessment of the shunt severity, identifies secondary volume overload of the pulmonary artery, left atrium and ventricle, and identifies the presence and severity of associated complications including DCRV, AR, PHTN, or aneurysm of membranous septum. The pulmonary to systemic flow ratio",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    can be estimated by echocardiography by Doppler methods although these are subject to technical limitations. The presence of normal left ventricular size is suggestive of a small restrictive uncomplicated VSD with small left to right shunt. On the other hand, enlargement of the left ventricle, left atrium, and pulmonary artery is indicative of a larger VSD with significant left to right shunt necessitating consideration of repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=see_link\">",
"     \"Echocardiographic evaluation of ventricular septal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Color flow Doppler, including color M mode, and spectral Doppler analysis across the VSD can determine the severity, timing and the direction of the shunt.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A proper continuous wave Doppler velocity of &ge;5",
"      <span class=\"nowrap\">",
"       m/s",
"      </span>",
"      across the VSD is suggestive of small restrictive defect with small left to right shunt. In the presence of significant systemic hypertension, the threshold velocity for a restrictive VSD is higher.",
"     </li>",
"     <li>",
"      On the other hand, lower velocities across the VSD suggest the presence of valvular pulmonary stenosis, DCRV or PHTN. Under those conditions, the right ventricular pressure is elevated and as a result the pressure difference between the left and right ventricle is reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When assessing the hemodynamic burden of a VSD and any associated lesions, it is imperative to obtain an accurate estimation of the right ventricular and pulmonary artery pressures. All echocardiographic windows should be used to acquire a clear distinct noncontaminated tricuspid regurgitant velocity signal to enable accurate estimation of the right ventricular and pulmonary artery systolic pressures. Finally, echocardiography provides an excellent noninvasive assessment of the degree of aortic valve distortion, prolapse and AR in patients with infundibular or membranous defects.",
"   </p>",
"   <p>",
"    Most echocardiographic assessment of VSD can be performed accurately using transthoracic echocardiography. Transesophageal echocardiography is reserved for patients with suboptimal precordial echocardiographic windows and when specific questions are not confidently answered using transthoracic echocardiography such as the degree if aortic valve distortion, severity of AR and the presence of vegetations when endocarditis is suspected. The potential role of three-dimensional echocardiography in the assessment of congenital heart diseases including VSD and especially in the evaluation of left ventricular volume is promising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371670\">",
"    <span class=\"h2\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult patients with congenital heart disease exhibit a great ability to adapt to the functional limitations imposed by their birth defect. By adjusting to these restrictions, such as walking at a slower pace, they tend to report no symptoms of dyspnea or fatigue even in presence of a significant hemodynamic impairment. Concern has been raised that this adaptability may result in lack of reported symptoms, which may delay care since the presence of symptoms is a common indication for repair.",
"   </p>",
"   <p>",
"    As a result, we advocate the use of exercise stress testing to objectively assess the exercise tolerance and functional aerobic capacity. The inability to achieve 70 percent of expected functional aerobic capacity is felt to be abnormal. More importantly, a documented deterioration in exercise capacity over time in an otherwise asymptomatic patient might be an early sign of functional decline. Such a finding may be useful in defining optimal timing of intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371677\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance imaging and computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging and computed tomography (CT) can provide accurate, reliable and reproducible assessment of cardiac structure and function in congenital heart disease when performed by an expert. These techniques offer certain advantages over echocardiography since they allow unrestricted evaluation of cardiac chambers and great arteries not compromised by air, bone, or surgical scar. Summation of disks on multiple tomographic slices during ventricular diastole and systole permits direct and accurate measurement of left ventricular volume and function. Such data is helpful in timing intervention or repair in adults with VSDs. However, these techniques have not been widely adopted in the evaluation of VSD primarily because echocardiography is widely available and provides sufficient information in most cases and CMR and cardiac CT have more limited availability.",
"   </p>",
"   <p>",
"    CMR or CT techniques may be particularly helpful for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMR phase contrast cine techniques enable quantitation of the pulmonary to systemic flow ratio",
"      <span class=\"nowrap\">",
"       (Qp/Qs)",
"      </span>",
"      with strong correlation with results obtained by cardiac catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMR or CT may be helpful for assessment of coexisting lesions in the pulmonary artery, pulmonary veins or aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMR or CT can identify lesions such as apical defects not well characterized by echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371684\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of echocardiography, cardiac catheterization (using angiography combined with oximetry or indicator dilution curves) was the only available diagnostic test to confirm and evaluate a clinically suspected VSD. However, with the development and widespread adoption of echocardiography, cardiac catheterization has evolved into an adjunctive clinical test reserved mainly for the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VSD whose hemodynamic significance is questionable to quantification of the shunt severity or",
"      <span class=\"nowrap\">",
"       Qp/Qs",
"      </span>",
"      ratio,",
"     </li>",
"     <li>",
"      VSD associated with DCRV or valvular pulmonary stenosis to assess the severity of the shunt, the gradient within and across the right ventricular outflow tract and pulmonary artery pressure.",
"     </li>",
"     <li>",
"      VSD with PHTN to assess the operability of the patient by measuring pulmonary artery pressure, cardiac index, pulmonary and systemic vascular resistance and the response to oxygen, vasodilators and nitrous oxide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indications for cardiac catheterization include evaluation of AR in patients with aortic valve prolapse, determination of whether multiple VSDs are present before surgery, determination of VSD anatomy if device closure is contemplated and performance of preoperative coronary angiography in patients at risk for coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Computer tomography of the coronary arteries has recently emerged as an alternative reliable preoperative diagnostic tool for assessment of coronary artery disease in selected patients. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371692\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of isolated VSDs depends on the type, size of defect, and associated hemodynamic abnormalities. Although many defects close spontaneously before adulthood, many others persist and could predispose to endocarditis, arrhythmias, heart failure, AR, DCRV or PHTN. Therefore, periodic clinical evaluation is recommended. In the presence of AR, DCRV or PHTN, such evaluation is best performed at an adult congenital heart disease center where the necessary medical, imaging and surgical expertise is available",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364844\">",
"    <span class=\"h2\">",
"     Spontaneous closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous closure occurs in 40 to 60 percent of individuals with VSDs, predominantly during early childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'Natural history'",
"    </a>",
"    .) In addition, spontaneous closure occurring between the ages of 17 and 45 years was observed in 10 percent of 188 adults with VSD followed for a mean of 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/25\">",
"     25",
"    </a>",
"    ]. Closure results from muscular growth around the defect, ingrowth of border-forming proliferative fibrous tissue, or, in the case of membranous defects, from an aneurysm of the tricuspid valve leaflet adhering to the edge of the defect. Spontaneous closure occurs for some muscular and membranous defects but not for inlet or infundibular defects. Although a VSD that has closed spontaneously is generally associated with an excellent prognosis, closure may occur with formation of an aneurysm of the membranous septum which may be associated with tricuspid regurgitation and rarely late right ventricular outflow tract obstruction and heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364851\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of endocarditis is ongoing in those with unrepaired VSD with an incidence of 22 to 24 per 10,000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The risk of endocarditis is higher in those with unrepaired VSD as compared to those who have undergone repair (RR 3.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/26\">",
"     26",
"    </a>",
"    ]. Other risk factors for endocarditis include age &gt;20 years old and male sex. VSD size is not a significant risk factor for development of endocarditis.",
"   </p>",
"   <p>",
"    When endocarditis is suspected, an echocardiogram is recommended to assess for vegetations around the border of the defect, within the defect, or on adjacent valves in the direction of the high velocity jet created by the VSD. Vegetations may be seen on the tricuspid valve with membranous VSD, and the aortic or pulmonary valves with infundibular defects. Transesophageal echocardiography remains the diagnostic procedure of choice in the evaluation of patients with suspected endocarditis given its greater sensitivity and specificity compared to transthoracic echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the increased risk of endocarditis in the presence of VSD, the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    does",
"    <strong>",
"     not",
"    </strong>",
"    recommend antibiotic prophylaxis for the acyanotic uncomplicated VSD with no prior history of endocarditis predominantly because of the lack of evidence supporting such widespread use of antibiotic prophylaxis and concerns about developing antimicrobial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364859\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias including atrial and ventricular premature beats and tachycardias have been observed in adult patients with VSD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. The reported incidence of ventricular tachycardias and sudden death in natural history studies of VSDs are 5.7 and 4.0 percent, respectively. In a series of patients with medically-managed VSD, age and pulmonary artery pressure were the best predictors for ventricular arrhythmias on 24 hour ambulatory ECG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/28\">",
"     28",
"    </a>",
"    ]. Arrhythmias are among the presenting signs of VSD in adults and a comprehensive evaluation is recommended to assess for candidacy for VSD repair in all adults with VSD and cardiac arrhythmias.",
"   </p>",
"   <p>",
"    In patients with VSD complicated by Eisenmenger complex, the reported incidence of ventricular tachycardia is 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. The hypertrophied right ventricle in these patients, as well as in those with DCRV, represents an ideal substrate for ventricular arrhythmias. Therefore some advocate annual Holter monitoring in Eisenmenger complex.",
"   </p>",
"   <p>",
"    Atrial arrhythmias, mostly atrial fibrillation, are also prevalent in adult VSD, especially with increasing age, left ventricular dysfunction and elevated pulmonary artery pressure. Treatment of these arrhythmias should be individualized, depending on their severity, frequency and associated symptoms such as syncope, and the presence of conduction delay, or ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1364866\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure due to chronic volume overload of the left ventricle occurs in patients with isolated medium or large VSDs and is rarely seen in adults since most of these are repaired during childhood. However, left-sided heart failure can develop in the setting of significant AR in association with a small residual infundibular or membranous VSD. Right-sided heart failure may occur in adults with VSD and significant valvular pulmonic stenosis, DCRV, or PHTN, particularly with Eisenmenger complex and a failing right ventricle. Under this circumstance, significant tricuspid regurgitation predominantly due to annular dilatation is noted on examination and echocardiogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11167278\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival ranges from excellent for patients with small restrictive VSDs with normal ventricular function and normal pulmonary artery pressure to limited for those with Eisenmenger complex [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19,27,29\">",
"     19,27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the NHS-2 study of 1252 patients with VSDs who were followed for &gt;15 years, the overall estimated 20 year survival rate was 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. For patients with normal estimated pulmonary artery systolic pressure, the 20 year survival rate was 97 percent. For patients with Eisenmenger complex, the 20 year survival rate was 54 percent. The most common reported causes of death in patients with VSD are heart failure and sudden death, followed by pulmonary embolism, myocardial infarction, and endocarditis.",
"   </p>",
"   <p>",
"    Patients with uncomplicated small VSDs, especially those involving the muscular and membranous septum, generally do very well as long as they do not develop left ventricular volume overload or pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3\">",
"     3",
"    </a>",
"    ]. In the NHS-2 study, nearly a third of initially medically managed patients with VSDs required VSD closure. However, patients with moderate shunts were included in the initially medically treated group. In later series of patients with small VSDs, the frequency of need for subsequent VSD closure was much lower (eg, less than one percent during mean seven year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/27\">",
"     27",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    VSD and aortic regurgitation occur most commonly with infundibular VSD because the associated deficiency or hypoplasia of the conal septum causes an anatomically unsupported right or left coronary cusp and aortic sinus. As a result, the unsupported coronary cusp is driven into the right ventricle by Venturi effect, making the VSD smaller during systole. During diastole, intraaortic pressure causes the aortic valve cusps to close, but the unsupported cusp prolapses down into the left ventricular outflow tract away from the opposing leaflets, resulting in progressive AR. The prevalence of AR increases with age (occurring in 87 percent of patients by age 20), and is 2.5 times more common with an infundibular VSD as compared to a membranous VSD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. The progressive nature of the AR, the potential associated morbidity, along with improved surgical technique in valve repair have led to the recommendation for early surgical intervention.",
"   </p>",
"   <p>",
"    VSD and DCRV occur only in association with membranous VSD. Progressive hypertrophy of an aberrant right ventricular muscle bundle in the direction of the VSD jet creates a DCRV with a proximal high-pressure right ventricular chamber in the right ventricular inflow and a distal low-pressure right ventricular chamber underneath the pulmonic valve. This condition develops in 3 to 10 percent of patients with membranous VSD and is characterized by the development of a loud systolic crescendo-decrescendo systolic murmur at left sternal border, often associated with a thrill, replacing the typical holosystolic murmur of VSD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26371633\">",
"     'Physical examination'",
"    </a>",
"    above.) The resultant right ventricular hypertrophy and right atrial enlargement are associated with ventricular and atrial arrhythmias respectively.",
"   </p>",
"   <p>",
"    VSD with irreversible chronic pulmonary vascular obstructive disease (known as Eisenmenger complex) develops in about 10 to 15 percent of patients with VSD, most commonly in the second and third decade [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients frequently experience symptomatic deterioration in their 40s when they present with dyspnea, chest pain, hemoptysis, arrhythmias, or syncope. Chronic systemic oxygen desaturation induces the release of erythropoietin resulting in secondary erythrocytosis. Patients with Eisenmenger complex are at risk for complications of cyanotic heart disease, including the following which are discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperviscosity syndrome and cerebrovascular events caused by secondary erythrocytosis due to chronic cyanosis",
"     </li>",
"     <li>",
"      Hemostatic problems and increased risk of bleeding due to prolonged prothrombin time, prolonged activated partial thromboplastin time, decreased levels of coagulation factors, decreased platelet count, and abnormal platelet function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemoptysis may be caused by pulmonary hemorrhage, pulmonary embolus, or in situ pulmonary thrombosis and infarction. The extent of potentially life-threatening intrapulmonary hemorrhage is not reflected by the volume of hemoptysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H7#H7\">",
"       \"Medical management of cyanotic congenital heart disease in adults\", section on 'Pulmonary bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild renal dysfunction and proteinuria",
"     </li>",
"     <li>",
"      Hyperuricemia with gout due to increased red blood cell turnover",
"     </li>",
"     <li>",
"      Increased risk of calcium bilirubinate gallstones",
"     </li>",
"     <li>",
"      Painful hypertrophic arthropathy of the long bone and scoliosis",
"     </li>",
"     <li>",
"      Acne, endocarditis and brain abscess &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with Eisenmenger complex have poor outcomes although generally better than those with primary pulmonary hypertension. Although, some may survive to their 60s, the majority succumb by their fourth or fifth decade from acute hypoxia, sudden ventricular arrhythmia, heart failure, massive hemoptysis, or complications of noncardiac surgery or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3,9,15\">",
"     3,9,15",
"    </a>",
"    ]. Pregnancy is contraindicated in patients with Eisenmenger complex, as for all patients with Eisenmenger syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26371701\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patient with an isolated VSD depends on the type of defect, its size, shunt severity, pulmonary artery pressure and vascular resistance and associated acquired complications including DCRV, AR and PHTN. Observational data suggest that surgical closure decreases the risk of endocarditis by at least half [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/26\">",
"     26",
"    </a>",
"    ]. Observational series also suggest that surgical closure in patients with significant shunts reduces pulmonary artery pressure and improves long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Therefore, repair of VSD should be considered in all adult patients who are symptomatic or have signs of left ventricular volume overload. Medical treatment is reserved for (1) asymptomatic patients with no evidence of left ventricular volume overload and (2) patients with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular volume overload who are",
"    <strong>",
"     not",
"    </strong>",
"    candidates for repair such as those with large defects and severe irreversible PHTN (Eisenmenger complex). (See",
"    <a class=\"local\" href=\"#H21904975\">",
"     'Indications for intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We recommend careful follow-up and monitoring for unoperated asymptomatic patients with VSD without signs of left ventricular volume overload. Although most patients with small VSDs do well during long-term follow-up, many develop complications. For example, in a series of 188 patients (mean age 29 years) with small unoperated VSD, approximately half of the patients (47 percent) had no complications during mean 13 year follow-up. Endocarditis and AR developed in 11 and 20 percent respectively. Age-related arrhythmias, most commonly atrial fibrillation, developed in 8.5 percent, [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/25\">",
"     25",
"    </a>",
"    ]. We recommend continued observation for development of symptoms, development of left ventricular dilatation or decline in functional aerobic capacity on stress testing.",
"   </p>",
"   <p>",
"    When the VSD involves the atrioventricular septum (Gerbode defect), periodic assessment includes surveillance for sinus node dysfunction and tricuspid regurgitation, which have been reported in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with previously repaired VSDs, significant shunts, residual heart failure, AR, PHTN, or other hemodynamic abnormalities should be seen at least annually at an adult congenital heart disease center.",
"   </p>",
"   <p>",
"    Patients with Eisenmenger complex should be managed conservatively according to recommendations for Eisenmenger syndrome and cyanotic congenital heart disease as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .) Given the specialized care that patients with Eisenmenger complex require, referral and follow-up at a tertiary care facility with expertise in the care of adult patients with congenital heart disease is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21904975\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of VSD has been historically performed surgically. However, percutaneous VSD repair has been growing given the desire of young adults to avoid surgery, [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Surgical and percutaneous VSD closure should be performed by surgeons and cardiologists with appropriate training and expertise.",
"   </p>",
"   <p>",
"    Indications for closure of a VSD in an adult are included in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease guidelines as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ]. Similar recommendations are included in the European Society of Cardiology and the Canadian Society of Cardiology guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Closure of a VSD is indicated when there is a",
"      <span class=\"nowrap\">",
"       Qp/Qs",
"      </span>",
"      &ge;2 and clinical evidence of LV volume overload.",
"     </li>",
"     <li>",
"      Closure of a VSD is indicated when the patient has a history of infective endocarditis.",
"     </li>",
"     <li>",
"      Closure of a VSD is reasonable when there is net left to right shunting with a",
"      <span class=\"nowrap\">",
"       Qp/Qs",
"      </span>",
"      &ge;1.5 with pulmonary artery pressure less than two thirds of systemic pressure and PVR is less than two thirds of systemic vascular resistance.",
"     </li>",
"     <li>",
"      Closure of a VSD is reasonable when there is net left to right shunting with a",
"      <span class=\"nowrap\">",
"       Qp/Qs",
"      </span>",
"      &ge;1.5 in the presence of LV systolic or diastolic dysfunction or failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Closure of a VSD is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with severe irreversible pulmonary artery hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determination of the optimal timing of operation in patients who have VSD and AR has been controversial. Surgical repair of VSD with AR should not be delayed in the asymptomatic patients until there is significant left ventricular enlargement or dysfunction as often recommended in isolated severe AR [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/36\">",
"     36",
"    </a>",
"    ]. Early intervention in VSD with AR, with closure of the VSD and repair of the aortic valve, is feasible and indicated depending on the defect type (subarterial or membranous), defect size and degree of valve distortion and AR severity, with better results achieved in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21904982\">",
"    <span class=\"h1\">",
"     SURGICAL REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary surgical repair for isolated VSD was previously performed through a ventriculotomy and has been more recently performed through a right atriotomy.",
"   </p>",
"   <p>",
"    Concomitant repair of other cardiac defects is frequently indicated. For example, in one series, 34 of 46 adult patients undergoing VSD repair needed concomitant repair of other defects, most commonly aortic or tricuspid valve repair [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When DCRV is present, the right ventricular outflow obstruction should be resected.",
"     </li>",
"     <li>",
"      When aortic valve prolapse and AR are present, careful inspection of the aortic valve and valve repair when possible are recommended to reduce the risk of progressive AR postoperatively. This often includes commissural suspension and plication of the elongated prolapsing cusp. In patients in whom aortic valve repair is not feasible because of extensive distortion, fenestration, or significant fibrosis or calcification, valve replacement should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/15\">",
"       15",
"      </a>",
"      ]. A study of 122 adolescents and adults with VSD and AR found that 49 needed aortic valve repair and 21 valve replacement (57 percent all together) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Expert intraoperative transesophageal echocardiography is very useful to assess adequacy of surgical repair, even for muscular VSDs, which are occasionally difficult to visualize because of overlying trabeculation.",
"   </p>",
"   <p>",
"    Observational data suggest that surgical closure decreases the risk of endocarditis by at least half [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/26\">",
"     26",
"    </a>",
"    ]. Observational series also suggest that surgical closure in patients with significant shunts reduces pulmonary artery pressure and improves long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The risk of operative mortality with surgical VSD closure was substantial in earlier series. An observational series of 1280 patients with VSD undergoing surgery between 1958 and 1990 reported a one-month mortality of 6 percent; 89.9 percent of deaths were due to cardiac causes (heart failure and sudden death) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. In a contemporaneous series of 41 patients undergoing surgical VSD closure, four early postoperative deaths were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/30\">",
"     30",
"    </a>",
"    ]. Three patients had aortic regurgitation and one had Eisenmenger complex. &nbsp;",
"   </p>",
"   <p>",
"    Improved cardioplegia, myocardial preservation, surgical techniques, patient selection and post operative care have led to a significant decline in operative mortality in isolated uncomplicated VSD to &lt;2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ]. A report from the Mayo clinic describing outcomes of surgical VSD repair in 46 adults demonstrated no operative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21904990\">",
"    <span class=\"h1\">",
"     LATE POSTOPERATIVE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with repaired VSD without residua have excellent outcomes and normal survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3\">",
"     3",
"    </a>",
"    ]. In a series of 516 patients who had undergone VSD repair, the 25year survival was 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ]. However, long-term survival is less favorable when repair is done at older age or in presence of PHTN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A later series of 46 adults followed at the Mayo clinic demonstrated survival rates at 5, 10, and 15 years after surgery of 100, 95, and 88 percent respectively which did not differ from the expected survival rate derived from a reference population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the prognosis after surgical repair of uncomplicated VSD is excellent in the majority of patients, long-term residua and sequelae are not uncommon including conduction disease, cardiac arrhythmias, residual VSD, endocarditis, tricuspid regurgitation, ventricular dysfunction, pulmonary hypertension, and aortic regurgitation.",
"   </p>",
"   <p>",
"    Ventricular arrhythmias including ventricular premature beats (20 to 34 percent) and less commonly ventricular tachycardia can occur many years after VSD repair [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/28,30,41\">",
"     28,30,41",
"    </a>",
"    ]. Their incidence increases with higher preoperative New York Heart Association functional classification, cardiomegaly, age at time of operation and increased pulmonary artery pressure. As noted below, late ventricular arrhythmias may be associated with postoperative conduction disease. Sudden death is rare but accounts for as much as 39 percent of all cardiac deaths after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial fibrillation develops in a minority of patients following VSD repair (eg, 10 percent in one post surgical series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ]). Atrial fibrillation typically occurs with persistent left atrial enlargement due to chronic volume overload or right atrial enlargement with residual PHTN.",
"   </p>",
"   <p>",
"    Conduction disease including right bundle branch block (18 to 100 percent) and left anterior hemiblock (30 percent), especially after ventriculotomy and patch closure of the defect are common following surgical VSD repair. Late sinus node dysfunction, including complete heart block requiring pacemaker placement, is infrequent (&le;2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/30,39,41\">",
"     30,39,41",
"    </a>",
"    ]. Late ventricular arrhythmias could be related to postoperative conduction disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"     19",
"    </a>",
"    ] and an association between postoperative conduction defect and late sudden death and ventricular arrhythmia has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/42\">",
"     42",
"    </a>",
"    ]. Therefore, patients who develop bifascicular block or transient trifascicular block after VSD repair should be followed yearly by history and electrocardiogram and have periodic ambulatory monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise stress testing to assess heart rate response to exercise and to exclude exercise induced malignant arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual VSD was reported in up to one-third of patients in the original surgical series. However, in a later Mayo clinic study, residual VSD was noted in only 7 of 46 (15 percent) following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ]. Residual VSD are often small and hemodynamically insignificant and reoperation for residual VSD is necessary in only 5 to 6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/3\">",
"     3",
"    </a>",
"    ]. Periodic followup evaluation is required to monitor for potential need for reoperation. The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended a follow-up assessment every three to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endocarditis risk after surgical repair is approximately half that in medically treated patients with a reported incidence of 0.8 to",
"    <span class=\"nowrap\">",
"     1.7/1,000",
"    </span>",
"    patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/26,27,30\">",
"     26,27,30",
"    </a>",
"    ]. In the absence of a prior history of endocarditis or residual VSD with prosthetic material, endocarditis prophylaxis is not recommended postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H8#H8\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'AHA guideline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tricuspid regurgitation due to septal leaflet traumatic detachment or iatrogenic entrapment during VSD repair has been reported. Tricuspid regurgitation may be aggravated by PHTN with associated tricuspid annular dilatation and should therefore be carefully monitored. In a series of 46 patients, moderate or greater tricuspid regurgitation was observed in 27 percent following VSD repair at a mean follow-up of 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longstanding left ventricular volume overload causes eccentric left ventricular hypertrophy and can which can progress to ventricular dysfunction. VSD repair promotes normalization of left ventricular mass and function. However, ventricular dysfunction with heart failure may persist or even worsen after repair particularly in patients with residual VSD, AR, abnormal septal wall motion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concomitant acquired cardiovascular diseases such as systemic hypertension and ischemic coronary disease.",
"   </p>",
"   <p>",
"    The degree of persistent PHTN after VSD repair depends on the severity of preoperative PHTN and the presence of residual VSD. Persistent PHTN is an indicator of impaired postoperative cardiac performance and risk factor for late sequelae.",
"   </p>",
"   <p>",
"    Aortic regurgitation is abolished or improved in up to 80 percent or more of patients following surgical VSD and aortic valve repair with better results achieved in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/43\">",
"     43",
"    </a>",
"    ]. A 5 percent incidence of significant AR necessitating reoperation was observed in one series of patients who had undergone VSD repair, with a mean interval between the first and second operation of seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21905006\">",
"    <span class=\"h2\">",
"     Percutaneous repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcatheter device VSD closure is a treatment option for isolated uncomplicated muscular VSDs, and for certain membranous VSDs, in selected patients with suitable anatomy. Appropriate anatomy for transcatheter closure includes a VSD location remote from the tricuspid and aortic valves with an adequate rim. Successful transcatheter closure has been accomplished in the presence of multiple muscular or membranous fenestrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32,44\">",
"     32,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technical success rate of transcatheter closure of selected muscular and membranous VSDs is high and the mortality rate is low [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In experienced hands, device closure of muscular VSDs using an Amplatzer device has a reported success rate of93 to 100 percent and a mortality rate of 0 to 2.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/46\">",
"       46",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Success rates for percutaneous closure of membranous VSDs with Amplatzer devices are also high. In a series of 104 patients with membranous VSDs, the defect was successfully closed in 96 percent and no deaths occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32\">",
"       32",
"      </a>",
"      ]. Among those successfully closed, a trivial residual shunt was present in 47 percent at the completion of the procedure, but this decreased to 16 percent at discharge and 1 percent after a median follow-up of 38.5 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar complication rates have been reported for percutaneous closure of muscular VSDs (3 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/46\">",
"     46",
"    </a>",
"    ]) and membranous VSDs (0 to 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32\">",
"     32",
"    </a>",
"    ]. Procedural related complications could include rhythm disturbance, conduction abnormalities, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of complete atrioventricular block is the most significant of the procedural complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32,46\">",
"     32,46",
"    </a>",
"    ]. In a series of 104 patients who underwent transcatheter closure of membranous defects, 6 percent developed complete heart block necessitating pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/32\">",
"     32",
"    </a>",
"    ]. Real-time three-dimensional transesophageal echocardiography has been increasingly used to guide such procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/47\">",
"     47",
"    </a>",
"    ]. Given the lack of data on long-term outcomes following catheter closure of VSD in adults, patients should be followed every one to two years at an adult congenital heart disease center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21905021\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568410\">",
"    <span class=\"h2\">",
"     Pregnancy with VSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of reproductive age with small VSDs as well as those with successfully repaired VSD without significant residua can complete pregnancy with no increase in risk to the mother or fetus. The risk is small when the shunt ratio is &lt;1.7 with normal pulmonary pressure and preserved functional aerobic capacity.",
"   </p>",
"   <p>",
"    Women with larger shunts and those with history of arrhythmias, residual ventricular dysfunction or PHTN are at higher risk of developing pregnancy related complication mainly arrhythmias and heart failure. High risk is posed by VSD in combination with moderate or more pulmonic stenosis or DCRV or significant left ventricular dysfunction (left ventricular ejection fraction &lt;40 percent). Pregnancy is contraindicated in patients with Eisenmenger complex. Therefore, such patients should be counseled against pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/22,48,49\">",
"     22,48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of Eisenmenger syndrome\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to what is observed with pregnancies of women with other congenital heart defects, the offspring of women with VSDs have an increased risk of congenital heart disease (3 to 7 percent).",
"   </p>",
"   <p>",
"    A literature review of studies published between 1985 and 2007 found the following rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with VSDs (combined repaired and unrepaired) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, cardiac complications were rare. Arrhythmias occurred in none of 66 pregnancies, heart failure in none of 74 pregnancies, and cardiovascular events (myocardial infarction, stroke, cardiovascular mortality) in 1 of 83 pregnancies.",
"     </li>",
"     <li>",
"      With respect to the fetus, preterm delivery occurred in 2 of 17 pregnancies, fetal mortality in 1 of 74 pregnancies, perinatal mortality in none of 74 pregnancies and recurrent congenital heart disease of any type in 2 of 74 pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568452\">",
"    <span class=\"h2\">",
"     Pregnancy with AVSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies of congenital heart disease in pregnancy, atrioventricular septal defects (AVSDs) are not differentiated from simple atrial septal defects, possibly leading to underestimation of risk.",
"   </p>",
"   <p>",
"    The above cited literature review found the following rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with AVSDs (combined repaired and unrepaired) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, arrhythmias occurred in 9 of 88 pregnancies, heart failure in 1 of 88 pregnancies, and cardiovascular events (myocardial infarction, stroke, cardiovascular mortality) in none of 88 pregnancies.",
"     </li>",
"     <li>",
"      With respect to the fetus, preterm delivery occurred in 3 of 48 pregnancies, fetal mortality in 1 of 88 pregnancies, perinatal mortality in 2 of 88 pregnancies, and recurrence of congenital heart disease of any type in 7 of 88 pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further details on complications were reported in one of the studies included in the review, a report from a national registry in the United Kingdom of 48 completed pregnancies in 29 women with AVSDs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/52/14154/abstract/51\">",
"     51",
"    </a>",
"    ]. Postpartum persistence of New York Heart Association class deterioration was reported in 23 percent and worsening of preexisting left AV-valvular regurgitation in 17 percent. However, symptomatic heart failure was diagnosed in only one pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21905014\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular septal defects (VSDs) are of varied size and shape and can occur anywhere in the ventricular septum. Hemodynamically significant VSDs cause LV volume overload and varying degrees of pulmonary hypertension (PHTN). (See",
"      <a class=\"local\" href=\"#H26371603\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VSD can be associated with other congenital heart defects or acquired abnormalities including AR, DCRV, and PHTN. The associated abnormalities influence the clinical presentation, cardiac examination, as well as hemodynamic significance of the VSD and alter treatment indications and options. (See",
"      <a class=\"local\" href=\"#H26371611\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26371619\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11167278\">",
"       'Prognosis and clinical course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21904975\">",
"       'Indications for intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough clinical, echocardiographic, and occasional invasive hemodynamic catheter evaluation is important in the assessment of VSD patients. These data help to determine the most appropriate timing of surgical or percutaneous closure in an effort to prevent adverse events or sequelae. (See",
"      <a class=\"local\" href=\"#H26371641\">",
"       'Clinical tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26371701\">",
"       'Medical management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21904975\">",
"       'Indications for intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival in VSD patients ranges from excellent for those with small restrictive VSDs, normal ventricular function, and normal pulmonary artery pressure to reduced for those with associated Eisenmenger complex. (See",
"      <a class=\"local\" href=\"#H11167278\">",
"       'Prognosis and clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with previously repaired VSDs who have significant persistent shunts, residual heart failure, AR, PHTN, or other hemodynamic abnormalities should be seen at least annually at an adult congenital heart disease center. (See",
"      <a class=\"local\" href=\"#H26371701\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with small VSDs as well as those with successfully repaired VSD without significant residua can complete pregnancy with no increase in risk to the mother or fetus.",
"     </li>",
"     <li>",
"      Women with moderate sized VSDs, those with arrhythmias, ventricular dysfunction, or PHTN are at higher risk of developing pregnancy related complications. (See",
"      <a class=\"local\" href=\"#H568410\">",
"       'Pregnancy with VSD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Eisenmenger complex should avoid pregnancy due to the high risk of maternal mortality. (See",
"      <a class=\"local\" href=\"#H568410\">",
"       'Pregnancy with VSD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/1\">",
"      Du ZD, Roguin N, Wu XJ. Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates. Cardiol Young 1998; 8:500.",
"     </a>",
"    </li>",
"    <li>",
"     Graham TP, Gutgesell HP. Ventricular septal defects. In: Moss and Adams Heart Disease in Infants, Children and Adolscents, Emmanouilides GC, Riemenschneider TA, Allen HD, Gutgesell HP (Eds), Williams &amp; Wilkins, Baltimore 1989. p.724.",
"    </li>",
"    <li>",
"     Prasad S. Ventricular Septal Defect. In: Diagnosis and Management of Adult Congenital Heart Disease, Gatzoulis MA WG, Daubeney PEF (Eds), Churchill Livingstone, Philadelphia 2003. p.171.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/4\">",
"      Van Hare GF, Soffer LJ, Sivakoff MC, Liebman J. Twenty-five-year experience with ventricular septal defect in infants and children. Am Heart J 1987; 114:606.",
"     </a>",
"    </li>",
"    <li>",
"     Abbott ME. Congenital heart disease. In: Leaf Medicine: A Pertetual System of Living Medicine, Nelson T (Ed), New York 1931. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/6\">",
"      Jacobs JP, Burke RP, Quintessenza JA, Mavroudis C. Congenital Heart Surgery Nomenclature and Database Project: ventricular septal defect. Ann Thorac Surg 2000; 69:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/7\">",
"      Van Praagh R, McNamara JJ. Anatomic types of ventricular septal defect with aortic insufficiency. Diagnostic and surgical considerations. Am Heart J 1968; 75:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/8\">",
"      Momma K, Toyama K, Takao A, et al. Natural history of subarterial infundibular ventricular septal defect. Am Heart J 1984; 108:1312.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Ventricular Septal Defect. In: The Clinical Recognition of Congenital Heart Disease, 4th ed, W.B. Saunders Company, Philadelphia 1994. p.396.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/10\">",
"      Goor DA, Lillehei CW, Rees R, Edwards JE. Isolated ventricular septal defect. Development basis for various types and presentation of classification. Chest 1970; 58:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/11\">",
"      Battin M, Fong LV, Monro JL. Gerbode ventricular septal defect following endocarditis. Eur J Cardiothorac Surg 1991; 5:613.",
"     </a>",
"    </li>",
"    <li>",
"     Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. British Medical Journal. 1959:II701-709.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/13\">",
"      Shepherd RL, Glancy DL, Jaffe RB, et al. Acquired subvalvular right ventricular outflow obstruction in patients with ventricular septal defect. Am J Med 1972; 53:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/14\">",
"      Ammash NM, Warnes CA. Ventricular septal defects in adults. Ann Intern Med 2001; 135:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/15\">",
"      Tatsuno K, Konno S, Ando M, Sakakibara S. Pathogenetic mechanisms of prolapsing aortic valve and aortic regurgitation associated with ventricular septal defect. Anatomical, angiographic, and surgical considerations. Circulation 1973; 48:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/16\">",
"      Laubry C, Routier D, Soulie P. Les souffles de la maladie de Roger. Rev Med Paris 1933; 50:439.",
"     </a>",
"    </li>",
"    <li>",
"     Ammash N. Ventricular septal defect. In: Warnes CA, ed. Adult Congenital Heart Disease. Dallas: American Heart Association; 2009:41-56.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/18\">",
"      Telagh R, Alexi-Meskishvili V, Hetzer R, et al. Initial clinical manifestations and mid- and long-term results after surgical repair of double-chambered right ventricle in children and adults. Cardiol Young 2008; 18:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/19\">",
"      Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87:I38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/20\">",
"      Hundley WG, Li HF, Lange RA, et al. Assessment of left-to-right intracardiac shunting by velocity-encoded, phase-difference magnetic resonance imaging. A comparison with oximetric and indicator dilution techniques. Circulation 1995; 91:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/21\">",
"      Debl K, Djavidani B, Buchner S, et al. Quantification of left-to-right shunting in adult congenital heart disease: phase-contrast cine MRI compared with invasive oximetry. Br J Radiol 2009; 82:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/22\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52:e143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/23\">",
"      Stauder NI, Miller S, Scheule AM, et al. MRI diagnosis of a previously undiagnosed large trabecular ventricular septal defect in an adult after multiple catheterizations and angiocardiograms. Br J Radiol 2001; 74:280.",
"     </a>",
"    </li>",
"    <li>",
"     Soto B, Coghlan CH, Bargerson LM. Angiography in Ventricular Septal Defects. In: Paediatric Cardiology, Anderson RH SE (Ed), Churchill Livingstone, Edinburgh 1987. p.125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/25\">",
"      Neumayer U, Stone S, Somerville J. Small ventricular septal defects in adults. Eur Heart J 1998; 19:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/26\">",
"      Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. Circulation 1993; 87:I121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/27\">",
"      Gabriel HM, Heger M, Innerhofer P, et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. J Am Coll Cardiol 2002; 39:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/28\">",
"      Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect. Results of 24-hour ECG monitoring. Circulation 1993; 87:I89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/29\">",
"      Ellis JH 4th, Moodie DS, Sterba R, Gill CC. Ventricular septal defect in the adult: natural and unnatural history. Am Heart J 1987; 114:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/30\">",
"      Otterstad JE, Erikssen J, Fr&oslash;ysaker T, Simonsen S. Long term results after operative treatment of isolated ventricular septal defect in adolescents and adults. Acta Med Scand Suppl 1986; 708:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/31\">",
"      Michel C, Rabinovitch MA, Huynh T. Gerbode's defect associated with acute sinus node dysfunction as a complication of infective endocarditis. Heart 1996; 76:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/32\">",
"      Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol 2007; 50:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/33\">",
"      Hijazi ZM, Hakim F, Al-Fadley F, et al. Transcatheter closure of single muscular ventricular septal defects using the amplatzer muscular VSD occluder: initial results and technical considerations. Catheter Cardiovasc Interv 2000; 49:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/34\">",
"      Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/35\">",
"      Silversides CK, Dore A, Poirier N, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: shunt lesions. Can J Cardiol 2010; 26:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/36\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/37\">",
"      Tweddell JS, Pelech AN, Frommelt PC. Ventricular septal defect and aortic valve regurgitation: pathophysiology and indications for surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2006; :147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/38\">",
"      Kostolny M, Schreiber C, von Arnim V, et al. Timing of repair in ventricular septal defect with aortic insufficiency. Thorac Cardiovasc Surg 2006; 54:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/39\">",
"      Mongeon FP, Burkhart HM, Ammash NM, et al. Indications and outcomes of surgical closure of ventricular septal defect in adults. JACC Cardiovasc Interv 2010; 3:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/40\">",
"      Uemura H, Kagisaki K, Adachi I, et al. Aortic valvar involvement in patients undergoing closure of ventricular septal defect via the pulmonary trunk. Int J Cardiol 2008; 129:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/41\">",
"      Meijboom F, Szatmari A, Utens E, et al. Long-term follow-up after surgical closure of ventricular septal defect in infancy and childhood. J Am Coll Cardiol 1994; 24:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/42\">",
"      Blake RS, Chung EE, Wesley H, Hallidie-Smith KA. Conduction defects, ventricular arrhythmias, and late death after surgical closure of ventricular septal defect. Br Heart J 1982; 47:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/43\">",
"      Ohkita Y, Miki S, Kusuhara K, et al. Reoperation after aortic valvuloplasty for aortic regurgitation associated with ventricular septal defect. Ann Thorac Surg 1986; 41:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/44\">",
"      Bridges ND, Perry SB, Keane JF, et al. Preoperative transcatheter closure of congenital muscular ventricular septal defects. N Engl J Med 1991; 324:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/45\">",
"      Carminati M, Butera G, Chessa M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur Heart J 2007; 28:2361.",
"     </a>",
"    </li>",
"    <li>",
"     Khalid O, Cao QL, Hijazi ZM. Catheter closure of ventricular septal defect. In: Cases in Adult Congenital Heart Disease, Gatzoulis MA WG, Broberg CS, Hideki U (Eds), Churchill Livingstone, London 2010. p.48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/47\">",
"      Acar P, Abadir S, Aggoun Y. Transcatheter closure of perimembranous ventricular septal defects with Amplatzer occluder assessed by real-time three-dimensional echocardiography. Eur J Echocardiogr 2007; 8:110.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Pregnancy in congenital heart disease: the mother and the fetus. In: Congenital Heart Disease in Adults, Perloff JK, Child JS (Eds), W.B. Saunders Company, Philadelphia 1991. p.124.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/49\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/50\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/52/14154/abstract/51\">",
"      Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13602 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14154=[""].join("\n");
var outline_f13_52_14154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21905014\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371595\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371603\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371611\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371619\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5506780\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371633\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371641\">",
"      CLINICAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371648\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371655\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371662\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371670\">",
"      Stress testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371677\">",
"      Cardiovascular magnetic resonance imaging and computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26371684\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371692\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1364844\">",
"      Spontaneous closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1364851\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1364859\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1364866\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11167278\">",
"      PROGNOSIS AND CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26371701\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21904975\">",
"      INDICATIONS FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21904982\">",
"      SURGICAL REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21904990\">",
"      LATE POSTOPERATIVE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21905006\">",
"      Percutaneous repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21905021\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H568410\">",
"      Pregnancy with VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H568452\">",
"      Pregnancy with AVSD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21905014\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13602|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/34/15907\" title=\"diagnostic image 1A\">",
"      Membranous and infundibular VSDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/40/31363\" title=\"diagnostic image 1B\">",
"      Echocardiogram of infundibular VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/14/15584\" title=\"diagnostic image 1C\">",
"      Parasternal long axis view of VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/16/20736\" title=\"diagnostic image 2\">",
"      Echocardiogram of inlet VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/52/19269\" title=\"diagnostic image 3\">",
"      DCRV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13602|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/10/39077\" title=\"figure 1\">",
"      Segments of the ventricular septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/25/20882\" title=\"figure 2\">",
"      Types of ventricular septal defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/8/8323\" title=\"figure 3\">",
"      Schematic PSAX  VSDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/25/5522\" title=\"figure 4\">",
"      Pathophysiology of aortic regurgitation with VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/3/33850\" title=\"figure 5\">",
"      Cardiac examination for VSD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3096?source=related_link\">",
"      Echocardiographic evaluation of ventricular septal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_52_14155="Root versus nerve pain";
var content_f13_52_14155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical distinction between root and nerve pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Root pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        Brief",
"       </td>",
"       <td>",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quality",
"       </td>",
"       <td>",
"        <p>",
"         Sharp",
"        </p>",
"        <p>",
"         Shooting",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Burning",
"        </p>",
"        <p>",
"         \"Asleep\" or \"numb\"",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Worse with",
"       </td>",
"       <td>",
"        <p>",
"         Coughing",
"        </p>",
"        <p>",
"         Straining",
"        </p>",
"        <p>",
"         Standing",
"        </p>",
"        <p>",
"         Sitting",
"        </p>",
"       </td>",
"       <td>",
"        Lying in bed at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relieved by lying down",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14155=[""].join("\n");
var outline_f13_52_14155=null;
var title_f13_52_14156="Genes associated with PCOS or component traits of PCOS";
var content_f13_52_14156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genes associated with PCOS or component traits of PCOS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symbol",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACVR2A",
"       </td>",
"       <td>",
"        Activin A receptor type IIA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        Androgen receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DENND1A*",
"       </td>",
"       <td>",
"        DENN/MADD domain-containing protein 1A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FBN3",
"       </td>",
"       <td>",
"        Fibrillin-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEM1B",
"       </td>",
"       <td>",
"        Fem-1 homolog b gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FTO",
"       </td>",
"       <td>",
"        Fat mass- and obesity-associated (BMI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HSD17B6",
"       </td>",
"       <td>",
"        17-beta-hydroxysteroid dehydrogenase type 6 (metabolic traits)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INSR",
"       </td>",
"       <td>",
"        Insulin receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IRS1",
"       </td>",
"       <td>",
"        Insulin receptor substrate 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LHCGR*",
"       </td>",
"       <td>",
"        Luteinizing hormone/choriogonadotropin receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MC4R",
"       </td>",
"       <td>",
"        Melanocortin 4 receptor (BMI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        POMC",
"       </td>",
"       <td>",
"        Proopiomelanocortin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PPARG",
"       </td>",
"       <td>",
"        Peroxisome proliferator-activated receptor gamma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SHBG",
"       </td>",
"       <td>",
"        Sex-hormone binding globulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SGTA",
"       </td>",
"       <td>",
"        Small glutamine-rich tetratricopeptide repeat-containing protein alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        THADA*",
"       </td>",
"       <td>",
"        Thyroid adenoma-associated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The genes in this table were selected based on supporting evidence from multiple reports or evidence of replication.",
"    <div class=\"footnotes\">",
"     * Identified by genome-wide association study.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Mark O Goodarzi.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14156=[""].join("\n");
var outline_f13_52_14156=null;
var title_f13_52_14157="Vaccines solid organ transplant";
var content_f13_52_14157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunization schedule for adult solid organ transplant candidates and recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"       Vaccine*",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"       Definition of fully immunized",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"       After solid organ transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Catch up schedule (if needed)",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"1\" rowspan=\"2\">",
"       Routine schedule once fully immunized",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3\">",
"       Visit 1",
"      </td>",
"      <td class=\"subtitle3\">",
"       Visit 2, 1-2 months later",
"      </td>",
"      <td class=\"subtitle3\">",
"       Visit 3, 6 months after visit 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Inactivated vaccines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diphtheria, tetanus",
"      </td>",
"      <td colspan=\"1\">",
"       3 doses, last within 10 years",
"      </td>",
"      <td>",
"       Td-1",
"      </td>",
"      <td>",
"       Td-2",
"      </td>",
"      <td>",
"       Td-3",
"      </td>",
"      <td>",
"       Td every 10 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       (Tdap)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hepatitis B",
"      </td>",
"      <td>",
"       3 doses",
"      </td>",
"      <td>",
"       Hep B-1",
"      </td>",
"      <td>",
"       Hep B-2",
"      </td>",
"      <td>",
"       Hep B-3",
"      </td>",
"      <td>",
"       Booster if titer &lt;10 lU/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       23-valent pneumococcal polysaccharide",
"      </td>",
"      <td>",
"       2 doses",
"      </td>",
"      <td>",
"       PPV23-1",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Complete 2 doses, second dose 5 years after first dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hepatitis A",
"      </td>",
"      <td colspan=\"1\">",
"       2 doses, at risk patients only&bull;",
"      </td>",
"      <td>",
"       Hep A-1",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hep A-2",
"      </td>",
"      <td>",
"       Recommended for patients at risk, complete 2 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inactivated influenza",
"      </td>",
"      <td>",
"       Annual administration",
"      </td>",
"      <td>",
"       Annually every fall",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Annually every fall including first year after transplant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Meningococcal vaccine",
"      </td>",
"      <td colspan=\"1\">",
"       1-2 doses, at risk patients only&Delta;",
"      </td>",
"      <td>",
"       Mening-1",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Recommended for patients at risk, complete 1-2 doses, 2nd dose 5 years after first",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Inactivated polio vaccine",
"      </td>",
"      <td colspan=\"1\">",
"       3 doses +1 booster at risk patients only",
"      </td>",
"      <td>",
"       IPV-1",
"      </td>",
"      <td>",
"       IPV-2",
"      </td>",
"      <td>",
"       IPV-3",
"      </td>",
"      <td>",
"       Recommended for patients at risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td colspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       Live vaccines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Measles-mumps-rubella",
"      </td>",
"      <td colspan=\"1\">",
"       Up to 2 doses",
"      </td>",
"      <td colspan=\"3\" rowspan=\"1\">",
"       Vaccine not recommended after transplantation",
"      </td>",
"      <td>",
"       Vaccine not recommended after transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Varicella",
"      </td>",
"      <td>",
"       2 doses",
"      </td>",
"      <td colspan=\"3\">",
"       Vaccine not recommended after transplantation",
"      </td>",
"      <td>",
"       Vaccine not recommended after transplantation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Absolute contraindications to all vaccines include anaphylactic reaction to prior dose or vaccine component and defer until resolution of acute, moderate or severe illness.",
"     <br>",
"      &bull; Hepatitis A - at risk includes all waiting for liver transplant and all with chronic liver disease and those at risk of exposure to hepatitis A.",
"      <br>",
"       &Delta; Meningococcal - at risk include those with anatomic/functional asplenia or travel exposure and college students.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14157=[""].join("\n");
var outline_f13_52_14157=null;
var title_f13_52_14158="Stress and sudden cardiac death";
var content_f13_52_14158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationships between emotional stress, myocardial ischemia or infarction, and ventricular fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 326px; background-image: url(data:image/gif;base64,R0lGODlhqwFGAeYAAP///4CAgH9/fwAAAIiIiLu7u0RERCIiIt3d3ZmZmWZmZjMzMxEREe7u7szMzFVVVQAz/3d3d0BAQKqqqr+/v/Dw8BAQEDAwMNDQ0LvJ/6CgoIig/wBmM0Rp/5mt/2BgYCJO/3BwcMDAwLCwsD8/PyAgIDNc/4i4oO7x/2aF/93k/1BQUODg4BFwQUSPaZnCrZCQkO718VV3/8zW/xFB/3eS/93r5HetkjOFXF9fXyJ6TqrMu8zg1rvWyWajhVWZd6q7/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACrAUYBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwoMKCKAwYMIEypcyLChw4cQI0oUMbBirgAkBGjcyLGjx48gQ4ocSbIkSRIBLKqsFUDAOQEpV8qE1fJlzJk4V9U0BzOnz1Q7y/X8SZRUUHJDiyr9dLRWBgiski6dqqlpIQ8QskJIAempIK+SwCLqsAGUVKpoK1kl5AEEJbFv/6EmImv2Ztq7ktYOalsIAoisKbKaENQhawcUf/16VWEiaw0AG0D8NYFChVbKcFEUhkADa1YPZDuAYAwYgAcaWTfMaAxBhqKzeGMz0ivIc2kIZVOMtpwhMgoUJjaA9SrD9QwavUej6DzIMhC4T1EMoguggwkVAGRwVUFjRofHgjYMZgRbtvlDtE27JQQhA+QOgtqn4Ao5xXCoIDwQ9rABPoD83mnlAVwA1MBZWdRRl9hnGTTWwQwqyACBCfolUt55GAqSHl/suddffMn9BoJwEEhHnHHtffifBykMhgIEA8pVyAwQqPAdYWVlR18h2g0S2Wt2ZSgkABtqtRUA7b0HYv91hv3WGAiLsfaYivllgNpfMRLyVGmegZYjaVnZmBUIM2wgIJBDpkmkSzwFqaZ56XVz4Zt3xcnNnHSiZec2eOY51Z7a9OmnUoBmI+igRGFk0qKMNurooxyhhKhsBUlk6aULSSABppxaStGkoBrlZqikOmNQqahCc2qqrC6zaquwGvNqmgQYkEoBA8R6yqzwEDDAAAqsUmspuApSrCIDFCBIsrqqNao7wwprKynHHpsIs81ewmuv0w6wwK8JAFDAAb8SUKuvCDzw6wINIPCrtw048O0ADwDg6wAHOGDvu9MKIu+vDygwrQER4EouA+oOEIG9BzAAr7vrNkAuvrh+y4D/vvfmq8C77iqbMAPZOrLtO9EOQADDADBwsiAEHKAsAewCsMDKALg7AcyDOHAxABE84ACz0bK8wCDuIlA0rsoeYGsCubbcgMQ021wtswYooLO+PQOAbbItIxDyIyND262yCRxQ9CDRbvyu1Qa8m0C63ibA9LsHlM1yvzWru0C4BhAQQbDH9i1u0wOz7fbUgiigwNy/HqC1so8r/nUjJbw7gAXzlEy24yqjPS3MDQyiwNANDBAuy/nu7O8A+j6AN9qOj7tz4CcXOywCDCQwOgClJ4Br6McqfjUhA0ywbAFdT77IB5avIM+9wTJrdwEOmxx0wqZTj6/p95q+76/Bqr0A/97dnz6+sbkCILjt79arPbkJNPCty+lL3n34v3as/q8gK3+IBpaDAaoawADIKSJo/lMFCyyHAVRFYGiMQGACU3GBX5Vgghh0RQh+9YEMelAVI/iVBiqCrUlYqxeC+yAifsWCeeCqcQZcYQwjcUJcpDCFiIiWBJslgQvQA1dee+AiSiiJGt7ihjQ7xA6/FoAQ/HAAXntAvRAwr2BR8V0FYFrigtU9B4wLXOKaWPoG4S0wTixfWiub4tzGs3c54AAnI+AEDDAxOg6AAV4ro/fUZjrGJcAAVaxZFSEGrGF90WS6wsAInvgrA0TRihdz3fG0CADhlTB3AJgAyDpXQ0QSoP9/gjjAwuhViN0VbxB2s5sBlsYsOGrtZJ8kxO5uaCsgBqxmF9OhrTqnQnUAMQF4BIAYTVe3SdZvcY4TBCHzB8XBFYJZuHIAH6MHuU82jmHAeloB96a+2qVPcNCEojXx1U1BCK5ow0yALs/mqk65853wjKc850nPeiKEEUDkGbtuOQgpAuBnBQAiFa12ydMJonO+eqayIlC3AYRuAdSs2SkZSghMwqx/6/vmyZjFUJvxzHEEM+fJisZPod0tZUlExgAgxdKWuvSlMI2pTFs6xkTkU32OnBcU31hGZbWNARD9HusO6bi5feuZMLwiviK6P3wdgIAR4x0iy0k7rcGwqQf/KCq4zglFpe7UYQowZPVSSoya9pIRZrUFES1BvdANcYbqSOtZr7WLtVZiAQtDK1zTIde5HqKvfkVWYNE6WEgAtrBam4RdKYHDThhRofc4bGElK1G6PU6vjGgsGfdKCM0W4rHE4+w7KBtYyrLzeJhdhGcvy1bJLhYepPWraZu5WQAkLGYf46O71Kg9TPYNmKGDmW5v61aRam1i4hvc/PR1Rn0li5DsqtgdMebGQxq0G7ENRbJAG8HXhWK1kVjiJV77idlalmsxm1nyUKu1eqEUAMAVXDGLCbT0JhGcJ1OA2ToWTdu6N5SjNKDUqEZQA2JSk+BIa9vKdQjwGiJaq91u/3YLIV5POPjB3rVXhjH8CPJ6YrZe2ywfgSW52l6WnVAUXK0mkExmjThYgwDny8Z2LKdN83EOWHD2jmk3ZVqOttg1RNUGp69CXJgQFT4edxeRZE4cuRFNVqxoP8yI0z4OdLALsdaMx1qEMqABgiPgzJZlPCwLeaMzVnL6IMq0h1Jzd70LXoEHgUlxKBjGubvXAhzgx4w5d15vW5t8G+fcgObKlXIkRHOF6kjWDa4Bfk7jARQQATcqFcZkBLT6AoloBkyg0r9ygFjvGK5RY/KQhAsjg9HmRj2Gi3FczCq8bPsuWBIazPwzhHmvySzs8S3XatOfuBzm25VF4MuJy5+vO/+LZg2reV1Gm9ekH/e+HW9RqF48Y4KFHCym/UxfAivn8LLmScdBOImipHauUplMQ4gSoM4ecsDGXS9SbrmfkCzysmAJslUODgHsvvdJOwfcYRH8ywxYmO12SVZ47xtlqHRo1wiozmD2jd6/W+EsnnwXBbutx+MqJ+PIKT1zD4wADbixhHm3zeumfG09FmvRRu44bLUsm+kM7b+5igACFoCbN1cApBsdYnESfVlnW7iVBdFj1KZSpwiIVt1K/FvLOa7SvCSeLCbg0DfdOWeOlmRIh1dbu+Gsm22WGTVrvABQMr3rEP22baeVVVuRnb10TkBJIUtRntur7YXIM8Pt9WX/g/ObgLZ2dtbBbsCSC3NhXI863dX5VKjdHexaXhZiHfF1VntLX3NT59ouazedAatvSp32yqWa0tTjz1vTYlo1R88sqD4M6sS7qt9LF8fqscvUpa4lsV/duFRrb6osa/XmvkcuyYcyftK2NfheCCxdb74REyYWsmHh4WEXNxMtO4XErov9TRAQARwPVfZJgVdZdL/94OfflDfBL0lQlvqebB8qbZV+Qyz5zEWxfh90f80US+GHAK6kPnxDVo7wf0bGgDIhgB5EgEFUL+FnW5AUOoAEPoLEgbCmYd1DTjFWK5P2cYczMdf1L/SiP6pEgl7lMVF1DhJ4CkElLYjwQvM3/wlnlwsEuDaQ5jg6Ey4RkFf+Zkv5FnE/qCxGBEiZN0src2But4MsCFILEEUQhF4PBYHblgsJAEH2l4Oew2GHMGaL4IANpoWxQIG8I0r3c1BFxnPp1IUcEy1LuDLjBFIj9WNaBjd7M4XlJEynkywvhg4zWAoHwGVfeAniVUD4JIAspgtqCDUXKAgT4IU8t3fpFnl02HXMJlHG03d5VWc5VHN8g4eC4E8AZWZ8lQvu4lZ8FC6HRADhBojDFYMiRUfDAmqsMyxlY0Bq01AcqFQPcEZKpXDJYjIL1j+lo29q1Yjt84OE8AA0w3NeFXXF53y8Mz+diFValT3a5nneo2em+P9P5EIuMAhGMpgLIVdKQ5N1s0hfL2NfnVWFznZKd9OFmcdab9cAkoQ+p1gvOmNo3vR9wgSGrFCIglA6BGkMP5OPq4gL60h4jXNa7xguLmY5mPaHwxJ0kOYwiFh2UFdM/giI5uQ7Y4R1NOMyPDgO1IeG5YCQotCKnvhR74U6w2aRZRYzAOhseQczsgdZmQhF/fho/vVPq4d5UsWMtQCTE6gLh2hOjRM7Y4WA3oJJwbZsI3g3tvd7rHRdQHONwig/+FKMzjQ4HJhJ7XYLTJlBawkKXagN/bcKbalrBnlAGyYJVOmS8TCXn1CD1rCDuNCD3uKQkKWPlZBkiJMIEXCXOuf/DnyZLWpoAP8lQ3h3mIxphrall4a5Do/ZLGrYMkjDPesiTRzjaiCYYo3UAAZzRwmzMC3jMDGzYAYgMTCUK8IYccwUVbnFMbIZOsREaW7kDZ2pKxQoPwqAKycjd+G2NbBkbirpNPJDAEgjTKzEME8DR9A5M4gzlNvoYzdjNrWVnRvlXvb4DcMZK4IZXekDcjUHOY6XNjAmi1W1cOakOPF5nOlTLCL5gP+kY7qTkS52n6zFkcJ5fX/ViFp2LHInSfb4np9TeXA0n6mGO5R3ndLZdcXCnVkJZ9wDnmRmnVCzmaK4DecJK2o4kt+zZ5XETMsXNL0poULlXr0plvTTgfZm/1zV9mt3tKKoOQCzeVlbuZDYUKKtQqSeOVNImqRKuqRMKlNGqiv2ZCkrMAAhEKVWGgCacqXxVAIWUKVaKhEGWgsVcAFOxAth4wpjegEVEKbhMKYd1Atn+gofYAENxKbesAIS8Atx+gowYAEjdAtkWEmTWV5w5Vkp1H2T8gFqqqfPIgsjYAGN6goXmGiigKjGlS0BUAJryqi7gAEX8AGbOgulQzYg01y4tqO9FS7CSJbSdTG69ZsqVmtuQzWpqTWalicaQKfBsKexUAE9FKqy8AAL01iilHEHdTLANZSoWEDTOWRbI6ME4HB/yDWVN2blliePWqfAwKuyMKfaGguaVP80L8eBKIliCGhQImkAJnltWwM5v5WWh1oAJSaLpJeWQ4IBfjoM3CoLAPSnsgBUrORmmOdl/NgvqLh6ktOg7hqtJRRSVwahzdZ095qv+hqptiACXToLlaaq0oafHJiqNvoArHpMPCpssRpqoUerPuqby5cmY1qmFRsMnroCwGqnyOCmsmKxt+CrF9BCNpsMeHoM+2oLIaCrP2sMilqzwjC0ttCvR0sMmaq0S6uzuoCvMPu0vpCr31oMTHsLLHABEiC1WGsL2aoMXbuzK3ABWzu2tYCv/ooMZ4sLRfspbNu2FGu2VJu1A/C2dQsLL9sMcZsL+PqmffsKOAu4efsLYxr/toXrCkFrKomruIq6to0bChWwSACQtM8QuGZqAZhbuaMQAHsbtaoSucGQqwIEupZrAe9CuXgrDYMrCBWQuqpbFZZDuJA7DWnqqwPwubVrCRXAupZjupyqu3P6KxYgtr8LNpbjudHAucAAQO/iPMtLCcE7vcqbDNDrCxjwYwNAu9ULCaJ7Ob5butRQAQEgvMjruuGLCNdLs9WwvYoLA5XzKz7UviJTAuUrDfJ7uhVEpfjbCAGQvbmrDSIgAQNAtwEsDv1LDBhwtRNUKV86wRQcAAq8CQ1cCBJcwRzcwR6MKRe8uRnRpCTMpJLiCRlMCIpSwizcwi7cKCfMv2wiFMQr/8A1PBsz7CeHIrQ5PA47HAkpPAiFIhs/zLU9LA5FDDY3vAhDHBtJrK9HHA5PbMNMEcVqMsW7asXfgMVMvMSK0MR4wcV6qsV1VZeSIMaJEMQaQsZlSai/gJmqpZmPgMZwmsPL9CtmjGSMGYaFeS15bGIW4sVpLMiI0BTUV4Vw/IWJrESfs8fXQpjhlAn99390bKZRHGWagMl0GQqVbAhqvCaf1UySuciG9ceMjAlApnOkfIac0Mm6sBaGdIxlQ2i2Cka6KGq1hIKbBj6EBKAFoIIW2GqadmnY5C3zYjzP9S46OQiurMKEjB49nE+guW6j94KUJDnWRQgvWCzAVC6h+f+TZtcwn7c2wLfL1fdXDvmKZbQzfUNHZHlzxvwrxrOB1UeW3Wwy3DxWhdDMuADLtYR8APZKKFOeBhcuCFaERkeXOyit13pLuCNq+4VIyylg5SkI/Kwhz+zJ0QxFxnlCbdaPyXLNwQKF0UhjueKwg5OHLQqxuvRe8fXPTfhjrxNOPhUsTFiUAdk17pJf/AeQrLOsBYDSxYLS+5zRr3zJ/5yQKrfS2VQrd4x+eYiNocWHcpOWjpdOmlOPv+yfRc0URq3CGx0x3BySgZhFx/TUgyCSK/dzPupF6eOHEBZWjWyufqdrkKyEJJtC6apOYxNvK0NMp6OubG0Abi0u30LYXT3/Df5clmkXVI7Xk7t0XTwHmHjXMgy9fHuX1cMiiKTjPYRw0UTy1UK80Ql6aJAnlD5taNE20uT3j0ZpaNGIn2RUis5GoWdneIQHZlGNzn9lPHL2hweLPH09LIITecGNbye0dwAA2iyB1GXpevUapIakbTxner5cPtjmeNWo2bayXQ4DP4ndCZ9syEDGPtuDADxljvsDVIDzjf5CLt8C2wuWL9YijjH6T2BVznX9TISpNiL9h+883PxXazY6rIQ21LT82aJ9C2BcDaA93myMfaZsCZrs4AtuCw1ODQ9+4RnemKdQ4Rp+4c1tE15dxZPC3LTQ4dKw4SaOKCg+CyoeDSyO/8IRjiEvLgsxDg0zLt41fh43Hgs5/gw7zglBXhQ/ThMj/MJKDikxTOQcnuRLHuVSXsJNDg0b/MFY7k4hnAmffOVZfilZ+uViDsK1+8nbKuILPLXfYOZpvqto7gts3ubF2w1xLudw+uZ3bufeUOdmiud6/sp+vgt8/uf9HOi4UL/IS+jZMOi4wDzTq+jYwOi3IL2/Ar6QrtiG7rUMdOnWIOm38L8XxOnxm+m3sEEDgLui/rykTrYilOrU4OlqOQA+6+qq/g09ROuYvuYQjOuI+w2KxOu1DuytAuuzMebGPk/C7smrjlZT3uwv9aSNS+xDNA/QXrjSLljyUO19e+10lf/tyV4I3K5x3v7tQrzs0z7u5B7aS0nt6Y7R684KSWapeXkK2l634X6gRkZbbUOYmEDcDEhEq7WYkYBE9tfu6k4LHrcwEMPvisiYliqNAy/H4p7u9259RmYAX7aYUNRpE0CWq6rMqinL3cN/J7NoAL9RgMY40BXyuCJ65eI2J6uipvlMBl/xNG9kAgNMTANwReU4QK2hnoicr+3XihZgnXitjTVgydmwK3NxjraczWnxFG/u2N5Zi0MvQORz3LTX+5ljh7OeyeTv41p9J1+v4uafxyKxSMSeZn/zU//uVp8yqv13/RPcQ8mh62qUrUPyjc1UxuV4goP3CtqwRMiwe9//9lrX7jaf+HGPPl7De8o0Lwo/Lw+Qo9YiPiQP3WUP+LXz3daWfCi7VdIn8y3L+OS++GT0CG0VDvXOtqiveY4Af1v49gjP7opP9d2+lzWP+xMPW7sP975/+0vp7MQPKa0/tq8f2h8c5scuT7+/57xv8Bgc/TRB/dKPCcmvCtl//UBs/a6w/dyvxGvu/eE/CeC/K+Rf/t0//uofs9Df/mr+/vB/5uw//72A6JezDfiPOfYPCACCg4SFhoeIiYqDHwOOAyuLkpOUlZaKjY+Rl5ydnp+goaKjpKWmp6IajwMwqK6oqo+tr7S1tre4ubq6LKsYu8CKvY+/wcbHyMnKy4kX/44lzMfOA9DR1tfY2dqKIY4f27jdA9/g5ebn6KgjjhrprusD7e7z9PX2AI4s96T5+/7/AJFJuBAQ1MCCCBMqJBUgxMJLDR9KnEjREIYRFSVdzMixo8ePIEPS0hCgpMmTKFOqXMmypcuXMGPKnEmzps2bOFfKE8kTgIQcAoIKHUq0qNGjSJMqXcq0qdOnUKNKnUq1aA4JPXtKoJC16zIKWL2C3Cq2bDCwZj2STcvWFtq2FdfCnWvqLd2Hcu/q/WR3L8K8ghIwaOC3cKK+hv8BBvCAAQFkBAwoGlBAUAMGCAwZeEwrMmTJhjwfu5y5EuLE+wA7MLAANCEDA0rDLn3K8//mQ5QDu37NWdHtQqIVBbdVYICg4gCGI7f9OLfv3ogW9FbwYJWjygkMTBgsCMGA1asqCzqN2h5gAgkWRBA/CHYEAN5juxpuyLmBBId+P/dEnxZyQv0lt5tzieiHCAEHWMbABIIMdx8ADOCX3AIAGKDAIeSVR89iDVComQGDRTCbAqAZEAECCzjyHmOOYPbIAg0UV1wCBDwi2W0HOHKAA/hUhgB3KDpy4W01DrBjco8UOUB2kR3gWQE5DoDeIxcO50CKAzzgHXYJRvCIA0FmyeIAMCLIAJkNRHnAcgecCeNyNxKggI0lrghAAo8kUMCZERLSQG6CDRLcj4SJKIiTFV7/aEiGGrrDoYeFWHhfhLF5h4ClDzwAgAMMFIAgbd0NMEFxjzmQG3OEHPBebhGs+MCFP65GAKc8RvCAqez9xlpmnjlmCJ4NDEcApFvemaCogzzg2rCESYdgA2kS8B+b0DoJZ4XN+VipfO1x5qtghCX7nn7BtSqIqTFyB5sjuzHaKDqP5qcAng8Ul9lmEVx4gIT3KaDopusu+V8CCQqIbQNzCtkjhDwCEKUjTOL5yL4FC6IrZ5FZOkh6jyAwHALVLZBAsQQnl6MCaUoIQMJCimbhtMa5rMC1t9lHQL6RPqYxPqBut7PBgjDQMADS+Wvxv4S4+6458Wp2Yaf2AgCl0Ixp/4rrp4IoQOGfehq36XeMxQks0RdSNgGkr/JG6yC4trfib732pioAE8QWIIL44GdAxRAmoKygMAoq2Y9dE3Yt4TQ3x6DUbQ5t8Yq+EsAdIQy0BiBoZwPYpngWYhjW0vU0Hem/URMNWphvt7inkQJ7vbIjlm8W5gFlF/BAb2HGRiSVSDrigMRMNijZ6lIWmaPHuymJX5ELHHAZ7A2EqWl1ECupaYdGLveIpom/Lp/lhQC/ep+FeKky0Lf7aWR7SA+iNOjbiD7JZezh8me4CgUYCv2u3N/J+/DLhvwkEQFIwU9/oChgNgAYwGsMsIFtYSAEmbGYCepFghZMRgUzOBcMcv/QGBv8IFs8KMJd/KQqKEyhClfIwha68IVCuUoJt0GSnNjwhjiciQQkkMMe+vCHM9nJDIf4ipIQ8YhIDIURk8jEJk5iiU6MohQHAcUpWpGJVbyiFoeYxS16kYNd/KIYGxjGMZrxXWU8oxoTk8Y1ulEvbXyjHNsSxznaUSx1vKMeeZLHPfrRI338oyApEshBGlIhhTykIgGSyEU6kh4lWIUFHknJhGTCEZuopCb9EQtHzGKToKzHMBxRjFCa0h3TqMYpV3kOcZCDlbDcBjyEGMtaWqMftsxlNA6iy14qIyK+DKYxNiLMYhrzmNgQARBvIgJkmjIAJIAhVEgQAGeGMgD/AliGAKppzU1iU5vc7GYlv6mMbYpTk+RMhjnPScl0ImOd7HSkO48Bz3gqcp6diEELbPCJetrTkPgcBA5OMAgftIADCE2oIF7ggh20IAaCsAEHeJBQhCbCn/8UZEAFcQIdCEKfOxCECwg6CBe8AAAtOCkAToADAHBApYrAaEb9uFEAxIADPQDAC1pQUpICwAYPBcANXCAIHRD0pZKQ6Uz1WFMA/OAGABhpTwdxA6gCgKIx6EFQK+pTQyh1qXZsqkMlyk+R+rQFPBDoCXzgA0EgdRFfBascm4pSHBB1qgDYQUsH0dEW5NSlML1oOOW6R7re4K1mFcQPunpTj7o1sIiIdSth10hXRdwUoqGQ7GTPWNlbaHazY+ysLT4L2i+KthakLe0WT0uL1Kr2iqx9hWtfO0VoSvMp1KStHJW5zJo0U7fADa5wh0vc4hr3uMhNrnKXy9zmOve50I2udKdL3epa97rYza52t8vd7nr3u+ANr3jHK4lAAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14158=[""].join("\n");
var outline_f13_52_14158=null;
var title_f13_52_14159="Iron deficiency testing";
var content_f13_52_14159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Testing for iron deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 411px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Receiver operating characteristic (ROC) curves showing the sensitivity and specificity of various tests for the diagnosis of iron deficiency [ferritin, red cell protoporphyrin, transferrin saturation, mean red cell volume (MCV), and red cell volume distribution width (RDW)]. Note that, at any given level of sensitivity or specificity, serum ferritin outperforms all the other tests shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from from Guyatt GH, et al, J Gen Intern Med. 1992; 7:145.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_52_14159=[""].join("\n");
var outline_f13_52_14159=null;
